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ABSTRACT 
 
Neuropsychiatric disorders affect a significant number of people across the globe and 
are a serious economic and social burden. As a class of diseases they are often poorly 
understood, difficult to treat, and can lead to a significant decline in normal function and 
quality of life. Recent evidence supports the notion that many neuropsychiatric disorders 
are neurodevelopmental in foundation, originating at least in part from abnormal activity 
during critical periods of brain development. Attentional processing is a higher order 
cognitive behaviour fundamental to many important brain processes and is known to be 
affected in a number of human neuropsychiatric disorders. The purpose of the research 
described herein was to better understand how changes in early brain development can 
have a long lasting effect on the central nervous system relevant to the etiology of 
neuropsychiatric disorders, and to utilize a novel approach to investigate the “two-hit” 
hypothesis of psychiatric disease by probing the effects of chemically (neonatal low-
dose domoic acid [DOM] treatment) and/or environmentally (social isolation rearing) 
induced changes in attentional processing. 
 
First, adult untreated rats were used to develop a latent inhibition (LI) paradigm that 
resulted in both deficient and abnormally persistent LI. Next, utilizing both the newly-
developed LI protocol and previously established protocols for prepulse inhibition (PPI), 
the behavioural consequences of neonatal DOM administration and social isolation 
housing, both alone and in combination, were measured. Results indicated a number of 
behavioural alterations in both sexes and across all treatment groups indicating that 
neonatal DOM treatment and isolation rearing affect both of these measures of 
attentional processing although not in identical ways. Subsequently, the regional 
expression profiles of various proteins involved in dopaminergic and GABAergic 
neurotransmission were quantified by Western blot analysis to investigate the potential 
molecular alterations responsible for the observed behavioural changes. No significant 
effects on these markers were observed in any treatment group, although large inter-
individual variations were noted. A preliminary post-hoc analysis of correlations 
between changes in PPI and protein expression resulted in a number of significant 
correlations and suggested that the various experimental manipulations were 
differentially affecting the signalling pathways involved. 
 
In conclusion, both neonatal low-dose DOM treatment and social isolation rearing affect 
the development of attentional processing in rats. However, each paradigm may exert 
these effects through different neuronal signalling systems and these different systems 
may be responsible for different aspects of the behavioural changes that were observed. 
Finally, this work illustrates the potential of a novel “two-hit” method for studying the 
development of neuropsychiatric disease as well as the complex interconnected 
processes that are affected by altered brain development. 
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Chapter 1 
 
 
 
General introduction 
  
2 
 
1.1   Overview of psychiatric disease 
Psychiatric diseases represent a diverse group of disorders and illnesses which 
can be classified in a variety of ways. The current Diagnostic and Statistical Manual of 
Mental Disorders (DSM) v.5 includes a number of categories outlined in Table 1.1 
(American Psychiatry Association, 2013). Such diseases have a devastating cost to 
society with regard to the economic impact and the personal cost to those affected and 
their families. 
The cost of treating mental illness was not historically considered a global health 
priority, with focus generally centered on communicable diseases as well as non-
communicable illnesses such as cancer and cardiovascular disease. The focus on mental 
illness has increased as we have gained a better understanding of the impact and cost of 
these diseases. The cumulative global effect of mental illness on lost economic output 
has been estimated to amount to US $16 trillion in the next 20 years, equivalent to 25% 
of the global gross domestic product (GDP) for 2010 (Bloom et al, 2011). Despite the 
high personal and economic costs, treatment rates for people with mental and substance 
use disorders are low, particularly in developing countries. Even in developed countries 
with modern healthcare, treatment is typically provided many years after the disorder 
first begins (Whiteford et al, 2013). 
In Canada, mental illness is a significant economic burden with the estimated 
total cost being as high as $51 billion in 2003 (Lim et al, 2008). This includes the cost of 
both direct government funded health care services as well as the indirect cost of lost 
productivity due to disability and premature mortality (Stephens and Joubert, 2001). 
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Table 1.1   Classification of mental disorders according to the DSM v.5 
Classification Example of disorders 
Neurodevelopmental disorders Autism spectrum disorder 
Attention deficit/hyperactivity disorder 
Schizophrenia spectrum and 
related disorders 
Schizophrenia 
Schizoaffective disorder 
Bipolar and related disorders Bipolar I disorder 
Bipolar II disorder 
Depressive disorders Major depressive disorder 
Premenstrual dysphoric disorder 
Anxiety disorders Specific phobia 
Generalized anxiety disorder 
Obsessive-compulsive and 
related disorders 
Obsessive-compulsive disorder 
Body dysmorphic disorder 
Trauma and stressor-related 
disorders 
Reactive attachment disorder 
Posttraumatic stress disorder 
Dissociative disorders Dissociative identity disorder 
Depersonalization/derealization disorder 
Somatic symptom and related 
disorders 
Somatic symptom disorder 
Illness anxiety disorder 
Feeding and eating disorders Anorexia nervosa 
Bulimia nervosa 
Elimination disorders Enuresis 
Encopresis 
Sleep-wake disorders Insomnia disorder 
Narcolepsy 
Sexual dysfunction Erectile disorder 
Male hypoactive sexual desire disorder 
Gender dysphoria Gender dysphoria in children/adolescents/adults 
Disruptive, impulse-control 
and conduct disorders 
Oppositional defiant disorder 
Antisocial personality disorder  
Substance-related and 
addictive disorders 
Alcohol use disorder 
Gambling disorder 
Neurocognitive disorders Neurocognitive disorder due to Alzheimer’s disease 
Neurocognitive disorder due to Parkinson’s disease 
Personality disorders Paranoid personality disorder 
Narcissistic personality disorder 
Paraphillic disorders Voyeuristic disorder 
Exhibitionist disorder 
Other mental disorders Unspecified mental disorder due to another medical 
condition 
Medication-induced movement 
disorders and other adverse 
effects of medication 
Tardive dyskinesia 
Antidepressant discontinuation syndrome 
Other conditions that may be a 
focus of clinical attention 
Relational problems 
Abuse and neglect 
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1.2   Schizophrenia and related psychiatric disorders 
One such widespread psychiatric illness that leads to great financial and personal 
cost is schizophrenia. This complex and debilitating mental disorder is characterized by 
impairments in the perception of reality and is found in approximately 1% of the general 
population, resulting in great emotional cost to those directly affected, as well as large 
financial cost to the economy worldwide (Knapp et al, 2004; Rössler et al, 2005). The 
estimated annual cost of healthcare for those afflicted in Canada alone is over 2 billion 
dollars. When combined with the added cost of increased unemployment, lost 
productivity and early mortality, the cost is estimated to be 6.8 billion dollars (Goeree et 
al, 2005).  
Believed to arise due to a combination of genetic susceptibility and 
environmental influence (Rapoport et al, 2005), schizophrenia manifests great variability 
in symptom profiles, developmental timecourse and response to treatment (Tamminga 
and Holcomb, 2005). While past research has identified a number of genetic linkages, 
developmental risk factors (see section 1.2.3) and neurobiological elements (see sections 
1.2.4 and 1.2.5), because of the highly complex and heterogeneous nature of the 
disorder, there is still much that is unknown about schizophrenia and as a result, current 
treatments are far from adequate (see section 1.2.6). 
 
1.2.1   Clinical characteristics and symptoms 
While the term schizophrenia was first introduced by Eugen Bleuler in 1911, it is 
believed that the disorder has been present in all cultures for centuries (Tamminga and 
Holcomb, 2005). The DSM v.5 identifies a category of disorders known as 
schizophrenia spectrum and related disorders. This category includes schizophrenia, 
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schizotypal personality disorder, and other psychotic disorders that are characterized by 
the key features that define this category and make up the diagnostic criteria. The 
specific diagnostic criteria for schizophrenia are as follows: Two or more of the 
following symptoms must be each present for a significant portion of the time during a 
1-month period (delusions, hallucinations, disorganized speech, grossly disorganized or 
catatonic behaviour, negative symptoms). Additionally, at least one of the first 3 stated 
symptoms must be present. Further, diagnostic criteria state that the level of functioning 
(occupational, interpersonal, self-care) must be compromised for a significant portion of 
the time, symptoms must persist for a minimum of 6 months, schizoaffective disorder, 
depressive disorder or bipolar disorder with psychotic features have been ruled out, and 
the disturbance cannot be attributed to the physiological effects of a substance or another 
medical condition. Finally, if there is a history of autism spectrum disorder or a 
childhood-onset communication disorder, a diagnosis of schizophrenia can only be made 
in the presence of prominent hallucinations or delusions that are present for at least 1 
month, in addition to other potential symptoms (American Psychiatry Association, 
2013). 
The diagnostic criteria for schizophrenia focus on a very specific set of 
symptoms. There are, however, a wide variety of symptoms outside of those used for 
diagnosis. This variety of symptom may be experienced in a multitude of combination, 
forms and intensities by people within the clinical population. Many of these symptoms, 
though reliably observed in people with schizophrenia, are also found in other disorders 
(Baribeau and Anagnostou, 2013; Sugranyes et al, 2011; Vöhringer et al, 2013). 
Furthermore, some characteristics, such as prepulse inhibition (PPI) deficits, cannot be 
detected without specific testing (see section 1.3.4.2), but are believed to be indicative of 
6 
 
serious brain dysfunction that can manifest itself as other, more readily observed 
symptoms (Braff and Geyer, 1990; Swerdlow and Geyer, 1998).  
 Thus in practice, the symptoms of schizophrenia are generally classified into 3 
categories of positive, negative and cognitive symptoms (Khan et al, 2013; Tandon et al, 
2009). The positive symptoms of schizophrenia refer to symptoms that are present in the 
clinical population that are not seen in unaffected individuals. These symptoms include 
hallucinations, delusions, psychomotor agitation and disordered thought (Strauss et al, 
1974; Tandon et al, 2013). Hallucinations are sensory perceptions that are not present in 
reality. These perceptions can take on many forms and affect any of the senses. While 
visual, tactile and olfactory hallucinations can occur, auditory hallucinations (such as 
hearing voices) are the most common (Lewandowski et al, 2009). Delusions are false 
beliefs that are strongly and consistently maintained, even in the face of obvious 
evidence to the contrary (Appelbaum et al, 1999; Iyassu et al, 2013). A common 
example found in people with schizophrenia are delusions of grandeur, which occur 
when a person believes that they have special powers or knowledge that others do not. 
Delusions of persecution or control are also common, with the person believing that they 
are being plotted against or that others are trying to control them through various means 
(Andreasen and Olsen, 1982; Engh et al, 2010). Psychomotor agitation is observed in a 
subset of people with schizophrenia and presents as hyperactivity or increased 
stereotypic movement (Powell and Miyakawa, 2006). Lastly, disordered thought is 
perhaps one of the most common symptoms of this disease and is characterized by 
disorganized and often irrational thinking (Andreasen and Olsen, 1982). 
 The negative symptoms of schizophrenia refer to symptoms characterized by a 
lack of normal behaviours. Such symptoms include blunted affect, anhedonia, alogia and 
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social withdrawal (Buchanan, 2007; Khan et al, 2013; Strauss et al, 1974). Blunted 
affect refers to a lack of emotional reactivity and a decreased range of emotions. This 
symptom is likely related to anhedonia, another common occurrence in schizophrenia 
whereby the person experiences a decrease or inability to experience happiness or 
pleasure. Alogia is poverty of speech, where a person’s speech lacks the level of content 
seen in normal conversation, such as giving only one word answers in response to 
questions. Finally, social withdrawal is a negative symptom likely related to those 
mentioned above. If a person is unable to interact normally with others, to experience 
emotional intimacy, or to derive pleasure from those interactions, they are more likely to 
isolate themselves socially (Andreasen and Olsen, 1982; Buchanan, 2007; Erhart et al, 
2006; Kane, 2013). 
 While schizophrenia symptoms were originally classified as only positive and 
negative symptom types, cognitive symptoms are now considered to be a core 
abnormality in the disorder (Aas et al, 2014). These symptoms include deficits in 
learning, memory and executive functioning, as well as attentional deficits, a topic 
which is central to this thesis (Gold and Harvey, 1993; Lin et al, 2014; Schmidt-Hansen 
and LePelley, 2012). The term executive function is used to indicate the higher order 
cognitive functions mediated largely in the prefrontal cortex (PFC) including problem 
solving, planning, initiation, hypothesis generation, cognitive flexibility, decision 
making, abstract thinking and judgment (Aas et al, 2014). Attentional deficits are also 
commonly found. Attentional processing is a complex process that allows a person to 
filter relevant and irrelevant information, hold and manipulate that information, and 
monitor responses to stimuli (see section 1.3) (Strauss et al, 2006). 
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Although not considered sufficient to meet diagnostic criteria alone, there are a 
number of other characteristics often found within the schizophrenia population 
including altered responses to novelty (Cortiñas et al, 2008) and an altered sensitivity to 
nicotine (Brown et al, 2012; Mobascher and Winterer, 2008). 
 
1.2.2   Subtypes and comorbidities 
As detailed above, there are a large variety of symptoms and characteristics 
observed in the schizophrenia population, with many people showing vastly different 
symptom profiles although they have been given the same clinical diagnosis. Symptoms 
can also change dramatically over time, even within the same person. This clinical 
heterogeny has lead to the suggestion that perhaps what we currently define as 
schizophrenia is actually a combination of disorders that often overlap in clinical 
presentation (Kirkpatrick et al, 2001). Additionally, there are a variety of specifications 
for schizophrenia outlined by the DSM including first episode vs. multiple episodes, 
current state (acute, partial remission, full remission), and with the presence of catatonia 
(American Psychiatry Association, 2013). 
While the negative and cognitive symptoms are reliably found in people with 
schizophrenia, they are not solely seen in schizophrenia and may be present in other 
neurological disorders. This finding, combined with the fact that positive and negative 
symptoms have been found to respond differently to drug treatment, suggests that the 
different groups of symptoms may be the result of different neural abnormalities 
(Rosenzweig et al, 2005). Additionally, similarities in symptom profiles, genetic links 
and risk factors have linked schizophrenia to other disorders such as autism spectrum 
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disorder (Baribeau and Anagnostou, 2013; Sugranyes et al, 2011) and bipolar disorder 
(Vöhringer et al, 2013). 
Comorbidity between schizophrenia and other disorders is common. People with 
schizophrenia are at an increased risk for substance abuse and addiction (Regier et al, 
1990). Psychiatric comorbidities are observed among people with schizophrenia and 
occur in a significant portion of patients. While numbers can vary widely, a study by 
Buckley et al, (2009) which compiled a variety of previous results into weighted 
averages stated that anxiety disorders are one common area of comorbidity with 
estimated prevalence including 15% for panic disorder, 29% for posttraumatic stress 
disorder (PTSD) and 23% for obsessive compulsive disorder (OCD). Perhaps the most 
common comorbidity is depression with an estimated 50% of people with schizophrenia 
also suffering depression (Buckley et al, 2009). Moreover, schizophrenia also presents 
with non-psychiatric disease states. There is a frequent comorbidity between epilepsy 
and schizophrenia with the disease occurring more often in people with epilepsy than 
within the general population (Clarke et al, 2012; Kandratavicius et al, 2012; Weber et 
al, 2009). Indeed, it has been found that as many as 32% of people with epilepsy display 
some type of psychiatric comorbidity (Karouni et al, 2010) and some medications are 
effective against symptoms of both epilepsy and schizophrenia (Liang et al, 2010).  
Some disorders do not necessarily show extensive comorbidity with 
schizophrenia or a similar symptom profile, but may still be associated with similar 
deficits. Such is the case with attention deficit hyperactivity disorder (ADHD) which, 
like schizophrenia, is associated with deficits in working memory, inhibition and 
attention (Ross et al, 2000). Furthermore, ADHD-like features are more prevalent in 
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young relatives of people with schizophrenia than in the general population, indicating a 
potential further link between these two disorders (Keshavan et al, 2003).     
 
1.2.3   Neurodevelopmental origins of psychiatric disease 
Although the cause of schizophrenia is not yet known, the prominent theory is 
that it is neurodevelopmental in origin and arises due to a combination of genetic 
susceptibility and environmental factors. According to this theory, events which occur 
long before the formal onset of the illness (potentially during gestation and/or early life), 
disrupt the normal development of the central nervous system (CNS) leading to 
significant and long-lasting changes in CNS functioning (Rapoport et al, 2005). 
Although schizophrenia can, and does, occur in people who have no family 
history of the disorder, the risk increases dramatically with the degree of genetic 
closeness to a person who is afflicted (Tamminga and Holcomb, 2005). The search for 
this genetic link to has resulted in a number of genes being associated with 
schizophrenia including neuregulin-1 (NRG1) (Stefansson et al, 2002), dysbindin 
(DTNBP1) (Straub et al, 2002), catechol-O-methyl transferase (COMT) (Egan et al, 
2001) and Disrupted in Schizophrenia 1 (DISC1) (Millar et al, 2000). While all of these 
candidate genes have been linked in some way with schizophrenia, the search for a 
concrete genetic link to the disorder has thus far been unsuccessful. The search for a 
genetic link is further compounded by the fact that, given the pattern of inheritance, 
schizophrenia likely results from multiple genes of susceptibility working in 
combination with environmental factors (Tamminga and Holcomb, 2005). 
While genetic factors likely contribute to the development of schizophrenia by 
causing an individual to be more vulnerable to the illness, a variety of early life events 
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have been implicated in a higher than average risk of developing schizophrenia. These 
events include maternal illness during gestation (Mednick et al, 1988), obstetric 
complications (Cannon et al, 2002; Geddes et al, 1999) and toxin exposure (Fiore et al, 
2004). It is believed that such events can lead to subtle alterations in the functioning of 
the CNS which may result in an increased vulnerability to environmental triggers later in 
life (Lieberman et al, 2001). 
   
1.2.4   Neuroanatomy of schizophrenia and related disorders 
A large variety of neuroanatomical alterations have been observed through post-
mortem examination of the brains of people with schizophrenia, with the hippocampus 
being one area where changes are often seen, (see Table 1.2 for a list of relevant brain 
areas and their primary functions). Changes include a decrease in cell count and 
disorganization of the hippocampal pyramidal neurons (Jönsson et al, 1999), as well as 
an overall reduction in hippocampal volume (Narr et al, 2005). Enlargement of the 
ventricles and a decrease in cortical volume are also commonly found (DeLisi et al, 
1991). Other neuroanatomical changes include but are not limited to reduced expression 
of tyrosine receptor kinase (Trk) B receptors in the hippocampus and PFC (Takahashi et 
al, 2000), reduced thickness of the corpus callosum (Bachmann et al, 2003), elevated 
levels of brain derived neurotrophic factor (BDNF) in the hippocampus and anterior 
cingulate cortex (Takahashi et al, 2000), reduced gray matter volume in the anterior 
cingulate cortex and throughout the brain (Takayanagi et al, 2013) and a decrease in the 
density of mossy fibre terminal synapses (Kolomeets et al, 2007). The neuroanatomical 
changes found in people with schizophrenia are as varied as the symptom profiles, with 
some changes being found only in a subset of the clinical population and/or at a certain  
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Table 1.2   Relevant brain areas and their primary functions (Carlson, 2007; Rosenzweig 
et al, 2005). 
 
Brain area Primary function(s) 
Amygdala 
Part of the limbic system. Involved in the processing of 
emotions. 
Corpus callosum 
A large bundle of axons that connects the corresponding 
regions of the cortex in each hemisphere. Facilitates 
interhemisphere communication. 
Cortex (cerebral cortex) 
The outermost structure of the brain. Consists of sensory, 
motor and association areas and is involved in a variety of 
processes including memory, attention, creativity, 
perceptual awareness, judgement, thought, language and 
consciousness. 
Entorhinal cortex Primary hub between the hippocampus and the cortex 
Hippocampus 
Part of the limbic system. Involved in learning, memory 
and spatial navigation. 
Hypothalamus 
Involved in the regulation of the autonomic nervous system 
and control of the pituitary gland. 
Nucleus accumbens 
(NAc) 
Part of the basal ganglia. Consists of a shell and a core. 
Receives dopamine innervations from the VTA. Implicated 
in reinforcement and reward. 
Prefrontal cortex 
(PFC) 
The anterior most region of the frontal lobe. Involved in 
many aspects of cognition, personality and executive 
functioning. 
Striatum 
Part of the basal ganglia. Made up of the caudate nucleus 
and putamen. Receives input from the cortex and transmits 
to the basal ganglia. 
Substantia nigra 
Part of the basal ganglia. Plays a role in reward, addiction 
and movement. 
Thalamus 
Part of the limbic system. Projects and receives sensory 
and movement information to/from the cortex 
Ventral tegmental area 
(VTA) 
Part of the basal ganglia. Where the mesocorticolimbic 
system projections originate. Involved in reinforcement 
and reward. 
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timepoint during disease progression. While this makes the specific attribution of 
symptoms difficult, studies attempting to link specific neurological changes to specific 
disease characteristics are ongoing (Brambilla et al, 2013; Palaniyappan et al, 2012; 
Takayanagi et al, 2013). 
 
1.2.5   Neurochemistry of schizophrenia and related disorders 
Although the cause of schizophrenia is not yet known, current research suggests 
that alterations in several neurotransmitter systems, notably the dopaminergic and 
glutamatergic systems, are likely involved in the profile of symptoms that have been 
described.  
 
1.2.5.1   The dopamine hypothesis 
Dopamine (DA) was the first neurotransmitter to be identified as playing a role 
in the symptoms of schizophrenia, with the DA hypothesis of schizophrenia stating that 
the positive symptoms of the disorder are caused by the hyperfunction of the DA system 
(Carlsson and Lindqvist, 1963). The reasoning for this early attention towards DA is 
based on two findings: Firstly, it was discovered that high doses of the DA agonist 
amphetamine produce psychotic-like symptoms similar to those seen in schizophrenia, 
in people unaffected by the disorder. Amphetamine will also exacerbate such symptoms 
in a person already experiencing schizophrenia induced psychosis (Lieberman et al, 
1987). Secondly, it was found that many of the drugs that were successful in treating the 
symptoms of schizophrenia were drugs that acted by blocking DA receptors (Matthysse, 
1973). A variety of drugs which act on the DA system have subsequently been used to 
treat schizophrenia including the older typical antipsychotics which were more effective 
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at blocking D2 receptors (Seeman and Lee, 1975) and newer atypical antipsychotics 
which have a greater affinity for the D3/4 receptors (Jardemark et al, 2002). 
In more recent years, our understanding of the role of DA dysfunction in 
schizophrenia has become increasingly complex. The DA theory of schizophrenia was 
reformulated to take into account findings of an overall imbalance in DA across the 
brain with hyperactivity in the subcortical regions and hypoactivity in the cortical 
regions (Davis et al, 1991; Knable and Weinberger, 1997). It was also suggested that 
this combined hypofrontality with hyperactivity in the nucleus accumbens (NAc) may be 
due to the involvement of the excitatory neurotransmitter glutamate (Glu) (Glahn et al, 
2005).  
More recent evidence now points to the involvement of the nigrostriatal pathway 
as a predominant source of DA dysregulation (Kuepper et al, 2012). Furthermore, 
evidence from translational research including studies in mice with a developmental 
overexpression of D2 receptors (Kellendonk et al, 2006) and studies of people declared 
high risk for the future development of schizophrenia (Howes et al, 2009), have 
suggested that excess DA may be present in the prodromal phase of disease development 
and therefore be an early pathological condition leading to irreversible brain 
dysfunction. See section 1.3.3.1 for more on DA receptors and pathways. 
 
1.2.5.2   The glutamate hypothesis 
While the early theories of neurological dysfunction in schizophrenia centered on 
the DA system, it is now know that other systems are implicated in the pathogenesis of 
the disorder. Altered functioning of the Glu system has been implicated in symptoms of 
schizophrenia, with the Glu hypothesis being proposed following the observation that 
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the administration of N-methyl-D-aspartate (NMDA) receptor antagonists produced 
schizophrenia-like symptoms in healthy people (Krystal et al, 1994; Malhotra et al, 
1996; Newcomer et al, 1999). In addition, administration of NMDA receptors 
antagonists worsens positive and cognitive symptoms in people with schizophrenia 
(Lahti et al, 1995; Malhotra et al, 1997). 
According to the Glu hypothesis, some symptoms of schizophrenia may be the 
result of Glu hypofunction, particularly in the PFC (Olney and Farber, 1995). 
Interconnections between DA and Glu are common in many areas of the CNS such as 
the mesocorticolimbic system (Laruelle et al, 2005), the hippocampus (Lisman and 
Otmakhova, 2001) and between glutamatergic afferents and subcortical dopaminergic 
nuclei (Lisman and Grace, 2005). It is therefore possible, and even likely, that the 
neuropathology of schizophrenia is the result of an altered interaction between both Glu 
and DA systems, with one of the most common theories being that hypofunction of the 
Glu system (particularly within the PFC) results in hyperactivity of the mesolimbic DA 
neurons (Coyle, 2006). It is important to keep in mind however, that other 
neurotransmitters have been implicated in these pathways, with γ-aminobutyric acid 
(GABA) in particular, being thought to play an important role. 
Investigation into the involvement of a variety of neurotransmitter systems in 
schizophrenia is essential, not only to learn more about this disorder, but to pursue 
potential new therapeutic targets that might impact the large variety of symptoms 
(Merritt et al, 2013). Using the Glu systems as a therapeutic target is also an area of 
great interest because the commonly prescribed DA antipsychotics have little to no 
effect on the negative and cognitive symptoms of schizophrenia, which are important 
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factors of successful social and functional treatment outcomes (Javitt, 1999; Ventura et 
al, 2009). 
 
1.2.6   Current therapies 
Therapies for schizophrenia focus on eliminating the symptoms of the disease, 
with antipsychotic medication being the cornerstone and first-line of treatment. 
Although a variety of medications are currently available to treat schizophrenia and new 
ones continue to be developed, issues of tolerability, effectiveness, safety and patient 
compliance are predominant.  
Both older “typical” antipsychotics and newer “atypical” antipsychotics have 
extensive and serious side effect profiles including movement disorders, significant 
weight gain, sedation, sexual dysfunction and cardiac issues (Leucht et al, 2013). These 
side effects, combined with difficulty in finding the optimal medication and dose for a 
given person often leads a patient to stop treatment, with an estimated 84% choosing to 
discontinue their medication at some point (Kreyenbuhl et al, 2011).  
Long-acting injectable (LAI) antipsychotic treatment is one option for dealing 
with patient non-compliance. However, because of issues with medication intolerance 
and symptom stabilization, LAI is recommended for use only in a sub-population of 
people, generally those with a history of non-compliance, frequent relapses or who are 
determined to pose a risk to others. Additionally, LAI may be used in cases where a 
person demonstrates a low level of insight about their illness and their need for 
treatment, or if the LAI is requested by the person (Llorca et al, 2013). 
One novel research path attempting to improve the outlook for those with 
schizophrenia is the use of pharmacogenetics to predict the response of patients to 
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various medications. While studies have identified some genomic variants of candidate 
genes that may be important in the way a person responds to treatment, this research is 
still in the early stages and not ready for clinical implementation (Tsermpini et al, 2014). 
The above discussion has focused solely on treatment of the positive symptoms 
of schizophrenia because they produce the more dramatic occurrences that often lead to 
a person seeking treatment, and generally must be stabilized with medication before 
other symptoms can be addressed. Currently used antipsychotics are largely ineffective 
for the treatment of negative and cognitive symptom. However, the negative and 
cognitive symptoms of schizophrenia are also debilitating and must be addressed in 
order for a person to have a good disease outlook (Erhart et al, 2006). Current research 
is focusing on modulation of different targets (e.g. NMDA receptors) with the potential 
of producing treatment for the negative and cognitive symptoms of schizophrenia, as 
well as producing drugs that are safer and better tolerated (see Cioffi, 2013 for review). 
Other non-pharmacological forms of therapy such as cognitive behavioural 
therapy have also shown some success but are generally only available once psychotic 
symptoms have stabilized (Jauhar et al, 2014). It is possible that some combination of 
medication(s) and therapy will be beneficial to some patients (Lin et al, 2014). 
While the outlook for those people affected by schizophrenia has improved 
somewhat, a diagnosis of this disease is still likely to result in substantial disability and 
potentially, in reduced life expectancy due to suicide (Caldwell and Gottesman, 1990; 
Radomsky et al, 1999). For this reason, further research is desperately needed not only 
to discover and test new treatments, but to learn more about what causes this devastating 
disease. For the foreseeable future, much of this research will be conducted in pre-
clinical animal models. The research described in this thesis will utilize two such animal 
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models, both alone and in combination. These and other current rodent models of 
schizophrenia are discussed in detail in section 1.5. It is, however, first necessary to 
describe two bodies of literature that are fundamental to the work in this thesis, namely 
attentional processing and the neurotoxin domoic acid (DOM). 
 
1.3   Attentional processing 
The brain has inherent limitations to the amount of information that can be 
processed at any given time (DeFockert, 2013). While attending to incoming 
information can be accomplished in both overt (shifting gaze to bring something of 
interest into view) and covert (choosing to listen to one voice over others in a group 
conversation) manners, in order for any person or animal to function effectively in 
everyday life it is necessary to filter that incoming information and select which is 
relevant for further processing (Kinchla, 1992). Attentional processing and information 
processing are the mechanisms that allow the brain to attend to and process the myriad 
of incoming information that we deal with on a day-to-day basis. In its simplest form, 
“attention” can be considered the gateway to the brain (Cohen, 1993).  
Attention is not a single phenomenon but is a term used to refer to a variety of 
complex processes that operates at different levels of awareness. These include the 
ability to sustain attention over time, the ability to shift attention, the ability to attend to 
a variety of incoming information, or the ability to attend selectively to a subset of 
environmental information while filtering out extraneous stimuli (Bushnell and Strupp, 
2008). Attention can also be classified as deliberate/controlled or passive/reflexive 
(Johnston and Dark, 1986). Thus, while we are conscious of much of the attentional 
processing that occurs, other information is believed to be processed “pre-attentively” 
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meaning that it is processed automatically, without conscious attention (Kinchla, 1992). 
This pre-attentive processing generally occurs within the first 100 ms after a stimulus is 
presented (Ellenbroek, 2004). Prepulse inhibition is one way to measure this automatic 
form of attentional processing (see section 1.3.4.2)  
 
1.3.1   Attentional processing in mental illness 
Attentional processing is a complex process made up of many components 
including alertness/arousal, focused attention, selective attention, divided attention and 
sustained attention/vigilance. Attentional deficits can arise from improper functioning in 
any one or in a combination of these processes (Strauss et al, 2006). Changes in the way 
the brain regulates attention and processes information have been observed in a number 
of disorders including Alzheimer’s disease (Parasuraman et al, 1992), Parkinson’s 
disease (Wright et al, 1990), bipolar disorder (Burdick et al, 2009), and schizophrenia 
(Nuechterlein and Dawson, 1984), as well as due to ageing (Davies et al, 1992). 
Deficits in attention have also long been identified as a core feature in 
schizophrenia and related neuropsychiatric disorders (Anscombe, 1987; Braff, 1993; 
Cornblatt et al, 1985; Nuechterlein and Dawson, 1984). Deficits in attention are present 
throughout the course of the illness in schizophrenia, can be found before the formal 
onset of the illness and can persist through treatment (Cornblatt and Keilp, 1994). 
Additionally, impaired attention can often be observed in the relatives of people with 
schizophrenia and has been considered as one of the more robust markers of the eventual 
emergence of the illness within those relatives (Erlenmeyer-Kimling et al, 2000; Parnas 
et al, 1982). 
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While the positive symptoms of schizophrenia are generally considered to be the 
most dramatic, often garner the most attention, and form the basis for much of the 
diagnostic criteria (see section 1.2.1) as well as therapeutic intervention (see section 
1.2.6) they may not be in fact core to the disorder. It has been suggested that a failure in 
the ability to reduce the processing of irrelevant incoming information leads to such 
information being afforded undue attention, resulting in the development of positive 
symptoms. It has therefore been hypothesized that the positive symptoms of 
schizophrenia may actually be a consequence of the impairments recognized as 
cognitive symptoms such as disrupted LI and PPI (Schmidt-Hansen and LePelley, 2012).   
 
1.3.2   Brain areas relevant to attentional processing 
A variety of cortical and subcortical areas have been implicated in attentional 
processing with the specific brain areas, pathways and neurotransmitters systems 
involved being dependent on which aspect of attentional processing is being considered 
(Hopfinger et al, 2000). Specific brain areas known to be involved in attentional 
processing that are relevant to the work in this thesis include the PFC, the hippocampus, 
the NAc, the ventral tegmental area (VTA), the amygdala and the entorhinal cortex (EC) 
(Cohen, 1993). See Table 1.2 for a brief description of the main role(s) of each area 
within the brain and sections 1.3.4.1 and 1.3.4.2 for more on the postulated role of these 
areas in the measures of attentional processing used in this thesis. 
 
1.3.3   Neurotransmission and attentional processing 
A number of neurotransmitter systems have been implicated in attentional 
processing (Agnoli et al, 2013; Evans and Drobes, 2009; Klinkenberg et al, 2011; Meck 
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and Williams, 2003; Pehrson et al, 2013; Sarter et al, 2003) including the DA, Glu and 
GABA systems.  
 
1.3.3.1   Dopamine 
Dopamine is a catecholamine neurotransmitter, a group which belongs to the 
larger classification of monoamines (Beaulieu and Gainetdinov, 2011). Widely 
distributed throughout the brain, DA plays important modulatory roles and has been 
implicated in a diverse array of processes including motor control, neuroendocrine 
function, cardiovascular control, cognition, emotion and reward (Dziedzicka-
Wasylewska, 2004). 
In the mammalian brain, four major DA pathways have been identified; the 
nigrostriatal, tuberoinfundibular, mesocortical and mesolimbic pathways (Prakash and 
Wurst, 2006). The nigrostriatal pathway projects from the substantia nigra to the dorsal 
striatum and is an essential component of the extrapyramidal motor system (Prakash and 
Wurst, 2006). The tuberoinfundibular/ tuberohypophysial pathway originates in the 
periventricular and arcuate hypothalamic nuclei and projects to the median eminence of 
the hypothalamus, as well as to the intermediate and posterior lobes of the pituitary 
gland (Beaulieu and Gainetdinov, 2011). The mesocorticolimbic pathway consists of the 
mesolimbic and mesocortical pathways respectively. The mesocortical DA pathway 
originates in the VTA but extends to the frontal cingulate cortex and the EC. The 
mesolimbic pathway also arises in the VTA, extending to the ventral striatum and parts 
of the limbic system. It is thought to be involved in motivated behaviour and reward. 
These projections, illustrated in Figure 1.1, are thought to play a role in emotionality, 
motivation and cognitive functions (LeMoal and Simon, 1991). Taken together, these 
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Figure 1.1   A midsagittal diagram of the human brain illustrating the major DA 
pathways. Figure reprinted with permission from CNSforum.com. 
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pathways are often referred to as the reward pathway and play an important role in 
mediating reward, including the rewarding effects of drugs. Accordingly, this pathway is 
often implicated in drug addiction (Dziedzicka-Wasylewska, 2004). 
The physiological actions of DA are mediated by the 5 types of metabotropic, G-
protein coupled receptors that are divided into two broad sub-families: D1-like and D2-
like receptors (Andersen et al, 1990; Beaulieu and Gainetdinov, 2011; Kebabian and 
Calne, 1979). The D1-like receptor group which includes D1 and D5 receptor subtypes, 
are coupled with adenylyl cyclase and are excitatory in nature (Tohyama and Takatsuji, 
1998), while the D2-like subtype includes D2, D3 and D4 receptors, are often also 
coupled to adenylyl cyclase but are inhibitory in nature (Tohyama and Takatsuji, 1998). 
As with other monoamine neurotransmitters, DA generally acts on neuronal circuits via 
relatively slow modulation of the fast neurotransmission that is mediated by Glu and 
GABA (Beaulieu and Gainetdinov, 2011). 
 Because of the importance of DA in regulating many aspects of brain functioning 
and the widespread network of DA projections, it is unsurprising that a number of severe 
mental disorders have been associated with the dysfunction or degradation of the DA 
system. For instance, Parkinson’s disease is believed to be caused by the degeneration of 
DA neurons in the substantia nigra and the subsequent loss of DA in the striatum 
(Hornykiewicz, 1998; Prakash and Wurst, 2006). Dopamine dysregulation in the 
mesocorticolimbic system has been linked to a number of problems including drug 
addiction (Kelley and Berridge, 2002), depression (D’Aquila et al, 2000) and 
schizophrenia (Sesack and Carr, 2002). Dysfunction in of the DA system has also been 
implicated in a variety of aspects of attentional processing (Nieoullon and Coquerel, 
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2003) with particular focus devoted to the role of the DA system in LI behaviour (see 
section 1.3.4.1 for more) (Young et al, 2005). 
 
1.3.3.2   Glutamate 
Glutamate is the principal excitatory neurotransmitter in the mammalian CNS 
(Ozawa et al, 1998). Glutamatergic pathways and synapses are found throughout the 
brain and nearly all neurons can be excited by Glu (Curtis and Johnston, 1974). Due to 
this widespread involvement in many aspects of CNS function, it is no surprise that 
proper functioning of the Glu system is of critical importance. This is particularly true 
during development where excitatory amino acids (EAAs) like Glu are involved in a 
variety of processes including synaptogenesis, dendritic and axonal structure, neuronal 
survival and synaptic plasticity. During such times of rapid brain growth and change, 
even small alterations can have significant and long lasting effects, both structurally and 
functionally. While underactivity can be detrimental, resulting in development being 
delayed or even permanently disrupted, overactivity can be equally as dangerous, 
resulting in neuronal alteration and cell death (McDonald and Johnston, 1990). 
Glutamate receptors are broadly divided into both ionotropic (iGluR) and 
metabotropic (mGluR) types. Ionotropic Glu receptors are further divided into three 
distinct types, NMDA receptors, α–amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
(AMPA) receptors and kainate (KA) receptors. Ionotropic receptors are cation-specific 
ion channels composed of 4 large subunits forming a central ion pore. At these 
receptors, the binding of Glu (or an analogue) results in a conformational change to the 
receptor, allowing sodium (Na
+
), potassium (K
+
) and/or calcium (Ca
2+
) ions to pass 
through the pore (Ozawa et al, 1998; Simeone et al, 2004; Traynelis et al, 2010). The 
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metabotropic receptors are linked through G-proteins to second messenger molecules 
and are further divided into three groups based on structure and function. Group I 
consists of mGluR1 and mGluR5 receptors, Group II consists of mGluR2 and mGluR3 
receptors and Groups III consists of mGluR4, 6, 7 and 8 receptors. Group I receptors are 
located primarily post-synaptically and activate phospholipase C, thereby producing 
diacylglycerol and inositol triphosphate as second messengers. Receptors from Group II 
and III are found primarily pre-synaptically and are negatively coupled to adenylyl 
cyclase. These intracellular messengers can regulate a variety of processes within the 
cell, including the modulation of voltage-gated and ligand-gated ion channels, as well as 
gene transcription (Meldrum, 2000; Ozawa et al, 1998; Simeone et al, 2004). 
In addition to being involved in normal functions such as synaptic plasticity, 
altered Glu functioning has been found to play a role in many diseases and disorders 
such as Huntington’s disease, Parkinson’s disease, seizure disorders, Alzheimer’s 
disease, depression and schizophrenia (Bettler and Mulle, 1995; Niciu et al, 2013; Olney 
and Farber, 1995). It is perhaps unsurprising then, that given the symptom profiles of 
some of these disorders, the Glu system has been found to play an important role in 
many aspects of attentional processing. Among a host of other observed changes, 
administration of NMDA receptor antagonists has been found to produce impairments in 
attention in healthy human subjects (Krystal et al, 1994) and animals (Dai and Carey, 
1994). A more recent study by Pehrson et al, (2013) found that systemic administration 
of an NMDA receptor antagonist impaired performance on attention tasks in a dose-
dependent manner, indicating that these receptors are critical for at least some aspects of 
proper attentional processing. The Glu systems can also influence attentional processing 
via its effect on other neurotransmitter systems. For example, Glu receptors within the 
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NAc are able to mediate the release of acetylcholine (ACh) within the PFC (Zmarowski 
et al, 2007). 
 
1.3.3.3   GABA 
Like Glu, GABA is an amino acid neurotransmitter found throughout the CNS. 
However, in contrast to Glu, GABA is inhibitory in nature (except during gestation in 
humans and gestation and the first week of life in rats; see below). GABA is the primary 
inhibitory neurotransmitter in the mammalian CNS, playing an important role in the 
regulation of neuronal excitability throughout the CNS (Kumar and Kuppast, 2012). 
GABA receptors are widely distributed throughout the brain and have particularly high 
concentrations in the cortex, hippocampus, basal ganglia, thalamus, cerebellum, and 
brainstem (Kumar and Kuppast, 2012). 
GABA receptors are classified into 3 subtypes; GABAA, GABAB and GABAC 
(Tohyama and Takatsuji, 1998). GABAA and GABAC receptors are ionotropic receptors 
and exert their inhibitory effect by increasing the passage of Cl
-
 across the membrane (in 
the case of mature neurons). This results in the hyperpolarisation of the postsynaptic cell 
(Chebib and Johnston, 1999; Harris and Allan, 1985). The GABAA receptor directly 
gates the Cl
-
 ionophores; it is selectively blocked by the alkaloid bicuculline and has 
modulatory binding sites for benzodiazepines, barbiturates, neurosteroids and ethanol 
(Chebib and Johnston, 1999). Less is known about the GABAC receptor which is 
pharmacologically different than GABAA (Bormann and Feigenspan, 1995). There is 
currently some debate on the classification of GABAC receptors as to whether they 
should be considered their own class of GABA receptors or if they should simply be 
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considered a subclass of GABAA receptors (Bormann and Feigenspan, 1995; Bormann, 
2000; Kumar and Kuppast, 2012). 
 GABAB receptors are metabotropic (coupled to G-proteins) and therefore 
indirectly alter membrane ion permeability and neuronal excitability. The activation of 
these receptor complexes produce a variety of effects including the inactivation of 
voltage dependent Ca
2+ 
channels and the gating of K
+
 ion channels. The GABAB 
receptors are widely distributed within the CNS and the peripheral nervous system and 
modulate the release of neurotransmitters by producing slow, prolonged inhibitory 
signals (Chebib and Johnston, 1999; Kumar and Kuppast, 2012). 
 There is a critical shift in the functioning of the GABA system that occurs during 
development. In the mature brain GABA is inhibitory, but in the developing brain 
GABA is often excitatory due to intracellular changes in Cl
-
 homeostasis. In immature 
neurons, the cotransporter for Cl
-
 (designated NKCC1) moves Cl
-
 into the cell, resulting 
in a high intracellular Cl
-
 concentration. As the neurons develops further, a different 
cotransporter (KCC2) is expressed which moves Cl
- 
out of the cell resulting in a lower 
intracellular Cl
-
 concentration. Because of this effect, the equilibrium potential for Cl
-
 is 
more positive in immature cells than it is in adult cells, and hence the opening of Cl
- 
channels is depolarizing such that GABA has the potential to excite the neurons to the 
point of firing (Ben-Ari et al, 2012; Cherubini et al, 1991). As brain development 
progresses, the equilibrium potential for Cl
-
 shifts such that GABA receptor activation 
results in a hyperpolarizing influx of Cl
-
. It is believed that this shift changing GABA 
from an excitatory to an inhibitory transmitter is complete by the middle of the second 
week of postnatal life in the rat, although the precise age may be dependent on the sex of 
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the animal, with the shift being further delayed in males compared to females (Nuñez 
and McCarthy, 2007). 
Considering the widespread role of GABA in the CNS, it is no surprise that 
GABA system dysfunction has been implicated in a variety of disorders including 
anxiety disorders, depression, autism and schizophrenia. Specifically, reductions in 
GABA transmission may be widespread in certain diseases like schizophrenia, 
potentially leading to a decrease in inhibitory neurotransmission (Rudolph and Möhler, 
2014). Such changes in inhibition within the brain often result in alterations to 
attentional processing. A study by Pehrson et al, (2013) found that the blockade of 
GABAA receptors resulted in dose-dependent impaired performance in attentional 
processing. This finding is supported by other studies that also concluded that proper 
functioning of the GABA system, specifically with regard to the GABAA receptors 
within the PFC, is a required component in attentional processing (Murphy et al, 2012; 
Paine et al, 2011).  
 
1.3.3.4   Other neurotransmitter systems 
While a complete description of all the neurotransmitter systems implicated in 
attentional processing is beyond the scope of this thesis, it is important to recognise that 
other systems are involved. These include the norepinephrine, serotonin and cholinergic 
systems which are implicated to greater or lesser degrees, depending on the aspect of 
attentional processing in question (Evans and Drobes, 2009; Gasbarri and Pompili, 2014; 
Klinkenberg et al, 2011; Logue and Gould, 2013). 
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1.3.4   Methods for assessing attentional processing 
As there are a variety of aspects to attentional and information processing, 
(outlined in section 1.3) so are there a variety of ways to test these phenomena. The test 
chosen depends on a number of factors including what is being assessed (e.g. sustained 
attention, selective attention, attention shifting) and the subject being tested (e.g. human, 
rodent) (Bushnell, 1998). As with any unobservable cognitive process, assessment of 
attention requires researchers to quantify something which can be observed and 
measured, such as behavior. The assessment of attention is further complicated because 
tests of attention typically measure more than one component of the process. 
Furthermore, attentional processing cannot be assessed in isolation without taking into 
account the sensory processes required to detect the incoming information and the 
response modality (e.g. motor or verbal) required to convey a result. Finally, many 
attention tasks overlap with other processes such as executive functioning and working 
memory. Because of these factors, many of the existing neuropsychological tests of 
attention actually assess a combination of attention, executive function, switching, 
inhibition and memory (Strauss et al, 2006). 
A number of methods exist for assessing attentional and information processing 
in humans and other animals including eye tracking and orienting behavior, paper and 
computer based tests such as the Conners’ Continuous Performance Test II (measures 
sustained attention and response inhibition) and the Paced Auditory Serial Addition Test 
(assesses working memory, divided attention and information processing speed). 
Behavioural tests are usually used in animals (see Bushnell and Strupp, 2009; Bushnell, 
1998; Strauss et al, 2006 for review) although some like latent inhibition (LI) and PPI, 
(the two tests of attentional and information processing used in this thesis) can be 
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applied to both humans and other animals. Observed across many different species in 
including rats and humans, LI and PPI are reliably disrupted in a variety of 
neuropsychiatric disorders including schizophrenia (Baruch et al, 1988; Braff et al, 
1978; Kohl et al, 2013) and have become widely used in studies of the neural alterations 
in schizophrenia as well as in the search for useful animal models of the disorder 
(Ellenbroek et al, 1996; Koch, 2013; Lubow, 1989; Moser et al, 2000; Zuckerman et al, 
2003). 
 
1.3.4.1   Latent inhibition 
Latent inhibition is a normal cognitive process whereby previous non-reinforced 
experience with a particular stimulus impairs the ability of that stimulus to subsequently 
enter into new associations. According to Lubow (1989), who first proposed the 
conditioned attention theory of LI, when a conditioned stimulus (CS) is followed by no 
consequence, the animal learns to ignore that stimulus. As a result, during later pairing 
of the CS with an unconditioned stimulus (US) the animal fails to attend to the CS and 
associative learning is impaired. Latent inhibition is an important adaptive mechanism 
for the processing of incoming information as normally, the ability to ignore a stimulus 
that was irrelevant in the past would be beneficial (Lubow, 1997). Observed across 
many different species, including rats and humans (Lubow and Gewirtz, 1995), LI is 
reliably disrupted in humans with schizophrenia (Baruch et al, 1988) and has become 
widely used in studies of the neural alterations of various psychiatric disorders, as well 
as in the search for useful animal models of such disorders (Lubow, 1989, 2005; Moser 
et al, 2000). While early studies focused on experimental manipulations and disorders 
that produced a lack of LI, more recently it has been suggested that different aspects of 
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the observed changes in LI (namely the disruption of LI vs. the abnormal persistence of 
LI) in the clinical population and within animal models might illustrate different aspects 
and symptom categories of schizophrenia (Weiner and Arad, 2009; Weiner, 2003). The 
use of LI in rodent studies of psychiatric disease is discussed in greater detail in the 
Introduction to Chapter 3 of this thesis (section 3.1).  
Latent inhibition can be assessed in a number of ways. In animals, the most 
common methods are through a conditioned taste aversion (CTA) task or a lick 
suppression conditioned emotional response (CER) task. In a CTA task the degree of 
aversion to an inert substance is measured both before and after that substance is paired 
with one that induces nausea. The animals will then display a different degree of interest 
in the inert substance, depending on the pre-exposure to that substance. In a lick 
suppression CER task, a particular stimulus such as a tone is paired with a mild shock 
that will affect the ability of the tone to suppress later drinking behaviour depending on 
the animal’s previous, non-reinforced experience with the tone during the pre-exposure 
phase (Figure 1.2). In this case, the presence of LI is determined by a finding of 
significant differences in performance between the animals who received pre-exposure 
to the stimulus, and those that did not (Alves and Silva, 2001; Joseph et al, 1993; 
Lehmann et al, 2000; Lubow, 1989; Zuckerman and Weiner, 2003; Zuckerman et al, 
2003). 
Experimental data suggest that LI may be controlled by a neural circuit involving 
the hippocampus, the EC, the NAc, and the mesolimbic dopaminergic projection from 
the VTA to the NAc (Schmajuk et al, 2001; Weiner and Feldon, 1997; Weiner, 1990). 
While the precise neural circuitry underlying LI is not currently known, a small number  
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Figure 1.2   To assess LI using a lick suppression conditioned emotional response task, 
animals in the pre-exposure (PE) group receive experience with the tone stimulus, while 
the animals in the non pre-exposure (NPE) group do not. All animals received pairings 
of the tone with a foot shock. The normal resulting behavior is that, when tested later on, 
animals in the NPE group will display suppressed drinking behaviour when a tone is 
played (no LI). The animals in the PE group will display no/reduced drinking 
suppression when a tone is played (LI). 
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of theoretical models have been proposed with the most well characterised being the 
Schmajuk-Lam-Gray (SLG) model proposed by Schmajuk et al, (1996) and the 
switching model proposed by Weiner, (1990).  
A simplified diagram of the SLG model is illustrated in Figure 1.3. According to 
this model, a variety of implicated brain areas are connected by excitatory Glu 
projections as well as inhibitory GABA and DA projections. The SLG model thus  
focuses on using a variety of techniques including lesion studies, pharmacological 
manipulations and computer modeling to determine the neurochemical associations 
between the various brain regions and how such connections may influence LI 
(Schmajuk et al, 1996, 2001). 
According to this model, LI is produced due to a series of events beginning when 
the animal first experiences the non-reinforced stimulus. Incoming sensory information 
leads to increased activity within the EC and thus the hippocampus, as the prediction of 
the CS by context increases. This leads to increased activity within the shell of the NAc, 
which leads to decreased activity within the VTA. Decreased activity within the VTA 
leads to a decrease in the thalamus via two pathways, firstly due to a decrease in activity 
in the core of the NAc, and thus, an increase in activity within the ventral pallidum, 
which leads to a decrease in the activity in the thalamus. Secondly, DA connections 
from the VTA to the thalamus also contribute to decreased activity. This decreased 
activity in the thalamus produces a retarding of the formation of the CS-US association 
within the amygdala (Schmajuk et al, 1996, 2001). The experiments used to construct 
this model utilized conditioned suppression experiments (similar to the ones used in 
Chapters 2 and 3 of this thesis), thus LI was evaluated based on the amount of 
behavioural suppression observed in the presence of a tone CS. Since this suppression   
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Figure 1.3   A simplified diagram illustrating the neural circuitry of the SLG model of 
attentional processing in latent inhibition. Brain areas are represented by boxes and the 
putative connections between those areas are illustrated by arrows with implicated 
neurotransmitter system stated. Solid lines indicate direct connections, dashed lines 
indicate indirect actions. Neurotransmitters include glutamate (Glu), dopamine (DA) and 
GABA. Excitatory pathways are designated by a +, inhibitory pathways are designated 
by a -. The nucleus accumbens is designated by NAc. Adapted from (Schmajuk et al, 
2001). 
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theoretically reflects the strength of fear response, it was postulated that the strength of 
the conditioned fear response was regulated within the amygdala (Killcross et al, 1997). 
The switching model, first proposed by Weiner (1990) is another theoretical 
model of LI circuitry. However, in contrast to the SLG model which focuses primarily 
on neural connections, the basis of the switching model is that LI is controlled by a 
“switching mechanism” executed within the NAc, based on inputs from a variety of 
brain areas (see Figure 1.4). The model was proposed based on earlier findings which 
indicated that administration of drugs that affect the DA system also showed an effect on 
LI, but only when administered during the conditioning phase and not the pre-exposure 
phase (Weiner et al, 1981, 1984, 1988). It was thus proposed that an explanation of LI 
behaviour cannot be limited to processes that occur during the initial exposure to a CS, 
but may be due to separate and/or additional processes occurring during the conditioning 
phase of the CS-US pairing (Weiner, 1990). 
According to this model, when an animal experiences a situation with the 
potential to produce LI, they experience two independent and conflicting experiences; 
stimulus-no event (during pre-exposure) and stimulus-reinforcement (during 
conditioning). These experiences compete for expression. So while the animal may learn 
that the stimulus is irrelevant during pre-exposure, it is during the conditioning stage that 
the irrelevance is manifested and the animal (if demonstrating LI) continues to treat the 
stimulus as irrelevant despite the fact that it now signals an outcome (Weiner, 2003). 
Latent inhibition is therefore the result of the animal remaining (during conditioning) 
under the control of the “CS- no US” relationship established during the pre-exposure 
phase.  
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Figure 1.4   A simplified diagram illustrating the brain regions and pathways involved in 
LI according to the switching model. Adapted from (Weiner, 2003). 
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The hippocampus and the NAc are the primary brain areas implicated in the 
switching theory, with the hippocampus computing the association of the incoming 
stimulus and then either inhibiting or activating a mechanism within the NAc which 
“switches” the animal’s behaviour, based on the context determined by previous 
behaviour with that stimulus. If the animal has previous experience with a stimulus, the 
hippocampus assigns a low attentional processing value to the stimulus, inhibiting the 
switching signal of the NAc. In this case, the animal will continue to respond to the 
stimulus according to past experience, namely, that there is no CS-US association. 
However, if the input from the hippocampus indicates a different context (lowering the 
effect of stimulus pre-exposure), or if the input from the amygdala indicates a strong 
relationship between the CS and US (higher association) then the switching signal 
within the NAc will be activated and the animal will respond according to stimulus-
reinforcement (Weiner and Feldon, 1997; Weiner, 1990, 2003). 
While it shares many similar characteristics with the SLG model (namely many 
of the brain areas and primary neurotransmitter systems believed to be involved) the 
switching model is unique in that it offers a potential explanation for the two types of LI 
abnormalities that can be observed in experimental animals (the disruption of LI and the 
abnormal persistence of LI). Inherent in the explanation provided by the switching 
model for this phenomenon is the theory of functional differences between the core and 
the shell of the NAc and their role in LI behaviour. Namely, that the pathway from the 
EC to the NAc shell is responsible for the “no switch” signal, which is responsible for 
inhibiting the switching mechanism of the NAc core, through the VTA (see Figure 1.4). 
Support for this theory is indicated by the finding that damage to the NAc shell disrupts 
LI and damage to the core produces abnormally persistent LI. Furthermore, this 
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occurrence is imitated by damage to the areas of input, where damage to the EC disrupts 
LI and damage to the hippocampus and the amygdala produce abnormally persistent LI 
(Weiner, 2003). Finally, the importance of DA functioning within the NAc is pivotal to 
the switching theory of LI circuitry, as the disruption of LI caused by the administration 
of amphetamine is due to the increased activation of the NAc, and the resulting 
activation of the switching response (thus identifying a relationship between the CS and 
US). Consequently, DA blockade results in the abnormal persistence of LI by preventing 
the elimination of the LI behaviour by blocking the “switching” ability (Weiner, 2003). 
 
1.3.4.2   Prepulse inhibition  
Prepulse inhibition is the normal suppression of the startle reflex that occurs 
when the startling stimulus (usually auditory) is preceded by a less intense, non-startling 
stimulus (see Figure 1.5) (Graham, 1975). This behaviour can be used to detect deficits 
in sensorimotor gating suggestive of the inability to properly filter incoming sensory 
information, which is an early stage of attentional processing (sometimes called pre-
attentional processing, see section 1.3) (Hazane et al, 2009; Swerdlow et al, 2000; 
Uehara et al, 2009). It has been proposed that PPI is due to a gating mechanism that 
protects the ongoing processing of the present stimulus from disruption by other 
incoming stimuli (Koch and Schnitzler, 1997). Prepulse inhibition changes have been 
observed in a number of clinical disorders including Huntington’s disease (Swerdlow et 
al, 1995), seizure disorders (Pouretemad et al, 1998), Tourette syndrome (Castellanos et 
al, 1996; Swerdlow et al, 2001b), OCD (Swerdlow et al, 1993) and schizophrenia (Braff 
et al, 1978; Ludewig et al, 2003; McDowd et al, 1993; Parwani et al, 2000). 
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Figure 1.5   Prepulse inhibition in a normal animal. Startle is lowered when the pulse is 
preceded by a prepulse. 
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The behavioural response to auditory startle itself is controlled by structures 
located in the brainstem, but the inhibition of the startle circuit is believed to be 
mediated by input from the forebrain (Weiss and Feldon, 2001). While the precise brain 
mechanisms underlying the mediation of PPI are not known, a number of models have 
been proposed (Fendt et al, 2001; Koch and Schnitzler, 1997; Koch, 1999; Li et al, 
2009; Swerdlow et al, 2000, 2001a). Although by no means a complete description of 
the brain areas and systems involved in this complex behaviour, Figure 1.6 illustrates the  
theoretical circuitry of the acoustic startle response and its inhibition by an auditory 
prepulse. According to this model, the relatively simple startle circuit (consisting of the 
cochlear nuclei, the caudal pontine reticular nucleus and the subsequent interneurons and 
motor neurons) receives input from the pedunculopontine tegmental nucleus in the 
presence of a non-startling prepulse, which receives inhibitory input from a variety of 
forebrain structures, primarily via the NAc. While the current knowledge of the specific 
role of some of these forebrain structure (such as the amygdala) on PPI is more limited, 
other regions such as the mPFC, the hippocampus and the NAc have been more 
thoroughly investigated. 
The involvement of the mPFC in the regulation of PPI is consistent with the 
proposed role of reduced PFC DA activation in schizophrenia. One explanation for this 
disruption is that decreased dopaminergic activity in the mPFC is linked to increased 
dopaminergic activity in the NAc via disinhibition of descending glutamatergic fibers 
(Koch and Bubser, 1994; Swerdlow et al, 2001a). This is consistent with the theory that 
many of the symptoms of schizophrenia are linked to increased DA activity in the 
mesocorticolimbic system, decreased DA activity in the PFC, and that these DA 
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Figure 1.6   A hypothetical model of the neural circuitry regulating the acoustic startle 
response and PPI. Shaded boxes indicate the brainstem structures responsible for the 
primary startle circuit (darker boxes) and the processing of normal auditory information/ 
mediation of prepulse information (lighter boxes). White boxes indicate the forebrain 
structures responsible for the modulation of PPI though inhibitory input. Arrows 
illustrate the connections between areas as well as the neurotransmitters and action 
(inhibitory or excitatory), if known. Based on models proposed by (Fendt et al, 2001; 
Koch and Schnitzler, 1997; Koch, 1999; Li et al, 2009; Swerdlow et al, 2000, 2001a).  
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abnormalities are regulated, at least in part, by abnormal glutamate function (see 
sections 1.2.5.1 and 1.2.5.2).  
Studies with animals have suggested that the hippocampus is capable of 
regulating PPI through its glutamatergic connections with other areas of the brain. A 
pathway of particular importance to the PPI circuitry is believed to be the Glu 
projections from the ventral hippocampus to the NAc (Bast and Feldon, 2003). The NAc 
is a major hub in the transfer and translation of information flowing between the limbic 
and cortical structures and has also been strongly implicated in PPI. The NAc has 
glutamatergic connections with the hippocampus, mPFC, and amygdala, as well as DA 
connections with the VTA. While the exact nature of the interactions are not yet 
understood, it is believed that interaction between Glu and DA within the NAc are 
important for modulating PPI. Increased DA in the NAc is typically found in animal 
models of schizophrenia, and the level of DA in the NAc is increased when the subject is 
exposed to DA agonist drugs such as apomorphine, which also alter PPI (reviewed by 
Koch and Schnitzler, 1997; Swerdlow et al, 2001a).  
While deficits in PPI are not likely to cause concern themselves, they are 
indicative of potential dysfunction in a number of brain areas and systems (Swerdlow 
and Geyer, 1998). Furthermore, the inability to properly process incoming sensory 
information could lead to the emergence of other schizophrenic behaviours, such as 
those seen in the positive category of symptoms (Braff and Geyer, 1990).  
 
1.4   Domoic acid 
Domoic acid is a naturally occurring environmental toxin produced by various 
marine organisms such as the red algae Chondria armata and a variety of phytoplankton 
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of the Nitzshia spp. (for review see Bates, 1988; Doucette and Tasker, 2008). The toxin 
enters the food chain by accumulating in filter feeding animals that are subsequently 
consumed by other organisms, including humans. While various shellfish and 
crustaceans can become contaminated with DOM, it is most commonly found in the blue 
mussel (Pulido, 2008). 
 In Canada during 1987 a major human poisoning incident occurred when over 
100 people became seriously ill after consuming mussels contaminated with DOM (Perl 
et al, 1990). The syndrome was termed “amnesic shellfish poisoning” and was 
characterized by symptoms which included vomiting, abdominal cramps, diarrhea, 
headache, confusion, disorientation and loss of short term memory. In some patients, the 
memory deficits were found to be persistent and were still present 4-6 months after 
DOM exposure (Teitelbaum et al, 1990). Those patients who were affected most 
severely experienced seizures, coma, respiratory distress, unstable blood pressure and 
even death (Perl et al, 1990). Post mortem studies on four people who died as a result of 
DOM exposure found damage to the hippocampus in the form of pyramidal neuron cell 
loss (Teitelbaum et al, 1990). 
Structurally similar to Glu, DOM can induce excitotoxicity by acting on both pre 
and post-synaptic Glu receptors. At low concentrations DOM is selective for KA 
receptors, in particular the low-affinity KA receptors, although at higher concentrations 
other receptors are also able to be activated (Tasker et al, 1996; Verdoorn et al, 1994). 
 Most of the work with DOM has focussed on toxicity and neurotoxicity (for 
review see Costa et al, 2010; Jeffery et al, 2004 ). Of particular relevance to this thesis, a 
study by Sobotka et al, (1996) investigated the neurotoxic potential of DOM by 
administering 0.22, 0.65 and 1.32 mg/kg of DOM to adult male and female rats through 
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intraperitoneal (i.p.) injection. Rats who received the highest dose (1.32mg/kg) 
displayed symptoms of toxicity with approximately 25% dying or being euthanized. 
Although minimal behavioural changes were seen in the surviving animals when 
behavioural testing began (1 day after dosing), animals who received the higher dose of 
DOM displayed a significantly exaggerated startle response. An examination of the 
brains of these animals revealed that a small number of animals displayed degeneration 
of hippocampal neurons in the CA1 and CA3 regions. 
 
1.4.1   Domoic acid exposure during development 
While the neurotoxic effects of DOM administration on the adult CNS have been 
well studied, the effects of DOM on the developing CNS are also of interest, particularly 
because the potentially toxic effects of EAAs and their agonists differ between the 
mature and the still developing brain. Indeed, a growing body of evidence suggests that 
the developing CNS may be more susceptible to the toxic effects of DOM. A study by 
Doucette et al, (2000), demonstrated that the potency of DOM is much higher at 
younger ages, with 5 day old rats requiring half the dose of DOM to achieve the same 
level of behavioural toxicity as 14 day old animals (1/17 of the adult dose).  
 
1.4.1.1   Prenatal exposure 
A small number of studies have looked at the effects of prenatal DOM exposure. 
Dakshinamurti et al. (1993) showed that intrauterine exposure to DOM caused 
hippocampal alterations that progress with age. By injecting 0.6 mg/kg of DOM into the 
caudal vein of pregnant mice on gestational day 13, they found that litter size, birth 
weight and hippocampal structure did not differ from control on postnatal day (PND) 1 
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but that morphological changes in the hippocampus were observed beginning on PND 
14. Neurochemical changes were also seen with an increase in KA receptors, Glu levels, 
and Ca
2+
 influx, as well as a decrease of GABA found in the hippocampus. Mice also 
displayed a reduced seizure threshold to a subsequent dose of DOM (Dakshinamurti et 
al, 1993). Levin et al. (2005), reported that a single prenatal exposure to DOM during 
midgestational development (with doses ranging from 0.3-1.2 mg/kg) produced dose 
related changes which included an increase in response latency in a spontaneous 
alternation task in the T-maze, as well as an increase in initial activity and a larger 
habituation score in the Figure-8 maze. In a more recent study by Tanemura et al. 
(2009), mice were given a single injection of DOM (1.0 mg/kg) on gestational day 11.5, 
14.5 or 17.5 and pups underwent a series of behavioural tests between 4 and 11 weeks of 
age. A variety of behavioural changes were observed including impairments in learning 
and memory and an increase in anxiety like behaviours, with results depending on the 
gestational day of DOM administration. 
 
1.4.1.2   Postnatal exposure 
Studies have also investigated the effects of DOM during the postnatal period. A 
number of studies using doses of DOM ranging from 0.05-1.5 mg/kg have been found to 
produce increasingly severe seizure behaviour including scratching, convulsions, 
electroencephalograph (EEG) alterations and death in neonatal rats (Wang et al, 2000; 
Xi et al, 1997). Another study by Levin et al. (2006), considered the effect of a range of 
DOM doses (0.025-0.1 mg/kg) on rat pups when administered twice per day, on PND 1 
and 2. While the higher doses proved to be lethal, they did report some effects at lower 
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doses, but these were less frequently observed than those seen following DOM exposure 
during mid-gestation (see section 1.4.1.1). 
A large series of studies in the Tasker, Ryan and Doucette labs at UPEI have 
investigated the behavioural, histological and histochemical effects of repeated low dose 
DOM exposure during a critical period of CNS development. Our protocol consists of a 
single daily subcutaneous (s.c.) injection of 20 µg/kg of DOM administered to Sprague-
Dawley rat pups from PNDs 8-14. This is a rapid period of brain growth and change 
which is considered to be a critical period of development for the CNS (Dobbing and 
Smart, 1974). Using this protocol, Doucette et al. (2003) demonstrated that this low dose 
of DOM did not produce overt behavioural toxicity. Domoic acid treated rats were later 
reported to show increased conditioned place preference in an olfactory conditioning 
paradigm, indicating that this low dose of DOM was biologically relevant and centrally 
active. 
Further studies at UPEI using the same low dose DOM treatment have shown 
that this protocol results in a wide variety of behavioural and histopathological changes 
that progress as the animals age. Many of these changes have relevance to understanding 
the process of epileptogenesis, such as seizure-like behaviour in response to a novel 
spatial environment (Doucette et al, 2004), reductions in both general and focal seizure 
threshold (Gill et al, 2010a) and seizure-related changes in hippocampal morphology 
such as mossy fibre sprouting (Bernard et al, 2007; Doucette et al, 2004). Of particular 
relevance to this thesis are a number of findings indicating the potential usefulness of 
this neonatal DOM treatment to model certain aspects of neuropsychiatric illness. 
Specific alterations found in this model to brain measures known to also be affected in 
schizophrenia include increases in hippocampal BDNF messenger ribonucleic acid 
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(mRNA), increases in hippocampal mossy fiber sprouting, a decrease in hippocampal 
cell counts and elevated trkB receptor expression (Bernard et al, 2007; Doucette et al, 
2004). The studies illustrating the behavioural findings relevant to the modeling of 
neuropsychiatric disease are reviewed in detail in the Introductions to Chapter 3 (section 
3.1) and Chapter 4 (section 4.1).  
 
1.5   Animal models of schizophrenia and related disorders 
Current research on neuropsychiatric diseases like schizophrenia is conducted by 
a variety of methods including genetic analyses, imaging studies, work within the 
clinical population, as well as the post-mortem analyses of patients. While much has 
been gained though these methods, the research of such disorders through the 
investigation of animal models also has much to offer. Currently, there are a number of 
animal models of schizophrenia that have aided researchers in the understanding and 
treatment of this disease as well as related diseases. However, many questions still 
remain, particularly with regard to neuropsychiatric disorders where the precise etiology 
and/or resulting brain dysfunction is not completely understood. Because of this lack of 
knowledge, our ability to successfully treat these disorders is compromised. 
Additionally, the more we learn about a disorder, the more our understanding of the 
disorder changes. It is not surprising, therefore, that what we require from animal 
models is also constantly changing and accordingly, so is their usefulness and 
applicability. New animal models are thus required in order for research to continue to 
advance and to further our understanding of these debilitating illnesses so that we may 
better aid those afflicted. 
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Animal models can be thought of as preparations developed for the purpose of 
studying a condition in the same or potentially in a different species. A variety of 
animals are used for modeling human disorders with the most common being rats and 
mice. Such models can be used to mimic a human condition in a variety of different 
ways, depending on the nature and purpose of the model (Geyer and Markou, 2000). 
Animal models provide a valuable way to study many complex human disorders. In 
addition to more obvious clinical applications such as testing new treatments or 
medications, they can also be used to study the underlying neurobiological mechanisms 
that contribute to the human disorder. 
Neuropsychiatric disorders often provide a unique challenge to model in animals 
since diagnostic criteria requires symptoms than cannot generally be directly assessed in 
animals (see section 1.2.1 for the diagnostic criteria of schizophrenia). However, while it 
may not be possible to create a complete animal model of a complex human disorder 
(due to the variability in symptom manifestation as well as the human aspect of some 
symptoms, such as auditory hallucinations), many of the core symptoms of 
schizophrenia have been successfully produced in animals. Improvements on current 
models as well as the development of new models have the potential to add significantly 
to our understanding of many aspects of schizophrenia (e.g. the role of genetics, 
molecular basis, therapeutic strategies) and will undoubtedly benefit human clinical 
practice (VanDenBuuse et al, 2005). Current animal models of schizophrenia can 
generally be grouped by type into genetic, surgical, pharmacological and 
developmental/environmental categories. It is, however, important to note that these 
categories are not necessarily mutually exclusive and that some models, although 
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generally placed with one particular group, may actually have characteristics of multiple 
groups. 
 
1.5.1   Genetic models 
A large number of genes have been identified as being “candidate genes” for 
schizophrenia. As a result, the number of animal models of schizophrenia which are 
genetic in nature is staggering (see Carpenter and Koenig, 2008 for review). Genetic 
mouse models are designed to investigate these genes of susceptibility with targeted 
mutations, which allow researchers to identify the functional significance of the gene 
and test the behavioural phenotype that emerges (O’Tuathaigh et al, 2007). 
One example of a candidate gene currently under investigation is DISC1. An 
assortment of genetic linkage and association studies support DISC1 as a susceptibility 
gene for a variety of neuropsychiatric disorders with depression and schizophrenia being 
at the forefront (Cash-Padgett and Jaaro-Peled, 2013). First proposed by (Millar et al, 
2000), mice used for this model have displayed enhanced locomotor activity (Hikida et 
al, 2007; Pletnikov et al, 2008), disrupted PPI (Hikida et al, 2007) and impaired social 
interaction (Pletnikov et al, 2008). Enlarged ventricles were also found in the brains of 
these animals, particularly on the left side (Hikida et al, 2007; Pletnikov et al, 2008). 
Some of the other more popular models making use of potential candidate genes include 
the NRG1 hypomorph (Stefansson et al, 2002), the DTNBP1 mouse (Straub et al, 2002) 
and the COMT knockout (Egan et al, 2001). 
Although genetically based animal models of schizophrenia are undoubtedly 
helpful, one must keep in mind that it is believed that in the majority of cases, genetic 
factors alone are not sufficient to produce the disease and therefore can only be a part of 
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the cause. Additionally, many proposed candidate genes offer only a loose connection 
with the disorder, highlighting the importance of non-genetically based models. 
 
1.5.2   Surgical models 
The most commonly studied and widely accepted surgical model of 
schizophrenia is the neonatal ventral hippocampal (NVH) lesion model. First proposed 
by Lipska et al. (1993) the NVH lesion model uses ibotenic acid (a Glu agonist) to 
lesion the ventral hippocampus of neonatal rats on PND 7 of development. Rats 
receiving the lesions display many aspects of the disorder when compared to control 
animals. Lesioned rats demonstrated a higher degree of activity in response to a novel 
environment and an amphetamine challenge in a novel environment, when tested in 
early adulthood (PND 56) but not at an earlier time point (PND 35) (Lipska et al, 1993). 
Deficits have also been observed in other behavioural measures including PPI (Lipska et 
al, 1995), LI (Grecksch et al, 1999), measures of working memory (Lipska et al, 2002) 
and social interaction, with rats who received NVH lesions spending less time in 
interacting socially compared to controls (Becker et al, 1999). Neurobiological changes 
such as an increase in hippocampal DA have also been found (Alquicer et al, 2004). In 
addition, antipsychotic drugs normalize some of the lesion-induced behaviors including 
the blockade of increased motor activity in a novel environment by haloperidol (Lipska 
et al, 1993) and an increase in the amount of time spent in social interaction following 
treatment with clozapine, but not with haloperidol (Becker and Grecksch, 2003). 
Other surgically-based models include the Neonatal Amygdalar Lesion Model 
(Daenen et al, 2003) where ibotenic acid is used to lesion the amygdala on PND 7, and 
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the Prefrontal Cortical Lesion Model (Miner et al, 1997) which uses ibotenic acid to 
lesion the PFC in neonatal or adult animals.  
Both surgically-based models and chemically-based models have successfully 
illustrated many aspects of schizophrenia, thereby fulfilling many issues of validity. The 
various models have succeeded in producing behavioural, neurochemical and 
neuroanatomical changes similar to those seen in the clinical population, and a number 
of these changes have been shown to be reversible with antipsychotic medications. 
However, the issue of etiological validity remains, as many of the models do not mimic 
the etiology of the clinical condition. 
 
1.5.3   Pharmacological models 
1.5.3.1   Amphetamine 
One of the earliest animal models of schizophrenia was that of amphetamine 
administration in rats. This model, proposed by Gambill and Kornetsky (1976) involved 
adult animals being given daily i.p. doses of increasing amounts of amphetamine. A 
more recent model, proposed by Abekawa et al, (2008) used repeated 2.5 mg/kg doses 
of methamphetamine to produce symptoms of schizophrenia in adult rats. This paradigm 
resulted in increased Glu levels in the medial PFC as well as disruptions to PPI. These 
PPI deficits were able to be reversed following treatment with olanzapine and 
resperidone (Abekawa et al, 2008). Other similar procedures have resulted in an 
upregulation of mGluR8 mRNA in the caudate putamen and NAc (Parelkar and Wang, 
2008), a decrease in glutamic acid decarboxylase (GAD)67 in the hippocampus, PFC, 
thalamus and amygdala, as well as behavioural alterations including changes to PPI and 
LI (Peleg-Raibstein et al, 2008). 
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1.5.3.2   NMDA receptor antagonism 
 Pharmacological blockade of NMDA receptors in adult animals has gained 
popularity as a model of schizophrenia following the implication of Glu in the disorder 
(see section 1.2.5.2). Both acute and chronic treatment with non-competitive NMDA 
antagonists like phencyclidine (PCP) and MK-801, will reliably produce a variety of 
schizophrenia-like symptoms in both animals and humans (Morris et al, 2005; Pouzet et 
al, 2005; Rung et al, 2005; Turgeon and Hoge, 2003). Administration of such 
compounds has also been found to exacerbate schizophrenia symptoms within the 
clinical population (Javitt and Zukin, 1991; Morris et al, 2005). 
 In animals, the PCP model results in a variety of behavioural changes indicative 
of schizophrenia including hyperlocomotion (Adams and Moghaddam, 1998), deficits in 
PPI (Geyer et al, 1984), social withdrawal (Sams-Dodd, 1997), and changes to spatial 
learning and memory (Wass et al, 2006). Elevated levels of both DA and Glu in the PFC 
and the NAc after PCP administration have also been found (Adams and Moghaddam, 
1998). It is important to point out however that some of these symptoms have a very 
specific window of detection, making the observation of the behavioural and 
neurochemical changes outlined above dependent on the time that has elapsed following 
drug administration (Adams and Moghaddam, 1998). 
Phencyclidine-induced behaviour changes have been shown to respond to some, 
but not other, currently prescribed antipsychotic drugs. While clozapine has been shown 
to successfully block PCP-induced hyperlocomotion (Freed et al, 1980), restore social 
behaviour (Steinpreis et al, 1994) and restore PPI deficits (Bakshi et al, 1994; Swerdlow 
et al, 1996), these same effects were not observed following haloperidol treatment 
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(Freed et al, 1980; Harte et al, 2007; Steinpreis et al, 1994) which did not produce any 
effect or did not ameliorate the behaviours to the same extent. 
 
1.5.4   Developmental/ environmental models 
Although schizophrenia generally arises in adolescence or early adulthood, it is 
increasingly regarded as being neurodevelopmental in origin (see section 1.2.3). It is 
believed that subtle perturbations in the developing brain result in a permanent change in 
brain development, increasing the risk of developing schizophrenia later in life.  
Developmental models of disease rely on the concept of critical periods in brain 
development. In brief, the nervous system is more vulnerable to insult during 
development than it is during adulthood. The reason for this is that during development 
the nervous system is undergoing a multitude of sensitive processes including neuronal 
proliferation, migration, differentiation, synaptogenesis, mylenation and apoptosis. 
During times of such rapid growth and change, even very small alterations to the normal 
process of events can have a significant and long lasting effect on the developing 
organism, potentially altering the functioning of the CNS for life (Rice and Barone, 
2000). These critical periods of developmental sensitivity are not limited to the prenatal 
period but extend into adolescence (Dobbing and Smart, 1974; Kaufmann, 2000; 
McDonald and Johnston, 1990; Vorhees, 1986). While in some cases no outward 
changes in behaviour or development are observed, current theories indicate that many 
disorders may be due, at least in part, to subtle changes during critical periods of 
development. 
Two of these potential perturbations, exposure to infection and environmental 
stress, are the most commonly used in developmental animal models of the disorder 
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(Cash-Padgett and Jaaro-Peled, 2013). More recently, a new neurodevelopmental model 
has been introduced; the neonatal domoate model was developed at UPEI and was used 
in the studies described in this thesis. 
 
1.5.4.1   The polyI:C model 
Prenatal exposure to infection (both of the mother and of the fetus) has been 
implicated in an increased risk of developing mental disorders. Presently it is believed 
that the maternal immune response to infection, particularly the pro-inflammatory 
cytokines that are released in such situations, can interfere with the normal development 
of the CNS and lead to increased risk of schizophrenia later in life (Brown et al, 2004a). 
Immunologically-based models seek to imitate this potential risk factor 
(Zuckerman and Weiner, 2005). Seeking to elicit the maternal immune response by 
mimicking viral exposure, Zuckerman and Weiner (2003) created the polyI:C model 
whereby pregnant rats are injected with polyriboinosinic-polyribocytidilic acid. The 
resulting adult animals display a variety of schizophrenia-like changes in behaviour 
including PPI deficits (Ozawa et al, 2006), LI deficits (Zuckerman and Weiner, 2003), 
increased sensitivity to the locomotor effects of amphetamine (Zuckerman et al, 2003), 
impairments in novel object recognition (Ozawa et al, 2006) and reduced social 
interaction (Shi et al, 2003). Neuroanatomical and neurochemical abnormalities have 
also been observed in this model, including alterations to hippocampal morphology 
(Zuckerman and Weiner, 2003), and increases in striatal DA release (Zuckerman et al, 
2003). Additionally, it has been found that both haloperidol and clozapine are able to 
reverse the LI effect (Zuckerman et al, 2003) but only clozapine improved novel object 
recognition (Ozawa et al, 2006). 
55 
 
1.5.4.2   The neonatal quinpirole model 
Repeated administration of the D2/D3 receptor agonist quinpirole early in 
development results in a long term increase in D2 receptor sensitivity. As a result of this 
treatment, adult animals display a variety of behavioural and neurological changes in 
adulthood consistent with schizophrenia and potentially, with other disorders that 
implicate DA dysfunction (Brown et al, 2004b, 2004c; Kostrzewa and Brus, 1991; 
Kostrzewa, 1995; Nowak et al, 2001). 
In a series of studies using this model, it was found that when given repeated 
doses of quinpirole during the neonatal period (1mg/kg/day i.p. from PND 1-21), male 
and female Sprague-Dawley rats displayed increased behavioural sensitization 
illustrated by hyperlocomotion, increased yawning, and increased jumping (Kostrzewa 
and Brus, 1991; Kostrzewa, 1995; Kostrzewa et al, 1990, 1993a, 1993b). Other 
behavioural effects include deficits in the MWM and in a skilled reaching task (Brown 
et al, 2002, 2004b, 2004c, 2005; Thacker et al, 2006). This neonatal quinpirole treatment 
protocol produces a significant decrease in nerve growth factor (NGF) in the 
hippocampus and PFC, as well as decreases in BDNF and acetyltransferase in the 
hippocampus and PFC (Brown et al, 2006; Thacker et al, 2006). Furthermore, some of 
the reported behavioural and neurochemical alteration have been found to be partially or 
totally blocked by the administration of the antipsychotic olanzapine (Brown et al, 2008; 
Thacker et al, 2006) as well as by the administration of nicotine (Brown et al, 2004b, 
2004c, 2006; Tizabi et al, 1999). 
 
 
 
56 
 
1.5.4.3   Environmental stress models 
A stressful environment can cause maladaptive brain development and 
functioning from the period of prenatal development up until adulthood. These effects 
can be modeled in animals in a variety of ways. Some stress paradigms such as mild 
chronic stress (Hill et al, 2012) and social defeat (Kudryavtseva et al, 1991; Venzala et 
al, 2012) are used most often to model depression in animals, while neonatal maternal 
separation (Schmidt et al, 2011) and social isolation rearing are used to model 
schizophrenia (see section 1.5.4.5 for more on isolation rearing). 
 
1.5.4.4   Neonatal domoate model 
 The neonatal domoate rat model uses repeated systemic injections of low doses 
of DOM, a Glu receptor agonist, to stimulate the Glu system of rats during the second 
postnatal week of life. Although the treatment produces no overt symptoms in rat pups, 
once the animals reach adulthood they display a host of behavioural, neuropathological 
and neurochemical alterations, many of which are progressive in nature as the animals 
age. While initially investigated as a potential animal model of temporal lobe epilepsy 
(Bernard et al, 2007; Doucette et al, 2004, 2007; Gill et al, 2009, 2010a, 2010b; Perry et 
al, 2009), more recent studies have found that the same protocol of neonatal DOM 
treatment can be used to model many of the characteristics of schizophrenia (Adams et 
al, 2008; Marriott et al, 2012). This animal model was discussed in section 1.4.1.2 and 
used throughout the work described in this thesis. 
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1.5.4.5   Social isolation rearing 
Since Hatch et al, (1963) first reported that housing rats in isolation produced 
abnormal behavioural reactivity, many studies have shown that rats who experience 
social isolation (housed one animal per cage for some period of time post-weaning, still 
in auditory, visual and olfactory contact with other animals) display a variety of 
profound behavioural, neurobiological and neuroanatomical differences when compared 
to those rats who are raised in groups (Ferdman et al, 2007; Hall, 1998; Lehmann and 
Feldon, 2000; Paulus et al, 1998; Weiss et al, 2004).  
Examples of behavioural alterations include locomotor hyperactivity (Einon and 
Morgan, 1978; Gentsch et al, 1988; Heidbreder et al, 2000), spatial working memory 
impairments (Einon, 1980) increased food hoarding behaviour (Heidbreder et al, 2000), 
impairments in reversal learning (Jones et al, 1991), a modified response to reward 
(Wongwitdecha and Marsden, 1995) and increased sensitivity to amphetamine (Jones et 
al, 1990). However, results indicate that these effects may vary according to the timing 
of the isolation, the timing of the testing period, the strain of rat used, and the other 
experiences of the animal (Gentsch et al, 1988; Han et al, 2012; Shao et al, 2009; Weiss 
et al, 2001; Wilkinson et al, 1994).  
A number of studies have also demonstrated that social isolation rearing can 
affect various measures of attentional processing. These are reviewed in detail in the 
introduction to Chapter 3 of this thesis (section 3.1) 
 
1.5.5   Limitations of current animal models 
Making progress in the study of neuropsychiatric disorders is impeded by the 
complex neurobiology of higher brain functions involved in these diseases, as well as 
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the ethical and practical issues with examining the living human brain (Nestler and 
Hyman, 2010). Animal models thus provide an invaluable service in this respect. There 
are, however, a number of limitations to current animal models. 
Many models seek to mimic the behavioural symptoms of the disorder (face 
validity) and then investigate the corresponding neurological changes. Still others take 
the opposite approach by attempting to alter brain systems thought to be affected in the 
disorder (construct validity) in the attempt to produce a behavioural phenotype similar to 
that seen in the clinical population. The issue with these approaches is that (as will be 
discussed later in this thesis) when dealing with complex behaviours such as those 
affected in these disorders, similar behavioural effects are not necessarily produced by 
the same neurological alterations. Our knowledge of the mechanistic basis for 
schizophrenia is limited; so is our ability to create animal models that mimic these 
mechanisms. Current models are often mechanistically speculative. Additionally, it is 
unlikely that the vast and variable behavioural phenotype produced in a disorder such as 
schizophrenia involves a single neurotransmitter system, or is due to changes in a single 
brain area. This is one possible explanation for why current animal models have shown 
poor predictive validity for drug efficacy in human disease (Markou et al, 2009). 
Issues of etiological validity are highlighted in many current animal models. 
While some models, particularly those in the developmental/environmental category, are 
able to mimic some aspects of the etiology of the disorder they are attempting to model, 
others do not. For example, while a dose of amphetamine may produce symptoms of 
schizophrenia in rodents, and the DA system is likely implicated in psychosis, this is not 
how schizophrenia develops in the clinical population. Furthermore, all of the models 
discussed above (sections 1.5.1-1.5.4) focus on only one intervention (genetic, 
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environmental, etc) while it is currently believed that diseases like schizophrenia are 
actually caused by multiple factors working together to produce the disorder. 
 
1.6   The two-hit approach to modeling neuropsychiatric disorders 
As our understanding of neurodevelopmental disorders advances, so does our 
ability to create better animal models. As discussed in section 1.2.3, schizophrenia is 
considered to be a neurodevelopmental disorder caused by some combination of genetic 
and environmental factors. In the past, efforts to model schizophrenia in animals have 
concentrated on using only one experimental intervention to attempt to produce disease 
characteristics in the model. Recently, attention has turned to the possibility of 
developing animal models that incorporate what has come to be referred to as a “two-
hit” approach. In doing so, researchers are able to create models that better mimic the 
etiology of the disorder. In animal models of schizophrenia, this usually takes the form 
of using two of the already established interventions described in section 1.5. The two 
manipulations may be from different categories of models (e.g. gene-environment 
models) or may be from the same model category (e.g. two developmentally based 
interventions). Established models that have been used in combination include maternal 
infection (Dalton et al, 2012; Deslauriers et al, 2013) and stress paradigms (Deslauriers 
et al, 2013), as well as a variety of gene-environment models and a combination of 
NMDA receptor antagonism and social isolation rearing. 
 
1.6.1   Gene-environment interaction models 
As schizophrenia is currently believed to be caused by some combination of 
genetic and environmental influences, it is no surprise that some of the first two-hit 
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animal models of the disorder implicated both a genetic manipulation and an 
environmental insult. A number of DISC1 transgenic mouse models (which display 
phenotypes relevant to both schizophrenia and depression) have been paired with both 
early immune action models and later life stress models (social isolation or social 
defeat). Results have shown changes in locomotion, PPI, LI, memory, as well as changes 
in measures of depression and anxiety, with many of the findings being the result of 
gene x environment interactions specifically (results reviewed in Cash-Padgett and 
Jaaro-Peled, 2013). Gene-environment models have also been investigated using the 
NRG1 mutant mouse model combined with various stress paradigms, cannabis 
exposure, and housing conditions (Karl, 2013). While the obvious advantage of such 
models is that they aim to mimic the current gene x environment theory of schizophrenia 
development, most candidate genes have only a loose connection with the disorder, 
many have not succeeded in producing behavioural symptoms and fewer still have been 
assessed for predictive validity. 
 
1.6.2   Two-hit models using social isolation rearing 
Social isolation rearing has been used a number of times in studies of potential 
two-hit animal models of schizophrenia. The majority of those studies combined it with 
NMDA receptor antagonism. A study by Ashby et al, (2010) assessed the effects of 
combined NMDA receptor antagonism via MK-801 (0.5mg/kg i.p 2x/day for 7 days 
from PND 56-62) and social isolation rearing (rats housed in isolation or in groups of 4 
from PND 21 onward) on locomotor behavior and hippocampal long term potentiation 
(LTP). Interestingly, while they found that both interventions produced effects on one or 
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both measures of interest, the combination of the two did not produce any detectable 
additive or synergistic effects.  
Another study which combined MK-801 treatment (0.5mg/kg i.p 2x/day for 7 
days from PND 56-62) with social isolation rearing (rats housed in isolation or in groups 
of 4 on PND21) on male rats was conducted by Hickey et al, (2012). While the results 
indicated that the experimental manipulations produced significant changes in locomotor 
activity, GAT-1 activity and GABAA receptor expression, they found no indication that 
the double hit produced any combined effects. 
In contrast, work by Lim et al, (2012) also used MK-801 treatment and social 
isolation rearing (rats housed alone or in groups of 4-5 from PND 21 onward), but 
administered the MK-801 during the post-natal period from PND 7-10 (0.2 mg/kg i.p. 
1x/day for 4 days) with behavioural testing occurring in adulthood. While this study 
found PPI deficits in all animals that were housed in isolation, the effects were more 
robust in those rats who also received MK-801. Additionally only the “two-hit rats” 
showed hyperlocomotion and impaired memory, indicating that MK-801 and social 
isolation rearing together produce greater effect than did either alone.  
The results of these studies and others with similar results (Gaskin et al, 2014; 
Gilabert-Juan et al, 2013; Hawken et al, 2013) indicate that MK-801 treatment and 
social isolation rearing may have potential as a two-hit animals model of schizophrenia 
but it may depend on the MK-801 treatment paradigm used. 
 
1.6.3   Neonatal DOM treatment and social isolation rearing as a potential 2-hit model 
As discussed in the previous section, a number of studies have combined the 
social isolation rearing model with a pharmacological model in an attempt to produce a 
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two-hit animal model of schizophrenia. The presence or lack of an additive effect in 
these studies appears to be the result of variations in the timing of the MK-801 treatment 
(postnatal vs. adolescence) indicating that social isolation rearing does show promise as 
one of the experimental manipulations of a two-hit animal model. To-date neonatal 
DOM treatment has never been combined with any other model in an effort to produce a 
two-hit model but has the potential to easily be combined with social isolation rearing in 
order to investigate the further potential of these models, both alone and in combination. 
Because both of these models produce behavioural and neurological changes in a 
progressive developmental manner, a model which combines both will follow the 
origins of diseases like schizophrenia, as well as increase our understanding of how 
these diseases develop. Additionally, a model that combines two or more interventions 
to produce changes is further in line with the current understanding of how 
neuropsychiatric disorders like schizophrenia develop. Both neonatal low-dose DOM 
treatment and social isolation rearing have modeled a number of behavioural and 
neurological characteristics of neuropsychiatric disorders individually. It is therefore 
possible that when combined, these early life manipulations will lead to a stronger and 
more extensive behavioural phenotype. While the possibility exists that a new model 
may be created that provides a basis for the testing of new pharmacological treatments, 
the immediate outcome of studying the combination of these two models is the potential 
to learn more about how a variety of factors may contribute to the behavioural and 
neurological changes seen in neuropsychiatric disorders, as well as to increase our 
understanding of how different experimental manipulations work together to produce the 
variety of changes seen in animal models. 
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1.7   Summary 
1.7.1   Statement of the problem 
 Neuropsychiatric disorders affect a significant portion of society and as a class of 
diseases, are often poorly understood and difficult to treat. These disorders are a serious 
burden to the economy, to society and to the families and people they affect. While 
treatments do currently exist, they are far from ideal and a diagnosis of a disorder such 
as schizophrenia is likely to lead to a significant decline in functioning and quality of 
life. 
Attentional processing is a higher order cognitive behaviour which is 
fundamental to many important brain processes and is found to be affected in a number 
of human neuropsychiatric disorders. It is believed that alterations in brain functioning 
during critical periods of nervous system development may be a contributing factor to 
such disorders. To date, research in our lab has revealed that chronic administration of 
low, sub-convulsive doses of DOM during a critical period of brain development can 
cause permanent alterations in behaviour and brain physiology in adulthood. Many of 
these subtle cognitive changes could be interpreted in the context of alterations to 
attentional processing, highlighting the potential usefulness of neonatal DOM treatment 
in modeling the attentional deficits present in many illnesses. 
 
1.7.2   Experimental purpose, hypotheses and objectives 
The purpose of the experiments described herein was to investigate the role of 
chemically (DOM) and environmentally (isolation rearing) induced changes in brain 
development on both relevant behavioural testing paradigms and region-specific 
expression of proteins previously associated with these behaviours. In doing so, the 
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intent was to use these experimental manipulations to better understand how early 
developmental alterations can have a long lasting effect on the CNS and how such 
alterations may contribute to the development of neuropsychiatric disorders, either alone 
or in combination as a novel approach to investigating the “two-hit” hypothesis of 
psychiatric disease.  
 
The specific hypotheses tested were: 
1) That both neonatal low-dose DOM treatment during the second week of 
postnatal life and social isolation rearing from weaning would lead to alterations in 
behavioural measures of attentional processing in adult rats. 
2) That the same experimental treatments would result in changes in protein 
expression relevant to the neurotransmitter systems previously implicated in those 
behaviours. 
3) That neonatal low-dose DOM treatment during the second week of 
postnatal life and social isolation rearing from weaning combined would lead to 
more dramatic and consistent behavioural and neurochemical changes than either 
intervention alone. 
 
To test these hypotheses, the thesis had 3 primary objectives as follows: 
 1) To investigate the effect of neonatal low-dose DOM treatment and social 
isolation rearing on behavioural measures of attentional processing.  
2) To explore the effects of neonatal low-dose DOM treatment and social 
isolation rearing on protein expression in the brain in systems known to be implicated in 
attentional processing.  
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3) To assess the interaction between neonatal DOM and social isolation rearing 
in rats and thereby better model aspects of human neuropsychiatric disorders. 
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Chapter 2 
 
 
 
Development of protocols to assess different aspects of latent inhibition behaviour 
in adult, untreated rats using a conditioned emotional response task  
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Summary 
 
Latent inhibition is a normal behavioural process that occurs when previous non-
reinforced exposure to a stimulus impairs the ability of that stimulus to subsequently 
enter into new associations. Both disrupted and abnormally persistent LI are believed to 
illustrate different aspects of impaired attentional processing and potentially different 
categories of symptoms in diseases like schizophrenia. In order to test for both forms of 
impaired attentional processing in studies described later in this thesis, it was first 
necessary to create paradigms to produce both LI and a lack of LI in adult, control 
animals. Therefore, the purpose of this study was to create and assess two different 
protocols for testing LI in adult rats.  
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2.1   Introduction 
Latent inhibition is a normal cognitive process whereby previous non-reinforced 
experience with a particular stimulus impairs the ability of that stimulus to subsequently 
enter into new associations. According to Lubow (1989), who first proposed the 
conditioned attention theory, when a CS is followed by no consequence, the animal 
learns to ignore that stimulus. As a result, during later pairing of the CS with a US the 
animal fails to attend to the CS and associative learning is impaired. This view of LI as 
learned inattention presents it as an adaptive mechanism, important for the proper 
processing of incoming stimuli, as normally the ability to ignore a stimulus that was 
irrelevant in the past would be beneficial (Lubow, 1997). Observed across many 
different species, including rats and humans (Lubow and Gewirtz, 1995), LI is reliably 
disrupted in humans with schizophrenia (Baruch et al, 1988; Gal et al, 2005, 2009; 
Lubow and Gewirtz, 1995; McDowd et al, 1993) and has become widely used in studies 
of the neural alterations of various psychiatric disorders (Bitanihirwe et al, 2010; 
Enomoto et al, 2011; Solomon et al, 1981; Weiner and Arad, 2009; Weiner and Feldon, 
1987), as well as in the search for useful animal models of such disorders (Lubow, 1989, 
2005; Moser et al, 2000; Zuckerman et al, 2003).  
More recently it has been suggested that different aspects of the observed 
changes in LI in the clinical population, and within potential animal models, might 
illustrate different aspects and symptom categories of schizophrenia (Weiner and Arad, 
2009; Weiner, 2003). According to this theory there are 2 ways of looking at changes in 
LI behaviour, namely, the disruption of LI versus the abnormal persistence of LI. 
Disruption of normal LI in experimental animals occurs when a control group displays 
LI while the experimental group does not. Abnormally persistent LI in experimental 
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animals is observed when the control group does not display LI, but the experimental 
group does (Weiner, 2003). See section 1.3.4.1 for an theoretical explanation of the 
brain systems involved in LI. 
According to this theory, dysfunctional attentional control can, therefore, be 
exhibited by these two opposing forms of LI behaviour. In the first case, disrupted LI is 
caused by a failure to inhibit attention to irrelevant stimuli. This behaviour would 
theoretically result in abnormally increased perception of salience and distractibility, 
potentially leading to psychotic symptoms such as those seen in the positive symptom 
category of schizophrenia. In the second case, abnormally persistent LI is caused by a 
failure to re-deploy attention when previously irrelevant stimuli become relevant again. 
This results in cognitive inflexibility and impairment in attentional shifting which are 
associated with the negative and cognitive symptoms of schizophrenia (Weiner and 
Arad, 2009). 
In order to fully assess potential changes in LI following experimental 
manipulations in animals (such as the studies described in subsequent chapters of this 
thesis), it is necessary to test for both the disruption of LI as well as the abnormal 
persistence of LI. Thus, it was first necessary to create LI protocols that would produce 
both a normal LI effect, and a lack of an LI effect in control animals. As discussed in 
Chapter 1, LI can be measured using a variety of paradigms. For the purpose of the 
current experiment, a conditioned emotional response task was chosen because its use in 
LI testing has been well document and it is possible to easily alter various aspect of the 
protocol to produce the desired behaviour in control animals (see Lubow, 1989 for 
review). 
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2.2   Materials and methods 
2.2.1   Experimental animals 
A total of 52 adult Sprague-Dawley rats were obtained from Charles River 
Laboratories (PQ, Canada). At the beginning of experimentation, male rats (n = 26) 
weighed approximately 350g, while female rats (n = 26) weighed approximately 250g. 
Upon arrival, all animals were single housed on a reversed light-dark cycle (lights on at 
7:00pm and off at 7:00am). All rats had ad libitum access to food and water (except 
during testing as outlined below), as well as an opaque PVC tube for environmental 
enrichment. Rats were left undisturbed for one week before behavioural testing began. 
Testing was conducted during the dark phase of the light/dark cycle using red lighting to 
maintain the dark environment. Animals were randomly allocated to either Experiment 1 
or Experiment 2 (n = 26 in each) and subsequently assigned to either a pre-exposure 
(PE) or non pre-exposure (NPE) group with both sexes equally represented (n = 6/7 rats 
per group), see Figure 2.1. All procedures were conducted according to the guidelines 
established by the Canadian Council on Animal Care and were approved in advance by 
the Animal Care Committee at the University of Prince Edward Island.  
 
2.2.2   Latent inhibition testing procedure 
Latent inhibition was assessed using a CER task that measured lick suppression 
behaviour, adapted from Weiner and Arad, (2009). Testing was conducted using a 
standard rat operant chamber (Med-Associates, VT, USA) equipped with a grid floor, 
tone-generating speaker and a drinking tube equipped with a lickometer. Experiment 1 
was intended to produce the normal LI effect in the animals, while Experiment 2 was 
intended to produce a disruption to the LI effect. The paradigm was similar for both 
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Figure 2.1   The division of experimental animals into the various groups needed for LI 
testing. PE signifies animals in the pre-exposure group, NPE signifies animals in the non 
pre-exposure group. 
 
  
Total rats 
n = 52 
Experiment #1 
n = 26 
Males 
n = 13 
PE group 
n = 7 
NPE group 
n = 6 
Females 
n = 13 
PE group 
n = 7 
NPE group 
n = 6 
Experiment #2 
n = 26 
Males 
n = 13 
PE group 
n = 6 
NPE group 
n = 7 
Females 
n = 13 
PE group 
n = 7 
NPE group 
n = 6 
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experiments with only the number of tone-shock exposures (the conditioning phase) 
altered in an attempt to produce the different effects. The testing protocols are described 
below and summarized in Figure 2.2. 
 
Acclimation to handling (days 1-3): Rats were handled individually for 2 minutes each 
day. Handling consisted of touching and stroking the rats as they moved freely about the 
homecage (days 1 and 2), picking up and holding the rats (days 2 and 3) as well as 
stroking and manipulating the rats while they were being held (day 3).  
 
Water restriction (day 3): All animals were placed on a 23 hour water restriction 
schedule beginning at the end of day 3. During all subsequent days of the test protocol 
rats received water for 1 hour each day in their home cages following testing, in addition 
to having access to water during some components of the test procedure. This water 
restriction schedule was modeled after the 23-hour water restriction commonly used in 
similar LI testing paradigms (Almey et al, 2013; Lehmann et al, 2000; Weiner and 
Feldon, 1987). The amount of water consumed during these times was recorded. This 
water restriction schedule was continued throughout the length of the experiment.  
 
Lick training (days 4-8): For 5 days, animals were placed individually into the operant 
chamber and allowed to drink for 20 minutes. The latency (in seconds) to first lick and 
the total number of licks were recorded. 
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Figure 2.2.   Latent inhibition testing protocol 
 
 
Note: Both the PE and NPE groups received the same treatment at all experimental 
stages except for the pre-exposure stage on Day 9 as indicated by *. On this day 
the animals in the PE group received 40 exposures to a 10 second, 80 decibel 
tone stimulus at one minute intervals, while animals in the NPE group were 
placed in the operant chamber for an equal amount of time but were not exposed 
to the tone stimulus.  
 
Testing procedures were identical for Experiments 1 and 2, except for Day 10, as 
indicated by **. On this day, animals in Experiment 1 received 2 tone-shock 
pairings within the 15 minute trial, while animals in Experiment 2 received 5 
tone-shock pairings, also within 15 minutes. 
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Pre-exposure (day 9): During the pre-exposure phase, animals were placed into the 
operant chamber with the drinking tube removed. Animals in the PE group received 40 
exposures to a 10 second, 80 decibel (dB) tone stimulus at one minute intervals. Rats in  
NPE group were placed into the operant chamber for an equal amount of time, but were 
not exposed to the tone stimulus. 
 
Conditioning (day 10): All rats were placed in the operant chamber with the drinking 
tube removed. Rats in Experiment 1 received 2 pairings of a 10 second tone immediately 
followed by a 1 second, 0.5 milliamp (mA) foot shock. Rats in Experiment 2 received 5 
pairings of the same intensity tone + foot shock. The tone-shock pairings were 
distributed at 5 minute intervals (Experiment 1) or 3 minute intervals (Experiment 2) so 
that the conditioning phase for all rats was a total of 15 minutes. 
 
Rebaseline (day 11): All rats were given a 20 minute drinking session, identical to that 
of the initial lick training phase. No tone or foot shock was administered. Latency (in 
seconds) to first lick and total number of licks were recorded. 
 
Test (day 12): All animals were placed in the operant chamber with the drinking tube 
exposed and were allowed to drink ad libitum. Immediately after the 100th lick was 
recorded, the tone (80 dB) commenced and continued until the 120th lick was recorded 
or 300 seconds had elapsed, whichever came first. The time to complete licks 80–100 
(A) and licks 100–120 (B) was recorded and used to calculate the lick suppression ratio 
using the formula A/(A+B). Consequently, a value of 0.003 indicates maximum drinking 
suppression during tone presentation and a score of 0.5 indicates no drinking 
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suppression. Following testing animals were replaced in their homecages and returned to 
normal housing conditions. 
  
2.2.3   Data analysis  
 Independent samples t-tests (1-tailed) were used for data analysis (SPSS Version 
19) with Levene’s test for equality of variance applied where appropriate. For all 
analyses p < 0.05 indicated a significant difference. Data for males and females was 
analyzed separately based on previous research and based on the intended use of the 
protocols established in this study. Sex differences in LI behaviour have been well 
documented in the clinical populations (Lubow et al, 2001), in healthy test subjects 
(Klosterhalfen et al, 2005), and in various animal models (Bethus et al, 2005). 
Additionally, previous studies using neonatal low-dose DOM administration have 
identified extensive sex difference within the model (Adams et al, 2008, 2009; Burt et 
al, 2008a, 2008b; Doucette et al, 2003, 2007; Gill et al, 2010, 2012; Marriott et al, 2012; 
Perry et al, 2009; Robbins et al, 2013; Ryan et al, 2011). As the purpose of the study 
described in this chapter was to develop experimental paradigms to be used in testing the 
neonatal domoate model and as the intention was to investigate sex differences in those 
studies by analyzing data from males and females separately, it was necessary to assess 
LI behavior in both sexes in this study. Values in text are expressed as Mean ± standard 
error of the mean (SEM). 
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2.3   Results 
2.3.1   Experiment 1 
2.3.1.1   Licking behaviour during training 
  Analysis of the average number of licks each animal made while in the operant 
chamber during the 5 days of lick training showed no significant difference between 
females in the PE group and those in the NPE group [t11 = 0.349, p = 0.734]. However in 
males, a significant difference between groups was found [t11 = 2.878, p = 0.015] with 
males in the PE group (2696.1 ± 273.43) licking on average more than those in the NPE 
group (1745.5 ± 156.83). Analysis of the latency to begin drinking after being placed in 
the operant chamber revealed no significant differences between PE and NPE groups in 
either the male or female animals. 
 
2.3.1.2   Licking behaviour during rebaseline 
  As with the licking behaviour observed during lick training, analysis of the 
number of licks taken by the rats during the single rebaseline day revealed that, in 
females, no significant difference was seen between those animals in the PE group and 
those in the NPE group [t11 = -0.484, p = 0.638]. In males, however, a significant 
difference between groups was again found [t11 = 2.364, p = 0.038] with males in the PE 
group (3772.0 ± 340.47) licking on average more than those in the NPE group (2661.5 ± 
314.7). With respect to the latency to begin drinking in the Rebaseline phase, no 
differences in drinking behaviour were observed between those animals in the PE groups 
versus the NPE groups in either sex. 
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2.3.1.3   Drinking behaviour in the homecage 
  T-tests were conducted to investigate the amount of water consumed by the rats 
in the 1 hour period when they were returned to their home cages following each day of 
the testing protocol. In both males and females, no significant differences between PE 
and NPE groups were observed in the amount of water consumed once they were 
returned to their homecages. See Table 2.1 for a review of these findings. 
 
2.3.1.4   Latent inhibition as measured by lick suppression 
 In males it was found that rats in the PE group (0.48 ± 0.091) displayed less lick 
suppression than did those in the NPE group (0.04 ± 0.012) [t11 = 4.451, p = 0.001], 
thereby exhibiting a significant LI effect (Figure 2.3A). Although females displayed the 
same general trend of less lick suppression in the PE group (0.20 ± 0.086) versus the 
NPE group (0.11 ± 0.050), the difference was not statistically significant [t11 = 0.920, p 
= 0.377] (Figure 2.3B). 
 
2.3.2   Experiment 2 
2.3.2.1   Licking behaviour during training 
  An analysis of the average number of licks each animal made while in the 
operant chamber during the 5 days of lick training showed that no significant differences 
in average number of licks between PE and NPE animals were observed in either males 
or females. In the analysis of latency to begin drinking after being placed in the 
chamber, no significant difference was seen between PE and NPE groups in neither male 
nor female animals. 
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Table 2.1   Mean ± SEM amount of water (mL) consumed by rats in each group during 
the one hour period after being returned to the homecage following testing. LT 
designates Lick Training. 
a,b
 indicates p < 0.05 for males versus females in the PE and 
NPE conditions respectively, within each row. 
 
 Male Female 
Stage PE NPE PE NPE 
Avg LT days 14.29 ± 0.988 
a
 13.63 ± 0.698 
a
 10.42 ± 0.681
 b
 10.70 ± 0.882
 b
 
Pre-exposure 25.73 ± 1.399
 a
 22.65 ± 1.435
 a
 18.87 ± 2.149
 b
 15.33 ± 3.048
 b
 
Conditioning 24.71 ± 1.175
 a
 24.82 ± 2.022
 a
 18.27 ± 1.329
 b
 19.67 ± 1.382
 b
 
Rebaseline 13.73 ± 0.509
 a
 14.12 ± 1.099
 a
 9.76 ± 1.136
 b
 9.47 ± 2.093
 b
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Figure 2.3   Mean lick suppression ratios for adult male (A) and female (B) rats when 
tested in a paradigm designed to produce normal LI in untreated animals (2 tone-shock 
pairings during the conditioning phase). Values represent Mean ± SEM. * indicates a 
significant difference between PE and NPE groups (p < 0.05). 
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2.3.2.2   Licking behaviour during rebaseline 
a
 
  When analyzing the number of licks taken on the rebaseline day, no significant 
differences between PE and NPE groups were observed in either males or females. An 
analysis of the latency to complete the first lick revealed no significant differences 
between PE and NPE groups in males or females. 
 
2.3.2.3   Drinking behaviour in the homecage 
  As in Experiment 1, an analysis of the amount of water consumed after being 
returned to their homecages after testing revealed no group differences were observed 
between PE and NPE animals in either sex. These findings continued throughout testing 
with similar results being seen on conditioning, pre-exposure and rebaseline days (see 
Table 2.2). 
 
2.3.2.4   Latent inhibition as measured by lick suppression 
  No significant differences in lick suppression were observed between PE and 
NPE groups in the male or female animals (Figure 2.4). 
 
2.4   Discussion 
 The aim of the present study was to produce the normal LI effect and a lack of 
the LI effect in adult, untreated animals by altering the testing paradigm. In Experiment 
1 the parameters chosen resulted in the production of normal LI in males, as 
demonstrated by the animals in the NPE group showing significantly greater suppression  
  
a
 Analyses in this section were conducted using data from only half of the animals because of 
a computer malfunction. 
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Table 2.2   Mean ± SEM amount of water (mL) consumed by rats in each group during 
the one hour after being returned to the homecage following testing. LT designates Lick 
Training. 
a,b
 indicates p < 0.05 for males versus females in the PE and NPE conditions 
respectively, within each row. 
 
 Male Female 
Stage PE NPE PE NPE 
Avg LT days 16.66 ± 1.725 
a
 16.74 ± 1.236 
a
 11.43 ± 0.751 
b
 12.66 ± 1.360 
b
 
Pre-exposure 27.25 ± 1.094 
a
 26.64 ± 1.977 
a
 17.09 ± 1.886 
b
 21.37 ± 1.383 
b
 
Conditioning 25.07 ± 1.181 
a
 29.10 ± 1.724 
a
 20.74 ± 1.886 
b
 19.88 ± 1.548 
b
 
Rebaseline 17.13 ± 2.131 
a
 17.33 ± 1.311 
a
 14.07 ± 1.347 
b
 13.42 ± 1.133 
b
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Figure 2.4   Mean lick suppression ratios for adult male (A) and female (B) rats when 
tested in a paradigm designed to produce a lack of LI in untreated animals (5 tone-shock 
pairings during the conditioning phase). Values represent Mean ± SEM. * indicates a 
significant difference between PE and NPE groups (p < 0.05). 
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of drinking behaviour during the tone, compared to those animals in the PE group. 
According to current theory (Lubow, 1997) this behaviour was produced because the 
animals in the PE group had been exposed to a prior unreinforced experience with the 
tone and learned that the tone stimulus was meaningless. Consequently, this prior 
unreinforced exposure to the tone retarded the leaning of the association between the 
tone and the shock stimulus during the later conditioning phase. When the tone was then 
played during testing, the animals did not display the freezing behaviour which would 
result in lick suppression because they had not made a strong (or potentially any) 
association between the tone and the shock. The opposite behaviour was seen in the NPE 
group animals. Rats in the NPE group did not have prior experience with the tone before 
the conditioning phase. Consequently, these animals presumably made a strong 
association between the tone and the shock, which caused the rats to display a fear 
response of freezing/lick suppression on presentation of the tone, believing that the tone 
predicted the onset of the shock. 
It was important to investigate how this behaviour may differ in males and 
females as sex differences have been previously reported in this model (Adams et al, 
2008, 2009; Burt et al, 2008a, 2008b; Doucette et al, 2007; Marriott et al, 2012; Robbins 
et al, 2013; Ryan et al, 2011). Sex-dependent analysis of the data in Experiment 1 
revealed that the LI effect was present in males (Figure 2.3A), but that females only 
displayed the same general trend (Figure 2.3B) and did not show a statistically 
significant LI effect. 
 Experiment 2 evaluated a protocol designed to produce a lack of LI despite the 
PE group having prior experience with the tone stimulus while the NPE group did not. 
This was accomplished by maintaining the same pre-exposure procedure as in 
110 
 
Experiment 1 (40 tone exposures for the animals in the PE group; no tone exposures for 
the animals in the NPE group), but by changing the conditioning phase so that all 
animals experienced 5 tone-shock pairings instead of 2. As predicted, there was no 
significant difference in lick suppression during testing between the PE and NPE groups 
(see section 2.3.2.4). Consistent with Experiment 1, the animals in the PE group 
received non-reinforced exposure to the tone during the pre-exposure phase, teaching 
them that the tone was irrelevant. However, the results of Experiment 2 indicate that if 
the animal receives 5 tone-shock pairings, they are able to make an association between 
the tone and the shock stimulus regardless of their previous exposure. Presumably this is 
because the tone has again gained relevance. As before, data from males and females 
was analysed separately and it was found that neither sex exhibited LI using this 
paradigm (Figures 2.4A and 2.4B) 
The sex differences observed in this study were not entirely surprising 
considering that the existence of sex differences in LI has been shown in clinical 
populations (Lubow et al, 2001), in healthy test subjects (Klosterhalfen et al, 2005), and 
in various animal models (Bethus et al, 2005). The reason(s) for sex differences in LI 
is/are currently unknown. Higher concentrations of estrogen has been proposed as one 
reason for the lack of LI in females, but studies examining the effect of estrogen on the 
LI behaviour of rats have lead to contradictory results. In some studies, the presence of 
high concentrations of circulating estrogen during the conditioning phase (caused by 
either being in the proestrus phase of the estrus cycle, or in response to treatment with 
estradiol in ovariectomized rats) has been shown to lead to disrupted LI (Arad and 
Weiner, 2008; Nofrey et al, 2008; Quinlan et al, 2010). Similarly, the presence of low 
concentrations of circulating estrogen during conditioning reportedly leads to intact LI 
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(Arad and Weiner, 2008; Nofrey et al, 2008; Quinlan et al, 2010). Other studies, 
however, have shown contrasting results, finding that the elimination of circulating 
estrogen by ovariectomy leads to disrupted LI, and estrogen replacement following 
ovariectomy eliminates this LI deficit (Arad and Weiner, 2009, 2010a, 2010b). These 
results suggest that estrogen facilitates selective attention, but the precise role of 
estrogen in LI behaviour remains unclear. 
Another possible explanation for the observed sex differences is the potential for 
various experimental paradigms to affect the sexes in different ways. As outlined by 
Lubow (1989), there are many experimental variables that can affect LI. These include 
the similarity of the pre-exposure stimulus and the conditioning stimulus, the number of 
stimulus pre-exposures, the duration of the pre-exposed stimulus and conditioned 
stimulus, the intensity of the pre-exposed stimulus and conditioned stimulus, the inter-
stimulus interval, the time between stimulus pre-exposure and conditioning, the time 
between conditioning and testing phases, as well as many others and among all of these 
there is the potential for interaction between variables. While the majority of studies 
involving LI were historically done on males only (both for human and animal studies), 
many recent studies have included females and have shown that testing paradigms which 
produce different effects in male and females are not unusual. While some studies have 
shown males exhibiting LI to a greater degree than females (Lubow et al, 2001), other 
studies have shown a stronger LI effect in females as compared to males (Klosterhalfen 
et al, 2005). Still other studies have found an LI effect only in female controls, but 
subsequently found LI alterations in both sexes following drug treatment (Wang et al, 
2012). It therefore appears that while both sexes are capable of displaying LI, the effect 
can likely be influenced by a multitude of experimental factors. This assertion is 
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supported by our finding that slight alterations to the paradigm can produce LI or a lack 
of LI in male animals. Such paradigm-dependant sensitivity may explain the lack of an 
LI effect in the females of this study.  
It appears that the issue with the females was that the animals in the PE group 
were still making a strong association between the tone and the shock. Despite their 
previous non-reinforced experience with the tone, they were not showing the learned 
irrelevance towards that stimulus. Therefore in order to produce an LI effect in females, 
we would need to alter the paradigm so that the tone is deemed irrelevant. While this 
could be accomplished in many ways, one option might include increasing the number 
of exposures to the tone during the pre-exposure phase (e.g. have the tone play 80 times 
instead of the 40 that were done in this study). By altering the paradigm during the pre-
exposure phase, thereby providing additional non-reinforced exposure to the tone, we 
would theoretically be increasing the likelihood that the tone will be ignored or deemed 
irrelevant during the conditioning phase. Another option is to alter the paradigm during 
the conditioning stage by decreasing the number of tone-shock pairings (for example, 
having only 1 pairing, instead of the 2 that was used in Experiment 1). This change 
would theoretically also lead to decreased salience of the tone stimulus. Finally, it is 
possible that some combination of paradigm alterations might be required (e.g. increased 
experience with the tone during the pre-exposure phase and reduced pairings of the tone 
with the shock during conditioning). For the purposes of the experiments described in 
Chapters 3 and 4 of this thesis, however, it was felt a higher priority that all animals 
experience the same behavioural testing paradigm. Thus, while it would be interesting in 
the future to determine if different testing procedures are able to be used to produce 
113 
 
identical LI effects in males and females, such protocol variations were not used for the 
later studies described in this thesis. 
The possibility that one of the sexes would show an LI effect while the other did 
not was not unexpected given past research that has shown LI of varying strengths in 
one sex vs. the other (Klosterhalfen et al, 2005; Lubow et al, 2001), or even a finding of 
LI in only one sex (Kaplan and Lubow, 2011) consistent with the current work. 
Furthermore it is difficult to indentify precisely how widespread this phenomenon may 
be given that many studies use exclusively male rats (Alves and Silva, 2001; Ellenbroek 
et al, 1996; Metzger and Riccio, 2009; Sandner et al, 2004; Shao et al, 2009; Solomon et 
al, 1981; Tenn et al, 2005; Weiner et al, 1984; Wilkinson et al, 1994). Further, a 
previous study by Wang et al, (2012) found a significant LI effect only in female control 
animals and not in males, but significant LI effects were observed in both sexes 
following drug treatment. 
In conclusion, we were able to produce both LI and a lack of LI in male animals 
by altering the number of tone-shock pairings used during the conditioning phase of the 
testing paradigm. Females displayed a lack of LI in both paradigms (Experiment 1 and 
Experiment 2). While producing the LI effect in females may be possible, it may not be 
possible to produce a consistent LI effect in both males and females using one 
experimental paradigm. Given the strong effects found in the males, and given that the 
purpose of this study was to develop protocols for a larger study where males and 
females will tested in a consistent manner, it has been concluded that this paradigm will 
be suitable for the subsequent studies. 
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Chapter 3 
 
 
 
Chemical and environmental effects on behavioural measures 
of attentional processing 
 
 
 
 
 
 
 
 
 
The data presented in this chapter has been submitted for publication to Neuroscience 
Letters (January 4 2014, manuscript #NSL-14-17) (latent inhibition results) and will be 
submitted to Behavioural Brain Research in May 2014 (prepulse inhibition results).  
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Summary 
 
Deficits in attention have long been identified as a core feature in schizophrenia and 
related neuropsychiatric disorders. The purpose of this study was to investigate the 
individual and combined effects of neonatal treatment with DOM and social isolation 
rearing (both putative animal models of schizophrenia) on LI and PPI; measures of 
attentional processing. Daily subcutaneous injections of DOM (20 μg/kg) or saline were 
administered to male and female rat pups from PND 8-14, a time of rapid brain growth 
and change. After weaning, rats were housed either alone or in groups of 4 until 
behavioural assessment began on PND 110. When tested for LI, neonatal treatment with 
DOM abolished LI behaviour in adult male rats regardless of housing condition when 
tested 48 hours after conditioning, but this effect was not observed in female rats. Social 
isolation rearing also reduced LI in male rats, but not to the same extent as DOM. When 
tested again 7 days later, single-housed male rats treated with DOM displayed LI 
whereas saline treated or group-housed DOM males did not. No significant differences 
were found in female rats at this time point. When tested for PPI, social isolation 
resulted in significantly lowered amplitude in male rats while DOM treatment appeared 
to make animals refractory to the effects of social isolation on PPI amplitude. Social 
isolation and DOM treatment caused an additive decrease in PPI startle latency that was 
observed in both male and female rats. We conclude that neonatal DOM and social 
isolation both impair attentional processing in adult male, and to a lesser extent female 
rats, although the mechanisms by which this occurs may be different.  
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3.1   Introduction 
Deficits in attention have long been identified as a core feature in schizophrenia 
and related neuropsychiatric disorders (Anscombe, 1987; Braff, 1993; Nuechterlein and 
Dawson, 1984). Characterized by impairments in the perception and expression of 
reality, schizophrenia is a heterogeneous disorder comprised of some combination of 
positive, negative and cognitive symptoms (American Psychiatry Association, 2013). 
Positive symptoms refer to abnormal behaviours that have been added to the behavioural 
repertoire. In patients these symptoms include hallucinations, delusions, psychomotor 
agitation and disordered thought (Strauss et al, 1974). The negative symptoms of 
schizophrenia are characterized by the absence of normal behaviour and include blunted 
affect, anhedonia, alogia, and social withdrawal (Strauss et al, 1974). Cognitive 
symptoms include attentional deficits as well as deficits in learning, memory and 
executive functioning (Gold and Harvey, 1993).  
Historically, treatment has focused primarily on the positive symptoms of 
schizophrenia and these symptoms are generally considered to be the most disruptive. 
More recently however, it has been suggested that a failure in the ability to reduce the 
processing of irrelevant incoming information (historically classified as a cognitive 
symptom) results in such information being afforded undue attention. This improper 
attentional processing may then result in the development of positive symptoms. It has, 
therefore, been hypothesized that the positive symptoms of schizophrenia may actually 
be a consequence of attentional impairments such as those illustrated by disrupted LI 
and PPI (Schmidt-Hansen and LePelley, 2012).  
Latent inhibition is a normal cognitive process whereby previous non-reinforced 
experience with a particular stimulus impairs the ability of that stimulus to subsequently 
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enter into new associations. According to Lubow's (1989) conditioned attention theory 
of LI, when a CS is followed by no consequence, the animal learns to ignore that 
stimulus. Then, during later pairing of the CS with a US, the animal fails to attend to the 
CS and associative learning is impaired. This view of LI as learned inattention presents 
it as an adaptive mechanism, important for the proper processing of incoming stimuli 
(Lubow, 1997). Normally the ability to ignore a stimulus that was irrelevant in the past 
would be beneficial, and often even necessary, to proper day-to-day functioning.  
It has further been suggested that different aspects of the LI changes observed in 
both clinical populations and animal models (namely the disruption of LI versus the 
abnormal persistence of LI) might illustrate different aspects and symptom categories of 
schizophrenia (Weiner and Arad, 2009; Weiner, 2003). According to this theory, 
disrupted LI is caused by a failure to inhibit attention to irrelevant stimuli. This 
behaviour would theoretically result in abnormally increased salience perception and 
distractibility, potentially leading to psychotic symptoms and therefore the positive 
symptoms of schizophrenia. However, abnormally persistent LI is caused by a failure to 
re-deploy attention when previously irrelevant stimuli become relevant again. This 
indicates cognitive inflexibility and impairment in attentional shifting which are 
associated with the negative and cognitive symptoms of schizophrenia (Weiner and 
Arad, 2009). 
Another measure of attentional processing is PPI, whereby there is normal 
suppression of the startle reflex when the startling stimulus is preceded by a less intense, 
non-startling stimulus (Graham, 1975). This measure of sensory-motor gating is 
believed to be controlled by structures located in the lower brainstem and mediated by 
input from the forebrain (Weiss and Feldon, 2001). Observed across many different 
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species including rats and humans, PPI and LI are reliably disrupted in a variety of 
neuropsychiatric disorders including schizophrenia (Baruch et al, 1988; Braff et al, 
1978; Kohl et al, 2013) and have become widely used in studies of the neural alterations 
of schizophrenia as well as in the search for useful animal models of the disorder and the 
preclinical evaluation of potential therapeutic agents (Ellenbroek et al, 1996; Koch, 
2013; Lubow, 1989, 2005; Moser et al, 2000; Zuckerman et al, 2003). 
Our laboratories at UPEI have previously reported that administration of low, 
sub-convulsant doses (20 μg/kg) of DOM (a Glu receptor agonist) to neonatal rats 
during a critical period of CNS development (Dobbing and Smart, 1974), results in later-
onset changes in behaviors consistent with both clinical schizophrenia and other animal 
models of the disorder. Excitatory amino acids, such as Glu, play a critical role in many 
physiological processes which occur during brain development, making proper Glu 
signaling necessary for correct maturation of the CNS (McDonald and Johnston, 1990). 
To date we have reported that DOM administered once daily from PND 8-14 produces 
altered responses to novelty and reward (Burt et al, 2008a, 2008b), changes in cognitive 
functioning (Adams et al, 2009; Doucette et al, 2007; Robbins et al, 2013), altered 
social interaction (Ryan et al, 2011) and changes in stress response (Gill et al, 2012). 
Many of these changes could be interpreted in the context of alterations to attentional 
processing. Indeed we have previously reported that both LI (assessed using a CTA 
paradigm) and PPI are impaired in adult rats following neonatal DOM treatment 
depending on the sex of the animal and the specific paradigm used (Adams et al, 2008a; 
Marriott et al, 2012). In these studies we found that male DOM treated rats show 
significantly decreased LI when tested 24 hours after conditioning (but not when tested a 
week later), while female DOM treated rats did not display an LI deficit at 24 hours 
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post-conditioning, but did show a deficit a week later (Marriott et al, 2012). 
Additionally, DOM treated rats displayed deficits in PPI that were dependent on both 
sex and time of day (Adams et al, 2008a; Marriott et al, 2012). 
Since Hatch and co-workers (Hatch et al, 1963) first reported that housing rats in 
isolation produced abnormal behavioural reactivity, many studies have shown that rats 
that experience social isolation (housed one animal per cage for some period of time 
post-weaning) display a variety of profound behavioural, neurobiological and 
neuroanatomical differences when compared to those rats who are raised in groups 
(Ferdman et al, 2007; Hall, 1998; Lehmann and Feldon, 2000; Paulus et al, 1998; Weiss 
et al, 2004). While many of the changes seen in socially isolated animals are believed to 
model some symptoms of schizophrenia, the effect of social isolation on LI is poorly 
understood. 
In rodents, disruptions of LI can be achieved using chemical, surgical and 
environmental interventions including social isolation (for a review of factors affecting 
LI see Lubow, 1989). Results reported following social isolation, however, indicate that 
the effects may vary according to the timing of both the isolation and the testing, as well 
as the rat strain used (Han et al, 2012; Shao et al, 2009; Weiss et al, 2001; Wilkinson et 
al, 1994). Shao et al, (2009) reported that male Wistar rats who were housed in isolation 
for 2 weeks during adolescence (PND 38-51) displayed deficient LI as compared to 
group housed animals when tested as young adults at PND 66, but not when tested 
immediately after the isolation period at PND 52. The same investigators later showed 
that LI was impaired in male Sprague-Dawley rats when they were housed in isolation 
from PND 21-34 and tested for LI at PND 56 (Han et al, 2012). In contrast, Wilkinson et 
al. (1994) examined the effect of 8 weeks of social isolation, both from weaning and 
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later in adulthood, and found that neither paradigm had any effect on the expression of 
LI. Further, in a study that looked at the effects of both pre-weaning maternal separation 
and post-weaning social isolation, Weiss et al. (2001) found that while maternal 
separation affected LI, social isolation conducted post-weaning did not. Of particular 
relevance to the current study, Feldon et al, (1990) looked at the effect of daily handling 
during the first 3 weeks of life and the effect of being raised in isolation from weaning at 
PND 21 onward, and found that rats raised in isolation may or may not display altered 
LI, depending on handling experience. These latter data indicate that the effects of 
isolation rearing on LI may be subject to interactions with other life experiences and 
suggest that combining a neonatal insult with an additional insult later in life (a so-called 
“2-hit” model) may better model neuropsychiatric disorders originating early in life. 
In contrast to the differing results reported with LI (above), PPI can be reliably 
disrupted by post-weaning social isolation (Domeney and Feldon, 1998; Geyer et al, 
1993; Stevens et al, 1997). Consistent with this distinction, a study by Wilkinson et al. 
(1994) found that 8 weeks of post-weaning social isolation resulted in deficits to PPI but 
not LI. This effect of social isolation on PPI has been shown to be reversible by various 
antipsychotics (Bakshi et al, 1998; Stevens et al, 1997; Varty and Higgins, 1995) and is 
routinely used in preclinical drug development (for reviews see Johansson et al, 1995; 
Swerdlow et al, 2008). While housing-mediated disruption of PPI has been produced in 
a number of studies there is some evidence that the effect can be altered by other 
experimental factors. Varty et al, (1999) demonstrated that rats must be isolated 
continually for more than 4 weeks after the time of weaning in order to produce the PPI 
deficits. While this disruption to the PPI behaviour has been shown to persist when 
tested a second time in experimentally naive rats, exposure to locomotor activity testing 
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either before or after the initial PPI test abolished the PPI effect in subsequent testing 
(Domeney and Feldon, 1998). Another study found the isolation rearing induced deficits 
in PPI were found in rats reared in solid bottomed cages, but not in rats that were raised 
in cages with wire grid floors (Weiss et al, 1999). Finally, it has also been suggested that 
strain differences may contribute to the presence and strength of the isolation rearing 
induced disruption of PPI (Varty and Geyer, 1998; Weiss et al, 2000). 
The study described in this chapter was designed to further investigate the 
individual and combined effects of neonatal DOM treatment and social isolation rearing 
on both LI and PPI in male and female rats. In doing this our purpose was to determine 
the potential usefulness of these paradigms, either alone or together, to model 
neurodevelopmental disorders like schizophrenia and to gain further understanding of 
the role of early life events in shaping attentional processing in adulthood.  
 
3.2   Materials and methods 
3.2.1   Experimental animals and injection procedure 
Experimental animals were born in-house from 10 untimed pregnant Sprague-
Dawley rats obtained from Charles River Laboratories (PQ, Canada). The day of 
parturition was designated PND 0. Within 24 hours of birth, litters were culled to 10-12 
pups with an even number of males and females where possible. On PND 7 pups were 
randomly assigned to either the DOM treatment group or the saline control group and 
ear-notched for identification purposes. From PND 8-14, pups were weighed and given a 
single daily subcutaneous (s.c.) injection of 20 µg/kg DOM (BioVectra DCL, PE, 
Canada) or saline. 
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On PND 21 rats were weighed, weaned and randomly assigned to either the 
social isolation housing condition (one rat per cage) or the group housing condition (4 
rats per cage), with both sexes and drug groups equally represented in each housing 
condition. Animals who were group housed were placed with non-littermates of the 
same sex and drug treatment. All cages were placed in the same colony room so that 
social isolation housed animals could still see, hear and smell other rats, without having 
physical contact. This resulted in 4 treatment groups for both males and females: Saline / 
Group housed (SG), DOM / Group housed (DG), Saline / Single housed (SS) and DOM 
/ Single housed (DS) (see Figure 3.1). All rats (n = 94) received ad libitum access to 
food and water (except during LI testing, as described below) and were left undisturbed 
until behavioural testing began in adulthood (PND 110). Animals were maintained on a 
reversed 12:12 hr light-dark cycle (lights off at 7:00am, on at 7:00pm). Testing was 
conducted during the dark phase of the light/dark cycle using red lighting to maintain the 
dark environment. All procedures were conducted experimenter blind, and according to 
the guidelines established by the Canadian Council on Animal Care and were approved 
by the Animal Care Committee at the University of Prince Edward Island. 
 
3.2.2   Latent inhibition testing procedure 
Latent inhibition was measured using a CER task (adapted from Weiner & Arad, 
2009) as developed in the study described in Chapter 2. The testing apparatus consisted 
of a standard rat operant chamber (Med-Associates, VT, USA) with a grid floor, tone-
generating speaker and a retractable drinking tube equipped with a lickometer. Prior to 
testing each animal was randomly assigned to either the PE or NPE group (see Figure 
3.1), with both sexes and all treatment groups equally represented (n = 6 animals per  
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Figure 3.1   The division of experimental animals into the various groups needed for PPI 
and LI testing. PE signifies animals in the pre-exposure group, NPE signifies animals in 
the non pre-exposure group.  
Total rats 
n = 94 
Males 
n = 47 
DOM 
n = 24 
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n = 12 
PE 
n = 6 
NPE 
n = 6 
Group 
n = 12 
PE 
n = 6 
NPE 
n - 6 
Saline 
n = 23 
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n = 11 
PE 
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NPE 
n = 5 
Group 
n = 12 
PE 
n = 6 
NPE 
n = 6 
Females 
n = 47 
DOM 
n = 23 
Isolated 
n = 11 
PE 
n = 6 
NPE 
n = 5 
Group 
n = 12 
PE 
n = 6 
NPE 
n = 6 
Saline 
n = 24 
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n = 12 
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n = 6 
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n = 6 
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n = 12 
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n = 6 
NPE 
n = 6 
             Sex         Drug treatment    Housing condition    LI group 
               (PND 8-14)        (PND 21 onward) 
            Final grouping      Final grouping 
            for PPI testing       for LI testing 
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group).  The testing protocol is summarized in Figure 3.2 and consisted of the following 
components: 
 
Acclimation to handling (days 1-3): Rats were handled individually for 2 minutes each 
day. Handling consisted of touching and stroking the rats as they moved freely about the 
homecage (days 1 and 2), picking up and holding the rats (days 2 and 3) as well as 
stroking and manipulating the rats while they were being held (day 3). 
 
Water restriction (day 3 onwards): All animals were placed on a 23 hour water 
restriction schedule at the end of day 3. They received water for 1 hour each day in their 
home cages following testing, in addition to having access to water during some testing 
phases. The amount of water consumed during these times was recorded. This water 
restriction schedule was continued throughout the length of the experiment. 
 
Lick training (days 4-8): For 5 days, animals were placed one at a time into the operant 
chamber and allowed to drink for 20 minutes. Latency to first lick and the total number 
of licks were recorded. 
 
Pre-exposure (day 9): During the pre-exposure phase, animals were placed into the 
operant chamber with the drinking tube removed. Animals in the PE group received 40 
exposures to a 10 second, 80 dB tone stimulus at 1 minute intervals. Rats in the NPE 
group were placed into the operant chamber for an equal amount of time, but were not 
exposed to the tone stimulus. 
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Figure 3.2   Latent inhibition testing protocol 
Note:  Both the PE and NPE groups received the same treatment at all experimental 
stages except for the pre-exposure stage on Day 9 as indicated by *. On this day 
the animals in the PE group received 40 exposures to a 10 second, 80 decibel 
tone stimulus at one minute intervals, while animals in the NPE group were 
placed in the operant chamber for an equal amount of time but were not exposed 
to the tone stimulus.  
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Conditioning (day 10): All rats were placed in the operant chambers with the drinking 
tube removed and received 2 pairings of a 10 second tone, immediately followed by a 1 
second, 0.5mA foot shock. The tone-shock pairings occurred at minute 5 and minute 10 
during the 15 minute trial. 
 
Rebaseline (day 11): All rats were given a 20 minute drinking session, identical to the 
ones in the initial lick training phase. Latency to first lick and the total number of licks 
were recorded. No tone or footshock was administered. 
 
Test 1 (day 12): All animals were placed in the operant chamber with the drinking tube 
exposed and allowed to drink. Immediately after the 100th lick, the tone was switched 
on. The tone was switched off after the 120th lick or after 300 seconds, whichever 
happened first. The duration to complete licks 80–100 (A) and licks 100–120 (B) were 
recorded and used to calculate the lick suppression ratio using the formula A/(A+B). 
Consequently, a score of 0.003 indicates maximum drinking suppression and a score of 
0.5 indicates no drinking suppression. Following testing, animals were returned to their 
homecages and the water restriction was ended. 
 
Test 2 (one week following Test 1): An additional testing day identical to the first 
occurred 7 days later (9 days post-conditioning). The animals had their water removed 
24 hours before testing and were given free access to water again following testing that 
same day. 
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3.2.3   Prepulse inhibition testing procedure 
Assessment of PPI began 7 days following the end of LI testing with n = 12 
animals per group (see Figure 3.1). All animals were weighed the day before PPI testing 
began to ensure that they fell within the proper weight range for the apparatus and to 
check that there were no weight differences between treatment groups. Group 
differences in weight have the potential to affect the startle measurement as heavier 
animals produce greater movement (as measured by the accelerometer) than lighter 
animals. 
 The startle apparatus was an SR-Lab from San Diego Instruments (CA, USA) 
and consisted of a clear tube that held the rat over the accelerometer, placed inside a 
sound attenuating chamber. A background white noise level of 70 dBs was maintained 
for the duration of testing. All animal received a 5 minute acclimation period to the test 
chamber before testing began. The experiment consisted of 3 blocks of trials. The 
intertrial interval averaged 15 seconds (ranging from 10-20 seconds). Measurement of 
the startle behaviours on all types of trials was obtained by measuring every 1 
millisecond (ms) for 100 ms after the onset of the startle pulse. Startle amplitude was 
calculated as the average of the 100 readings.  
 Block 1 consisted of 6 white noise startle pulses (40 ms, 120 dBs). This was used 
to normalize and establish a baseline for each animal’s individual startle response. The 
response to pulse 1 measured initial startle, and the average of pulses 2-6 were used to 
calculate the baseline startle. The data from these trials was not included in the 
calculation of the PPI measures. 
 Block 2 contained 3 types of trials: (1) Startle alone pulses, like those in block 1, 
(2) no stimulus trials, during which no stimulus other than the background white noise 
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was administered, and (3) prepulse-pulse trials, which consisted of a 20 ms prepulse (4, 
8, 12, or 16 dBs above the background noise) followed 100 ms later (onset to onset) by 
the startle pulse. Eight trials of each type were administered in random order. Data 
collected during the no stimulus trials was used to measure the activity of the animals 
during testing. 
 Block 3 consisted of 5 final startle pulses identical to those in block 1. This data 
was used to test for within-test habituation and was not included in the calculation of the 
PPI behaviours. Additionally, the data from the startle pulse trials (blocks 1 and 3) were 
used to determine if there was any difference between the two groups in their startle 
amplitudes, independent of PPI. 
 Three different prepulse inhibition measures were analyzed. These were (1) the 
maximum startle amplitude (Vmax), (2) the average startle amplitude (%PPI), and (3) 
the latency to maximum startle amplitude (Tmax). These are depicted in Figure 3.3. 
Values for Vmax and %PPI were calculated for each experimental condition by taking 
the average of the startle alone pulse trials (A) and the prepulse-pulse trials (B) and 
using the following formula: Vmax or %PPI = 100-(100*(B/A)). Values for Tmax were 
calculated by taking the average latency for the startle alone pulse trials (A) and the 
prepulse-pulse trials (B) and using the following formula: Tmax = B-A. See Appendix A 
for greater detail. 
 
3.2.4   Data analysis  
 Unless otherwise stated, 3-way ANOVAs (sex x drug treatment x housing 
condition) were used to analyze weight data, 3-way ANOVAs (drug treatment x housing 
condition x LI group) were used to analyze the LI data, and 2-way ANOVAs (drug  
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Figure 3.3   A graphical representation of startle amplitude and how each variable was 
determined. %PPI = Average startle amplitude, Vmax = Maximum startle amplitude, 
Tmax = Latency to maximum startle amplitude.   
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treatment X housing condition) were used to analyze the PPI data, with repeated 
measures (dB level) used where appropriate (SPSS Version 19). Post-hoc comparisons 
were conducted using Bonferroni t-tests, with Levene’s test for equality of variance used 
where appropriate. A result of p < 0.05 indicated significance. Latent inhibition and PPI 
data for males and females were analyzed separately because sex differences in both 
measures have been well documented in the clinical populations (Kumari et al, 2004; 
Lubow et al, 2001), in healthy test subjects (Klosterhalfen et al, 2005), and in various 
animal models (Bethus et al, 2005; Lehmann et al, 1999). Additionally, previous studies 
using neonatal low-dose DOM administration have identified extensive sex difference 
within the model (Adams et al, 2008a, 2009; Burt et al, 2008a, 2008b; Doucette et al, 
2007; Marriott et al, 2012; Robbins et al, 2013; Ryan et al, 2011). Values in text are 
expressed as Mean ± SEM. Furthermore, the analysis of baseline startle behaviour 
conducted as a normal part of PPI testing is highly dependent on the weight of the 
animal, requiring the analysis of each sex separately for those measures. 
 
3.3   Results 
3.3.1   Weight 
 A summary of the recorded weights of all experimental groups can be found in 
Table 3.1. An analysis of the weights of the rats during the injection protocol (PND 8-
14) found a main effect for sex [F1,124 = 4.122, p = 0.044] with males weighing more 
than females, and a main effect for day [F4.54,562.59 = 2167.898, p < 0.001] with weight 
increasing with day. No significant effects were observed for drug treatment, nor were 
any interactions found between any of the variables. When data for males and females 
were analyzed separately, a main effect for day was observed in both males [F4.33,268.50 =  
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Table 3.1   Mean ± SEM for the weight (in grams) of rats during development and testing.  
Day SAL DOM 
Before 
weaning 
Males (n=32) Females (n=32) Males (n=32) Females (n=32) 
PND 8 18.49 ± 0.318 18.03 ± 0.259 18.68 ± 0.252 18.08 ± 0.273 
PND 9 20.69 ± 0.370 20.24 ± 0.331 20.86 ± 0.291 20.07 ± 0.306 
PND 10 22.94 ± 0.408 22.37 ± 0.306 23.07 ± 0.318 22.23 ± 0.325 
PND 11 25.30 ± 0.409 24.82 ± 0.331 25.48 ± 0.353 24.75 ± 0.324 
PND 12 27.50 ± 0.471 27.09 ± 0.330 27.83 ± 0.378 27.11 ± 0.367 
PND 13 29.95 ± 0.470 29.28 ± 0.344 29.92 ± 0.396 29.34 ± 0.397 
PND 14 32.17 ± 0.495 31.38 ± 0.389 32.20 ± 0.440 31.52 ± 0.424 
 Single housed Group house Single house Group Housed 
After 
weaning 
Males (n=11) Females 
(n=12) 
Males (n=12) Females 
(n=12) 
Males (n=12) Females 
(n=12) 
Males (n=12) Females 
(n=12) 
PND 21 54.73 ± 1.161 
 
52.08 ± 1.184 53.41 ± 1.612 52.42 ± .996 53.08 ± 1.515 50.67 ± 1.227 53.58 ± 1.221 52.33 ± 1.003 
Pre-PPI 686.73 ± 25.795 
 
396.00 ± 
19.055 
701.83 ± 26.655 369.33 ± 
11.922 
656.67 ± 16.877 387.91 ± 
10.961 
678.08 ± 31.120 396.33 ± 
19.065 
       
Note: PND signifies the postnatal day on which the measurement was obtained.
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1026.880, p <0 0.001] and females [F4.29,266.09 = 1148.832, p < 0.001], but no significant 
differences between experimental groups were observed, nor were any interactions 
present. 
Weights were recorded when animals were weaned on PND21. A main effect for 
sex was found [F1,87 = 4.201, p = 0.043] with males (53.68 ± 0.683g) being heavier  
than females (51.88 ± 0.787g). No main effects for drug treatment or housing condition 
were found, nor were any interactions present. When data for males and females was 
analyzed separately, no significant differences were found. 
Animals were weighed again prior to PPI testing. There was a significant main 
effect for sex [F1,86 = 377.519, p < 0.001] with males (680.70 ± 12.636g) weighing more 
than females (387.38 ± 7.862g). When the data for males and females was analyzed 
separately, no significant differences were found in any variable, nor were any 
interactions present. 
 
3.3.2   Latent inhibition 
3.3.2.1   Licking behaviour during training 
No significant differences in any variable were found in either sex when 
measuring the average number of licks taken or the latency to begin drinking during 
training. 
 
3.3.2.2   Licking behaviour during rebaseline 
No significant differences in any variable were found in either sex when 
measuring the average number of licks taken or the latency to begin drinking during 
rebaseline. 
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3.3.2.3   Drinking behaviour in the homecage 
An analysis of the amount of water consumed by each rat after being returned to 
the homecage after testing revealed no significant effects in any variable, in either sex, 
during training days, conditioning days, or rebaseline days. There was, however, a 
significant effect for housing seen in the males on the pre-exposure day [F1,39 = 5.392, p 
= 0.026] with group housed animals (33.65 ± 1.112ml) consuming on average more 
water than single housed animals (30.27 ± 0.834ml). However, this effect was no longer 
present on subsequent days, and there is, therefore, no reason to believe this would have 
impacted later testing. 
 
3.3.2.4   Latent inhibition - Test 1 (48 hours after conditioning) 
Results obtained in Test 1 (48 hours after conditioning) are summarized in 
Figure 3.4. An analysis of the data obtained for male rats showed the expected 
significant main effect for LI group (PE vs. NPE) [F1,39 = 7.098, p = 0.011], with PE rats 
displaying less suppression of licking (shorter latencies) during the tone than NPE rats 
(0.173 ± 0.038 and 0.069 ± 0.022, respectively) indicating the presence of LI. The 
analysis also revealed a significant main effect for drug treatment [F1,39 = 14.424, p < 
0.001], with DOM treated rats showing greater lick suppression (0.050 ± 0.011) than 
saline treated rats (0.196 ± 0.041). A significant interaction between drug treatment and 
LI group was also observed [F1,39 = 5.241, p = 0.028]. 
Independent t-tests were used to further investigate the LI effects, as indicated by 
a significant difference in lick suppression ratios between PE and NPE groups within a 
particular treatment. In saline treated males, the SG group displayed a strong LI effect 
[t6.79 = 2.248, p = 0.031] with the PE group (0.250 ± 0.079) showing less lick  
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Figure 3.4   Effects of neonatal DOM treatment (20 μg/kg) and housing condition on the 
expression of LI in a CER paradigm. Lick suppression ratio values are presented for 
adult male (A) and female (B) rats when tested 48 hours post-conditioning. Values 
represent Mean ± SEM, asterisk indicates a significant difference between PE and NPE 
groups, illustrating the presence of LI (p < 0.05). n = 5-6 animals per group.  
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suppression than the NPE group (0.057 ± 0.034). Similarly, although not statistically 
significant, the SS group showed a marked tendency to display LI (Figure 3.4A). In 
contrast, the LI effect was completely abolished in all animals that received neonatal 
DOM treatment regardless of housing condition, with neither the DG group [t10 = 0.108, 
p = 0.459], nor the DS group [t10 = 0.804, p = 0.220] showing an LI effect (Figure 3.4A).  
An analysis of the data for female rats also showed a significant main effect for LI group 
[F1,39 = 7.377, p = 0.010] with PE rats (0.161 ± 0.044) displaying less suppression of 
licking during the tone than NPE rats (0.031 ± 0.013), but unlike in males no significant 
effects of drug treatment or drug x PE/NPE group were observed in female rats. 
Subsequent comparisons between groups using t-tests indicated that in females neither 
the SG [t10 = 1.236, p = 0.123] nor the SS [t5.03 = 1.223, p = 0.138] group displayed LI, 
but both of the DOM treated groups did show an LI effect, illustrated by the PE groups 
having significantly less lick suppression than the NPE groups (DG [t5.05 = 2.656, p = 
0.023] and DS [t9 = 1.938, p = 0.043]) (Figure 3.4B). 
 
3.3.2.5   Latent inhibition - Test 2 (9 days after conditioning) 
When tested again one week later to determine if the effects on LI were 
persistent, male rats showed a significant main effect for LI group [F1,39 = 4.992, p = 
0.031] with animals in the PE group (0.170 ± 0.036) showing less lick suppression than 
those in the NPE group (0.074 ± 0.020), consistent with the results obtained at 48 hrs. In 
contrast, the female rats showed neither a significant main effect for LI group nor for 
drug treatment (though the latter was approaching significance), nor were any 
statistically significant interactions present.  
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Independent t-tests were again used to further investigate the LI effects and the 
data are illustrated in Figure 3.5. In males at this time point, the data obtained for SG 
and SS groups was suggestive of persistent LI but was not statistically significant [t6.07 = 
1.245, p = 0.130 and t5.87 = 1.747, p = 0.066 for SG and SS, respectively] and as seen at 
48 hrs, the DG group showed no evidence of LI [t10 = 0.204, p = 0.421]. Surprisingly, 
however, the DS group displayed a significant LI effect [t10 = 1.961, p = 0.039] at this 
time point (Figure 3.5A) whereas none was seen at 48 hrs (Figure 3.4A). Although 
significant main effects were absent, data for females were also investigated further 
using t-tests in order to remain consistent with the analysis of male data, but as expected 
based on previous analysis, no LI effect was observed in any group (Figure 3.5B). 
 
3.3.3   Prepulse inhibition 
3.3.3.1   Analysis of %PPI 
Data obtained were analyzed for %PPI (the average of 100 measures, taken every 
ms for 100 ms after the startling pulse). In male rats, significant main effects were found 
for dB level [F2.58,110.76 = 65.940, p < 0.001], drug treatment [F1,43 = 5.329, p = 0.026], 
and a significant interaction was found between drug treatment and housing condition 
[F1,43 = 4.371, p = 0.042]. When these effects were further investigated using t-tests 
(Figure 3.6), significant drug effects were found in the single housed males (Figure 
3.6C), with SS males displaying significantly lowered %PPI (meaning they displayed on 
average less inhibition of startle in the presence of a prepulse) as compared to DS males 
at 74dBs (-1.380 ± 9.643) (20.944 ± 5.360) [t21 = 2.070, p = 0.026], 78dBs (7.368 ± 
9.138) (37.168 ± 4.086) [t21 = 3.066, p = 0.003] and 86dBs (40.385 ± 4.177) (61.840 ± 
2.453) [t21 = 4.522, p < 0.001]. These drug effects were not seen in the group housed rats 
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Figure 3.5   Effects of neonatal DOM treatment (20 μg/kg) and housing condition on the 
expression of LI in a CER paradigm. Lick suppression ratio values are presented for 
adult male (A) and female (B) rats when tested one week after the initial test. Values 
represent Mean ± SEM, asterisk indicates a significant difference between PE and NPE 
groups, illustrating the presence of LI (p < 0.05). n = 5-6 animals per group.  
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Figure 3.6   Mean ± SEM % PPI in male rats at various prepulse dB levels. Panel A 
displays data for all experimental group while panels B-E display the same data, broken 
down to illustrate the effect of drug treatment on group housed rats (B), the effect of 
drug treatment on isolation housed rats (C), the effect of housing condition on saline 
treated rats (D) and the effect of housing condition on DOM treated rats (E). Asterisk 
indicates a significant difference from the comparison group(s) (p < 0.05). n = 11-12 rats 
per group 
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(Figure 3.6B). Significant housing effects were found in the saline treated males (Figure 
3.6D), with single housed rats showing significantly lower %PPI as compared to group 
housed rats at 74dBs (-1.380 ± 9.643 vs 22.472 ± 5.154) [t21 = -2.234, p = 0.018], at 
78dBs (7.368 ± 9.138 vs 30.329 ± 6.052) [t21 = -2.129, p = 0.023], at 82dBs (32.791 ± 
4.535 vs 46.338 ± 5.784) [t21 = -1.820, p = 0.042] and at 86dBs (40.385 ± 4.177 vs 
57.296 ± 5.010) [t21 = -2.567, p = 0.009]. This housing effect was not observed in the 
DOM treated rats (Figure 3.6E). Analyses of other measures revealed no significant 
differences in initial startle, movement during testing, baseline start at the start of 
testing, baseline startle at the end of testing or startle habituation. 
Aside from the expected dB effect [F2.08,89.58 = 54.442, p < 0.001], no significant 
differences were observed in the female rats (Figure 3.7). No significant differences 
were observed in movement during testing, baseline startle at the end of testing or startle 
habituation. Females showed a significant drug treatment x housing effect for initial 
startle [F1,43 = 4.180, p = 0.047] and a significant drug group effect for baseline startle at 
the beginning of testing [F1,43 = 4.155, p = 0.048], but when these effects were 
investigated further using t-tests, no further significance was observed. 
 
3.3.3.2   Analysis of Vmax 
Analysis of the maximum startle amplitude of each animal during PPI testing 
(Vmax) revealed results very similar to the analysis of %PPI (section 3.3.3.1). Male rats 
showed a significant main effect for dB level [F2.48,106.83 = 51.137, p < 0.001] and drug 
group [F1,43 = 5.555, p = 0.023] as well as an interaction between drug group and 
housing [F1,43 = 5.831, p = 0.020]. When these effects were further investigated using t-
tests (Figure 3.8), significant drug effects were found in the single housed males, with 
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Figure 3.7   Mean ± SEM % PPI in female rats at various prepulse dB levels. Panel A 
displays data for all experimental group while panels B-E display the same data, broken 
down to illustrate the effect of drug treatment on group housed rats (B), the effect of 
drug treatment on isolation housed rats (C), the effect of housing condition on saline 
treated rats (D) and the effect of housing condition on DOM treated rats (E). Asterisk 
indicates a significant difference from the comparison group(s) (p < 0.05). n = 12 rats 
per group 
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Figure 3.8   Mean ± SEM Vmax in male rats at various prepulse dB levels. Panel A 
displays data for all experimental group while panels B-E display the same data, broken 
down to illustrate the effect of drug treatment on group housed rats (B), the effect of 
drug treatment on isolation housed rats (C), the effect of housing condition on saline 
treated rats (D) and the effect of housing condition on DOM treated rats (E). Asterisk 
indicates a significant difference from the comparison group(s) (p < 0.05). n = 11-12 rats 
per group  
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SS males displaying significantly lowered Vmax (meaning they displayed less startle 
inhibition) compared to DS males (Figure 3.8C) at 74dBs (-1.194 ± 9.522 vs 21.520 ± 
5.788) [t21 = 2.078, p = 0.025], at 78dBs (6.867 ± 9.748 vs 40.670 ± 4.449) [t21 = 3.247, 
p = 0.002], at 82dBs (31.866 ± 4.336 vs 44.556 ± 3.578) [t21 = 2.272, p = 0.017] and at 
86dBs (41.812 ± 3.433 vs 62.778 ± 3.067) [t21 = 4.569, p < 0.001]. These drug effects 
were not seen in the group housed rats (Figure 3.8B). Significant housing effect were 
found in the saline treated males (Figure 3.8D), with single housed rats showing 
significantly lower Vmax than group housed rats at 74dBs (-1.194 ± 9.522 vs 22.535 ± 
5.287) [t21 = -2.229, p = 0.019], at 78dBs (6.867 ± 9.748 vs 30.732 ± 6.497) [t21 = -
2.070, p = 0.026], at 82dBs (31.866 ± 4.336 vs 45.531 ± 6.064) [t21 = -1.803, p = 0.043] 
and at 86dBs (41.812 ± 3.433 vs 58.933 ± 5.161) [t18.83 = -2.762, p = 0.007]. This 
housing effect was not observed in the DOM treated rats (Figure 3.8E). Additional 
analyses revealed no significant differences for initial startle, baseline startle at the start 
of testing, baseline startle at the end of testing, habituation or movement during testing. 
Aside from the expected significant difference for dB level [F1.92,82.74 = 39.055, p 
< 0.001], no significant differences were observed in the Vmax of female rats (Figure 
3.9). Further, no significant differences were observed in baseline startle at the end of 
testing, habituation or movement during testing. When assessing initial startle, a 
significant interaction between drug treatment and housing was found [F1,43 = 5.036, p = 
0.030] and a significant drug effect was found for baseline startle at the start of testing 
[F1,43 = 4.278, p = 0.045] but when these effects were investigated further using t-tests, 
no significant differences between specific groups were observed. 
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Figure 3.9   Mean ± SEM Vmax in female rats at various prepulse dB levels. Panel A 
displays data for all experimental group while panels B-E display the same data, broken 
down to illustrate the effect of drug treatment on group housed rats (B), the effect of 
drug treatment on isolation housed rats (C), the effect of housing condition on saline 
treated rats (D) and the effect of housing condition on DOM treated rats (E). Asterisk 
indicates a significant difference from the comparison group(s) (p < 0.05). n = 12 rats 
per group 
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3.3.3.3   Analysis of Tmax 
 Data were analyzed for the latency for animals to reach the point of maximum 
startle amplitude during PPI testing. Male rats showed a significant interaction effect for 
drug treatment by housing [F1,43 = 4.996, p = 0.031]. When this effect was investigated 
further using t-tests (Figure 3.10), significant drug effects were found in the single 
housed males, with DOM treated rats startling fast than saline treated rats (Figure 3.10C) 
at 78dBs (-2.994 ± 1.501 vs 2.886 ± 1.633) [t21 = -2.656, p = 0.008] and at 86dBs (-
1.850 ± 1.633 vs 3.007 ± 1.974) [t21 = -1.908, p = 0.035]. This effect was not observed 
in the group housed rats (Figure 3.10B). Significant effects of housing condition were 
also observed in the DOM treated rats with single housed males startling significantly 
faster than group housed males (Figure 3.10E) at 78dBs (-2.994 ± 1.501 vs 3.313 ± 
2.018) [t22 = -2.508, p = 0.010] and 86dbs (-1.850 ± 1.633 vs 3.143 ± 1.700) [t22 = -
2.118, p = 0.023]. These effects were not seen in the saline treated males (Figure 3.10D). 
No significant effects were found for initial startle, baseline startle at the end of testing, 
or movement during testing. A significant main effect of housing condition was found 
for the measures of baseline startle at the start of testing [F1,43 = 8.149, p = 0.007] and 
habituation [F1,43 = 4.518, p = 0.039] but when investigated further no significant group 
differences were found. 
In female rats there were no significant main effects for any variable and no 
interactions between variables were present, although the variable for housing condition 
was approaching significance [F1,43 = 3.993, p = 0.052]. In order to remain consistent 
with the analysis conducted for the males, these data were further investigated using t-
tests (Figure 3.11). A significant effect for housing was found in the DOM treated 
females whereby the single housed rats (-2.562 ± 1.609) startled significantly faster than  
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Figure 3.10   Mean ± SEM Tmax in male rats at various prepulse dB levels. Panel A 
displays data for all experimental group while panels B-E display the same data, broken 
down to illustrate the effect of drug treatment on group housed rats (B), the effect of 
drug treatment on isolation housed rats (C), the effect of housing condition on saline 
treated rats (D) and the effect of housing condition on DOM treated rats (E). Asterisk 
indicates a significant difference from the comparison group(s) (p < 0.05). n = 11-12 rats 
per group  
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Figure 3.11   Mean ± SEM Tmax in female rats at various prepulse dB levels. Panel A 
displays data for all experimental group while panels B-E display the same data, broken 
down to illustrate the effect of drug treatment on group housed rats (B), the effect of 
drug treatment on isolation housed rats (C), the effect of housing condition on saline 
treated rats (D) and the effect of housing condition on DOM treated rats (E). Asterisk 
indicates a significant difference from the comparison group(s) (p < 0.05). n = 12 rats 
per group.  
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the group housed rats (3.532 ± 2.535) at 78dbs [t22 = -2.029, p = 0.028] (Figure 3.11D). 
No significant differences were found for initial startle, baseline startle at the start of 
testing, baseline startle at the end of testing, habituation or movement during testing. 
 
3.4.   Discussion 
The aim of the present study was to investigate the effects of neonatal DOM 
treatment and isolation rearing on attentional processing as measured by LI and PPI. 
This study was conducted to learn more about how early life interventions might be 
useful either alone or together in modeling this particular aspect of schizophrenia in rats, 
as well as to provide a foundation for future mechanistic studies on the systems 
responsible for normal and abnormal attentional processing. The results show that sex, 
housing status and neonatal DOM treatment all affect LI and PPI and that the 
interactions between these variables are complex. 
 
3.4.1   Latent inhibition   
One of the more dramatic and consistent results obtained from this study was that 
neonatal treatment of male rats with DOM completely abolished the significant LI effect 
observed in saline treated rats at 48 hours regardless of housing condition (Figure 3.4A). 
Indeed, mean lick suppression ratios for DOM-treated males pre-exposed to the tone 
were almost identical to those obtained in non pre-exposed males treated with saline 
(Figure 3.4A). These data can be interpreted as evidence that at least in male rats, 
neonatal treatment with DOM is highly disruptive to the development of normal LI, and 
is consistent with data we have published previously on DOM-mediated changes in 
sensory gating (Adams et al, 2008a; Marriott et al, 2012) and other behavioural 
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correlates of schizophrenia (Adams et al, 2009; Burt et al, 2008a, 2008b; Doucette et al, 
2007; Gill et al, 2012; Robbins et al, 2013; Ryan et al, 2011). While this abolition of LI 
in the DOM treated males could be due to any number of factors, it is possible that given 
the extensive involvement of DA and GABA in LI behaviour (see sections 1.3.4.1 and 
section 4.1), that one or both of those systems has been altered. This theory will be 
further explored in Chapter 4.  
The effects of neonatal DOM on the development of LI in female rats at 48 hours 
produced a markedly different result. In females, both single and group-housed rats 
treated with DOM displayed significant LI (and both groups of saline-treated female rats 
showed a tendency toward significant LI) (Figure 3.4B). The reason for this sex-
dependent effect of DOM on LI is unclear, but may be indicative of differential timing 
of key events in brain development between males and females. In the current study both 
male and female rats received DOM injections from PND 8-14. Therefore, if either the 
circuitry responsible for LI expression (see section 1.3.4.1), or the expression of proteins 
(e.g. receptors) responsive to DOM, differs temporally in female rats, the robust drug 
effect observed in males may be lost in females. Sex differences in LI behaviour have 
been observed in both the clinical population (Lubow et al, 2001), in healthy test 
subjects (Klosterhalfen et al, 2005), and in various animal models (Bethus et al, 2005). 
Moreover, there are recent data indicating that Glu receptor expression profiles differ 
temporally in male and female neonatal rats (Galanopoulou, 2008) as well as there being 
potential sex differences in the excitatory/inhibitory tone of the neonatal GABA system 
(Nuñez and McCarthy, 2007). Such sex differences in the major excitatory and 
inhibitory systems of the CNS could partially account for the effects observed but this 
requires further investigation. Additionally, part of the effect seen here is similar to what 
154 
 
we observed in a previous study, where male DOM treated rats showed decreased LI 24 
hours following conditioning, but female DOM treated rats did not (Marriott et al, 
2012). Furthermore, the presence of sex differences in adult rats treated neonatally with 
DOM following this same protocol has been well establish both behaviorally and 
histopathologically (Adams et al, 2008a, 2009; Burt et al, 2008a, 2008b; Doucette et al, 
2003, 2007; Gill et al, 2010; Robbins et al, 2013; Ryan et al, 2011) 
Social isolation has been reported previously to impair measures of attentional 
processing including LI, although results vary (Feldon et al, 1990; Han et al, 2012; Shao 
et al, 2009; Weiss et al, 2001; Wilkinson et al, 1994). In the current study, male rats that 
were group housed and received injections of saline exhibited a strong LI effect as 
displayed by a significant reduction in lick suppression following pre-exposure to the 
tone (Figure 3.4A). While the same general trend was observed in those animals that 
received saline but were housed in isolation (SS), there was no significant difference 
between the PE and NPE groups (Figure 3.4A). However, mean lick suppression ratios 
differed by more than two-fold in these two groups of SS male rats, suggesting that the 
failure to produce significant LI may be more a reflection of the increased variability in 
the number of licks in the NPE group. Single housing has been reported to produce 
changes in water consumption during testing paradigms without accompanying changes 
in water consumption in the home cage although results are contradictory with Jones et 
al. (1989) reporting that isolation reared rats showed decreased drinking whereas 
Hawken et al. (2013) reporting increased drinking. Regardless, altered water 
consumption might be impacting on the measures of LI in the male SS animals. 
Additionally, previously published data, using a taste aversion paradigm to asses LI, 
suggests that the housing effect may be a graded effect. In that study LI was produced in 
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male saline-treated animals reared in groups of two-three and deficits in LI were evident 
at 24 hours post exposure in their DOM treated counterparts (Marriott et al, 2012). 
Data on housing effects obtained with female animals again provided very 
different results. When tested 48 hours post-conditioning, female rats that were either 
group or single housed and received injections of saline did not display statistically 
significant LI (Figure 3.4B) although it could be argued that the saline treated females 
(in both housing groups) are displaying a trend towards LI and that the lack a 
statistically significant LI effect in these groups may be a function of variability and 
small sample size. Indeed, data presented in Chapter 2 of this thesis confirmed previous 
unpublished findings in our laboratory demonstrating that LI is more difficult to produce 
in female rats and may require different paradigms than are needed with males.  
It is uncommon for studies of LI to include more than one test session. However, 
other investigators have reported that the LI effect can persist for a very long time 
(Guanowsky et al, 1983), and given the theory that the lack of LI, as well as the 
abnormal persistence of LI might model different aspects of psychiatric disorders 
(Weiner and Arad, 2009; Weiner, 2003), a second test session conducted 7 days after the 
first was included in the current study. This was also consistent with our previous study 
that assessed the effect of neonatal DOM treatment on adult LI using a CTA paradigm, 
in which DOM treatment affected LI in male rats 24 hours post-conditioning (but not 1 
week later), and affected LI in female rats 1 week post-conditioning (but not at 24 hours) 
(Marriott et al, 2012). 
Therefore, to determine if the effects of DOM treatment and/or housing 
condition produced different effects after a one week delay, each rat was re-tested at 9 
days post-conditioning (one week following the initial test). While the effects seen in 
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male rats at 48 hours post conditioning indicated that DOM treatment abolished LI 
(Figure 3.4A) results from the second test session suggested that there is an abnormal 
permanence of the LI effect as evidenced by a significant LI effect in the DS group 
(Figure 3.5A) while no LI effect is observed in any other group. While an explanation 
for this effect requires further study, one argument is that the effects of DOM manifest 
mainly in the short-term whereas social isolation produces longer lasting disruptions of 
LI, and that the effect of social isolation on LI at 48 hours was simply masked by the 
profound disruption of LI induced by neonatal DOM (i.e. a “plateau effect”). If this is 
the case, it lends further support to the idea that various aspects of LI might illustrate 
various aspects of schizophrenia, and indicates the further potential of neonatal DOM 
treatment to comprehensively model this disorder. When females were tested again one 
week later, no significant LI effects were seen in any group (Figure 3.5B). 
 
3.4.2   Prepulse inhibition 
 Both neonatal DOM treatment and social isolation rearing had a profound effect 
on the PPI of male and to a lesser extent, female rats, but these effects were different for 
the various measures of PPI. 
In saline treated male rats, social isolation resulted in significantly lowered %PPI 
at the 74, 78 and 86 dB prepulse levels (Figure 3.6). Similarly, social isolation resulted 
in significantly lowered maximum startle (Vmax) at the 74, 78 and 86 dB level in saline 
treated males (Figure 3.8). This effect is consistent with what has been previously 
reported (Domeney and Feldon, 1998; Geyer et al, 1993; Stevens et al, 1997) and 
confirms that our social isolation paradigm is producing strong and consistent deficits in 
measures of the amplitude of PPI.  
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Interestingly, this expected PPI deficit due to social isolation was not observed in 
the DOM treated rats. In fact, there was no significant difference in the %PPI or Vmax 
behaviour between the group housed and social isolation housed DOM rats, suggesting 
that neonatal DOM treatment may result in animals being refractory to the effect of 
isolation rearing on PPI. One potential reason for this finding could be that DOM treated 
rats have a different response to social isolation compared to saline treated rats. Our 
laboratory has previously observed that neonatal DOM treatment results in altered social 
interaction (McInnis, 2009; Ryan et al, 2011) and has reported an altered response to 
novelty (Burt et al, 2008a). Because the effects of social isolation or social housing rely 
on both the behaviour of the test subject as well as the other animals, if the DOM treated 
rats experience social isolation and social activity in a different way than control 
animals, it could theoretically result in housing condition having a different effect on 
them. For example, if DOM treated rats are generally less interested in social interaction, 
isolation rearing may not be as stressful for them as it would for saline treated rats. 
 Another interesting result of this study is that we did not observe the reduction in 
%PPI due to DOM treatment that we have previously observed and reported. In our 
previous studies we have reported that neonatal DOM treatment produces a decrease in 
%PPI in male rats (Adams et al, 2008a) when tested during the light phase of the 
light/dark cycle, and in female rats (Marriott et al, 2012) when tested during the dark 
phase of the light/dark cycle. Such differences in sex and time of day testing on PPI are 
not surprising in that many studies have found sex differences in PPI in both humans 
(Kumari et al, 2004) and rats (Lehmann et al, 1999), with males consistently displaying 
greater PPI, particularly at lower prepulse levels. The time of day during which testing 
occurs has also been found to affect PPI in experimental animals, with a study in our lab 
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on female PPI behaviour finding that although startle and PPI were not affected by the 
estrous cycle, the time of day during which testing occurred could have an effect, with 
greater %PPI demonstrated when the rats were tested during the dark cycle (Adams et 
al, 2008b). One possible reason for the lack of a PPI deficit observed in the group 
housed animals in the current study may be the age at testing. In our previous studies 
PPI was tested at PND 90 whereas in the present study the animals were approximately 
135 days old by the time PPI testing began. Thus a DOM-induced PPI deficit may 
present only in early adulthood and disappear as the animal ages.  
In the clinical population of people with schizophrenia, PPI deficits are reliably 
observed in non-medicated, first-episode people (Ludewig et al, 2003). While it has 
been suggested that PPI deficits are present at the early stages of diagnosis but may 
change as the disease progresses, some studies have indicated that this is not the case by 
observing similar PPI behaviours in people experiencing acute, first-episode psychosis 
and those that are clinically stable (Parwani et al, 2000). However the results of such 
studies are confounded by the fact that most long-term patients are receiving treatment, 
making it difficult to dissociate age-related changes from treatment-dependent changes.  
Another possibility is that the housing conditions differed between the current 
and previous studies. In our previous studies, animals were housed in groups of 2 or 3 
rats per cage while in the present study, animals in the isolation group were housed 
alone and animals in the social group were housed in groups of 4. As the results of this 
study illustrate, housing conditions can have a dramatic effect on PPI behaviour. Studies 
that aim to investigate the effect of social vs. isolation rearing on PPI usually house 
animals in the social condition in groups of 3-4 (Bakshi et al, 1998; Domeney and 
Feldon, 1998; Varty and Geyer, 1998; Varty et al, 1999; Weiss et al, 2000) as was done 
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in the current study. Perhaps there is some lower limit to the number of animals needed 
in a cage in order to produce a true “social housing” environment and the housing 
conditions in our previous studies, where many animals were housed primarily in groups 
of 2, has contributed to an altered PPI behaviour. 
 An interesting study by Weiss et al. (1999) found that the PPI deficits caused by 
social isolation housing occurred in rats raised in solid bottomed cages, but not rats 
raised in grid-floor cages. It is possible that raising animals in grid-floor cages 
represented a form of chronic mild stress that made the rats refractory to the normal 
isolation induced PPI deficits. Furthermore, this finding lends support to the idea that 
social isolation rearing induced deficits in PPI are fragile and may offer an explanation 
as to why we observed PPI disruptions in those isolation housed animals that were 
treated with saline, but not those that were treated with DOM. 
 The analysis of Tmax (the latency to the point of maximum startle amplitude) 
provided very different results from the first two measures. Both social isolation and 
DOM treatment appeared to decrease the latency to startle in an additive manner in both 
male and females rats. As illustrated in Figure 3.10A, male rats who were treated with 
DOM and who were housed in isolation after weaning displayed significantly faster 
startle times on PPI trials versus those animals in other groups, whose startle times were 
very similar for most dB prepulse levels. Similar results were seen in the females (Figure 
3.11A) where once again, neonatal DOM treatment and isolation rearing appear to be 
having an additive effect and produced faster startle times on prepulse trials. This effect 
was significant at the 78 and 86 dB levels, although the other dB levels displayed a 
similar trend. Furthermore, as there were no significant differences in latency to startle 
when measuring the baseline startle behaviour (without a prepulse) these effects cannot 
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be attributed to baseline differences in startle behvaiour in the case of either sex. While 
the meaning of these reduced latency values is unknown, it suggests alterations to the 
inhibitory processes regulating startle latency. 
Analysis of the latency to maximum startle is not reported in most of the 
published literature. Lyall et al. (2009) found that rats treated neonatally with the 
NMDA receptor antagonist MK801 and tested at PND56, displayed a prepulse-induced 
delay in startle response time, but found no changes in average startle amplitude or peak 
startle amplitude. In a study on the effects of iron deficiency conducted by Burhans et al. 
(2006), both male and female rats that were fed an iron deficient diet from weaning until 
adulthood displayed lowered baseline startle amplitudes, but showed no changes in 
maximum startle amplitude on PPI trials. Furthermore, Tmax was significantly longer on 
PPI trials in iron deficient female rats, but the effect was not observed in iron deficient 
male rats (Burhans et al, 2006). Other studies have measured Tmax, but only for 
measures of baseline startle, not for PPI. For example, a study conducted by Clark et al. 
(2005) showed that C57BL/6J mice display a significant lowering of the baseline startle 
reflex and an increased latency to peak startle amplitude during baseline startle tests in 
response to the cholinesterase inhibitor physostigmine. Additionally they found 
significantly increased PPI following treatment with physostigmine, although it is 
unclear if this result was obtained by measuring the average startle amplitude or the peak 
startle amplitude, and they did not report on startle latency for the PPI trials. There are 
also a small number of studies that did test for Tmax according to the written methods, 
but did not discuss the results in publication. While including the latency to maximum 
startle is uncommon in the literature, the findings of this study highlight the future 
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potential of using this measure to more fully understand the outcome of experimental 
manipulations that may affect PPI. 
 
3.4.3   Conclusion 
Based on the results described we can conclude that neonatal DOM treatment 
abolishes LI behaviour in adult male rats, regardless of housing when tested 48 hours 
after conditioning. This effect is not observed in female rats treated with an identical 
paradigm, further reinforcing the need to study both male and female animals in 
subsequent studies. Social isolation rearing from weaning until adulthood may also have 
an effect on LI, but does not alone appear to produce the dramatic reduction in LI 
observed in other models, although our data do support further study on whether social 
isolation produces abnormally persistent reductions in LI, as well as whether the effects 
of neonatal DOM and social isolation are synergistic either through the same or different 
pathways mediating this measure of attentional processing. Neonatal DOM treatment 
has a strong effect on all measures of PPI assessed in this study although it appears to be 
countering the ability of isolation rearing to affect startle amplitude and working in an 
additive manner with isolation rearing to affect startle latency. 
Furthermore, the results of this study lend support to the practice of conducting 
multiple assessments of LI behaviour after conditioning has occurred. Testing LI once 
only a short time following conditioning may result in missing important information 
about how these behaviours are expressed over time. Additionally the results of this 
study support the addition of an analysis of latency to maximum startle when testing 
PPI. Finally, the ability of neonatal DOM treatment to produce persistent changes when 
combined with another model is encouraging and illustrates the potential of combining 
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this model with other models in pursuit of a 2-hit (or multi-hit) model of 
neuropsychiatric disorders.  
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Chapter 4 
 
 
 
Effects of chemically and environmentally induced changes in brain 
development on neurochemical measures of attentional processing 
 
 
 
 
 
 
 
 
 
 
 
The data presented in this chapter is being included in a manuscript to be submitted to 
Behavioural Brain Research in May of 2014. 
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Summary 
 
Neonatal DOM treatment and social isolation rearing both lead to significant and long 
lasting changes in behavioural measures of attentional processing in adult rats. To 
continue investigating these effects, neurochemical analyses of putative neurotransmitter 
systems in relevant brain areas were conducted on tissue obtained at the conclusion of 
behavioural testing. Protein markers of interest were selected based on the current 
understanding of the brain areas and systems involved in the observed behavioural 
changes, their involvement in disorders observed in the human clinical population, and 
the results of previous findings in these models. From PND 8-14, male and female 
Sprague-Dawley rats were treated with either 20µg/kg of the Glu agonist DOM or with 
saline (controls). Upon weaning at PND 21 animals were housed in either a socially 
isolated condition (1 animal per cage) or a social housing condition (4 animals per cage). 
Following behavioural testing in adulthood (described in Chapter 3), brain tissue was 
obtained and assayed semi-quantitatively for protein markers of both DA and GABA 
system activity using Western blot analysis. Results indicated some interesting trends 
but no significant differences were found in the overall expression of D1 receptor, D2 
receptor, tyrosine hydroxylase, GAD65 or GAD67 protein in either the PFC or 
hippocampus of any experimental group. These results indicate that other 
neurotransmitter systems and/or brain areas are likely involved in the behavioural 
changes that were previously observed. It is also possible that other methods or 
increased statistical power may be required to detect these changes. 
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4.1   Introduction 
The discovery that both neonatal treatment with low-dose DOM and social 
isolation rearing produce significant and long lasting behavioural changes raises the 
obvious question of what specifically has been altered in the brains of these animals to 
cause the observed behavioural effects? While it is possible that the early life 
interventions described in Chapter 3 might have affected the brain in a multitude of 
ways, an inference of which systems and areas might be affected can be made by 
considering both the previous literature on these models as well as our understanding of 
how the brain is involved in the observed behavioural changes. 
The extensive literature documenting the involvement of the DA system in many 
facets of abnormal LI behaviour makes it an obvious target for investigating the basis of 
the LI abnormalities observed in Chapter 3. Furthermore, while the administration of 
DA agonists leads to disrupted LI (as seen in male DOM-treated rats when tested 48 
hours post-conditioning, see Figure 3.4A), the administration of DA antagonists results 
in the abnormal permanence of LI (seen in the DOM treated females at 48 hours and the 
DOM treated/ single housed males at 9 days post-conditioning, see Figures 3.4B and 
3.5A) (Weiner and Arad, 2009). Consequently, whether increased or decreased, changes 
in dopaminergic system markers were considered likely candidates for investigating the 
neurobiological basis of the observed behavioural changes. 
In addition to DA, the GABAergic system has been previously implicated in PPI 
behaviour (Bast and Feldon, 2003; Guo et al, 2013; Heldt et al, 2004).While the specific 
role(s) of GABA in modulating PPI are not known, it is reasonable to assume that the 
transmitter functions to inhibit neurotransmission. In Chapter 3, DOM-treated/single 
housed animals showed a decreased latency to maximum startle in PPI (see Figures 3.10 
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and 3.11). Disinhibition due to a reduction in GABA system function could be one 
explanation for this result.  
 
4.1.1   Dopamine 
Historically, DA was the first neurotransmitter system to be implicated in 
schizophrenia, with the predominant hypothesis being that symptoms of the disorder 
were caused by excessive DA transmission in the forebrain (Snyder, 1976). It is, 
therefore, not surprising that much of the early research on this disease concentrated on 
the DA system. Indeed, when Solomon et al. (1981) first proposed the LI model of 
schizophrenia they showed that proper functioning of the DA system is required for 
normal LI behaviour. Weiner et al. (1981, 1984, 1988) also conducted a series of studies 
demonstrating how the administration of the DA agonist amphetamine, which produces 
and exacerbates some of the positive symptoms of schizophrenia (Angrist et al, 1974, 
1980; Janowsky and Davis, 1976; Lieberman et al, 1987; Snyder, 1973), resulted in a 
lack of LI. Additionally, it has been shown that potentiation of LI behaviour can be 
produced by the administration of the D2 receptor antagonist haloperidol (Christison et 
al, 1988; Weiner and Feldon, 1987; Weiner et al, 1987). These animal studies 
implicating the role of the DA system in LI are further supported by similar effects being 
observed in the human clinical population (see Weiner 2003 for review).  
 Dysfunction of the DA system has also been implicated in altered PPI behaviour. 
A study by Swerdlow et al. (1986) was the first to suggest a role for the DA system in 
PPI by showing that inducing hyperactivity of DA in the forebrain produced PPI deficits 
similar to those seen in the clinical population. In a study which further characterized the 
role of DA in PPI, Mansbaeh et al. (1988) found that treatment with the DA agonists 
173 
 
apomorphine and d-amphetamine resulted in a significant decrease in PPI, while 
haloperidol prevented the apomorphine-induced PPI deficit but had no effect when 
administered alone. Furthermore, the DA system has been extensively implicated in 
attentional processing, particularly with regard to the behaviours discussed in this 
chapter (see section 1.3.4.1 for more on LI and 1.3.4.2 for more on PPI). 
Previous work with the neonatal DOM model used herein has also produced data 
that imply alterations to the DA system. A study by Robbins et al. (2013) found that 
neonatal DOM treatment lead to significantly less tyrosine hydroxylase (TH) 
immunoreactivity in the right mPFC of male rats, and significantly greater TH 
immunoreactivity in the left core and right shell of the NAc in female rats. Although Gill 
et al. (2012) found no statistically significant differences in protein markers of DA 
function, it was noted that neonatal DOM treatment resulted in a consistent trend of 
lowered D2 receptor protein (assessed by Western blot) of the cytosol/membrane 
fraction of the anterior portion of the brain (which included the PFC), in male DOM 
treated rats. Animals in both of these studies received the same DOM treatment protocol 
described herein, but rats were housed in smaller groups of 2-3 animals. 
Changes in the DA system have been also been observed in rats who were reared 
in social isolation but results have been varied and sometimes contradictory. An in-vivo 
microdialysis experiment conducted by Jones et al. (1992) found that rats reared in 
isolation showed higher DA levels in both the dorsal striatum and NAc following 
systemic administration of 2 mg/kg d-amphetamine, as well as higher post-mortem DA 
concentrations in the mPFC, but not in subcortical areas. In contrast, a study by Leng et 
al. (2004) found no change in DA, DOPAC or homovanillic acid in the mPFC, NAc or 
caudate putamen of rats. One possibility is that these DA changes are strain dependant, 
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as a study by Trabace et al. (2012) found increased DA and a reduction in DA turnover 
in a variety of brain areas including the PFC, NAc, hippocampus and striatum, but these 
results were observed only in Lister Hooded rats and not in Wistar rats. 
 
4.1.2   GABA 
Another neurotransmitter system that has been implicated more recently in 
schizophrenia is the GABA system (Benes and Berretta, 2001). GABA is the major 
inhibitory neurotransmitter in the mammalian CNS, with GABAergic interneurons 
exerting inhibitory control over circuits throughout the brain. Alterations to a variety of 
GABA system markers have been found in the post-mortem brains of people with 
schizophrenia, particularly in the hippocampus. These changes include decreased 
somatostatin and parvalbumin containing interneurons, as well as decreases in glutamic 
acid decarboxylase (GAD) (Konradi et al, 2011). In the mammalian CNS, GAD is the 
enzyme responsible for converting glutamate into GABA and occurs in two isoforms, 
GAD65 and GAD67 (Soghomonian and Martin, 1998). 
While the role of GABA in PPI has not been investigated as extensively as the 
role of DA, studies have suggested that this system plays an important role in PPI 
behaviour, particularly within the hippocampus and the NAc (Bast and Feldon, 2003; 
Swerdlow and Geyer, 1998) (see section 1.3.4.2 for more on the role of GABA in 
attentional processing in PPI). Specifically, Guo et al. (2013) showed that inducing a 
temporary decrease in hippocampal neurogenesis in adolescent mice lead to a PPI deficit 
in adulthood, as well a reduction in PPI-related activation of hippocampal and prefrontal 
neurons. This effect was reversed by bilateral infusion of a GABAA receptor agonist into 
the hippocampus. They also found a reduction of GABAergic inhibitory neurons in the 
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dentate gyrus. Additionally, both the PPI deficits and the decrease in GABAergic 
neurons were avoided when mice were exposed to environmental enrichment during 
adolescence (Guo et al, 2013). A study that assessed the effect of genetic GAD65 
knockout on mice found PPI deficits that were reversed by the atypical antipsychotic 
clozapine (Heldt et al, 2004).  
Assessment of the role of GABA in regulating LI behaviour has produced 
conflicting results. A study by Delamater et al. (2009) reported that LI behaviour is not 
mediated by GABAergic mechanisms because systemic injections of a GABAA receptor 
inverse agonist failed to affect LI behaviour. Another study showed that a reduction in 
GABA activity in the PFC did not affect LI (Enomoto et al, 2011). However, 
Bitanihirwe et al. (2010) reported that prenatal immune activation in mice lead to both 
LI changes (abnormally enhanced LI) and a reduction of GABAergic markers in the 
hippocampus, but not the PFC. See section 1.3.3.3 for more on the role of GABA in the 
theoretical framework of attentional processing. 
Previous results at UPEI have indicated that neonatal DOM treatment may have 
a long lasting effect on the GABA system. In a study that investigated a number of 
GABA system markers in the hippocampus of rats treated neonatally with DOM and 
housed in groups of 2-3 animals per cage, Gill et al. (2010) found decreased GAD65/67 
combined immunostaining in the ventral dentate gyrus (females) and ventral CA3 area 
(males) of the hippocampus. They also found that DOM treated rats displayed a 
significantly lower number of parvalbumin containing neurons in the dorsal dentate 
gyrus, the mid dentate gyrus and the mid CA3 subfield. These results were often present 
in only one sex. Additionally, they found no change in the number of somatostatin 
containing neurons in any brain area (Gill et al, 2010). A small study by (Adams-
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Marriott, 2009) which used 120 day old rats that were housed in groups of 2-3, found a 
significant decrease in GAD67 immunostaining in the CA3 of the left hemisphere of 
female adult rats treated neonatally with DOM.  
 The effect of social isolation rearing on GABAergic system function has been 
minimally investigated with a study by Harte et al. (2007) indicating that rats reared in 
isolation exhibited a reduction of parvalbumin and calbindin immunoreactive cells in the 
hippocampus, as well as PPI deficits. 
The purpose of the experiments in the current chapter was to assess a variety of 
protein markers for both DA and GABA systems in the brains of adult animals that had 
been treated neonatally with DOM or saline, and housed either in isolation or in groups 
following weaning. Protein markers of interest were selected based on the current 
understanding of the brain areas and systems involved in the observed behavioural 
changes (Chapter 3), their involvement in disorders observed in the human clinical 
population, and the results of previous findings in these models (both social isolation 
and neonatal DOM treatment). 
 
4.2   Materials and methods 
4.2.1   Experimental animals and tissue processing 
Experimental animals were the same rats used for behavioural testing in Chapter 
3. When testing was completed animals were euthanized and tissue was obtained for 
analysis of proteins of the systems of interest. Brain tissue from 45 animals was 
processed for protein analysis through Western Blot with both sexes and all treatment 
groups being equally represented giving an n = 4 for each group in each sex. Animals 
were deeply anesthetized with isofluorane and immediately decapitated. Each brain was 
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rapidly extracted from the skull and the hemispheres were separated. The PFC and 
hippocampus were dissected out and flash frozen by immersion in liquid nitrogen. 
Tissue was then stored at -80
o
C until needed. All procedures were conducted 
experimenter blind, according to the guidelines established by the Canadian Council on 
Animal Care and were approved by the Animal Care Committee at the University of 
Prince Edward Island.  
 
4.2.2   Protein isolation and assay 
Each sample was weighed and placed in 20ml/g of ice cold homogenization 
buffer (HB) (pH 7.4; 10mM TrisHCL, 300mM sucrose, 2mM EDTA) with Roche 
protease inhibitor (30µl/ml HB) (Roche Applied Science, IN, USA). Tissue was 
homogenized using a Polytron 3100 tissue tearer (Brinkman Instruments, ON, Canada) 
at 30,000 rpm for 30 seconds. The homogenate was then centrifuged at 2300 rpm for 20 
minutes at 4
o
C. The resulting supernatant, which contained both the membrane and 
cytosol fractions, was divided into 100 µl aliquots and stored at -80
o
C for later analysis. 
All samples were assayed using the Bradford method to assess the concentration of total 
protein present.  
 
4.2.3   Western blotting procedure for dopaminergic markers 
Samples were mixed with Laemmli buffer with beta-mercaptoethanol (0.05%) 
added, and denatured by boiling for 3 minutes. Forty µg of each sample was loaded on 
to 8% bis-acrylamide gels and protein separated through electrophoresis (Bio-Rad 
PowerPac HC High-Current Power Supply, Bio-Rad Laboratories Inc., ON, Canada) at 
0.06 constant amperage and a maximum of 200 volts. A standard sample common to all 
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gels was loaded into the first lane of each gel in order to control for inter-gel variations. 
Protein was then transferred on to PVDF membranes using a 0.2 constant amperage, a 
maximum of 25 volts and a maximum of 50 watts for 30 minutes (Bio-Rad PowerPac 
HC High-Current Power Supply, Bio-Rad, ON, Canada). All blots were notched for 
identification purposes. 
Following blocking with 5% milk in PBS-T for 1.5 hours at room temperature, 
blots were incubated overnight in rabbit anti-D2 (1:500, Alomone Labs, Jerusalem, 
Israel), rabbit anti-D1 (1:1000, Alomone Labs, Jerusalem, Israel) mouse anti-tyrosine 
hydroxylase (1:1000 or 1:500, Millipore, MA, USA) or mouse anti-β-actin (1:5000, 
Sigma-Aldrich, USA) at 4
o
C. The following day, blots were rinsed 3 times each in 10ml 
of PBS-T for 10 minutes. Blots were then incubated with the appropriate secondary 
antibody (rabbit 1:5000, rabbit 1:5000, mouse 1:5000 and mouse 1:20,000 respectively, 
Sigma-Aldrich, USA) for 1.5 hours at room temperature. An additional 3 PBS-T rinses 
were then conducted and protein bands were visualized by a one minute incubation in a 
chemiluminescent detection reagent (ECL Prime, Amersham, GE Healthcare Life 
Sciences, PQ, Canada) followed by UV exposure using the UVP BioSpectrum Imaging 
System (UVP, CA, USA). Optical density of the bands was measured using ImageJ 
(NIH) with values being normalized against β-actin and the control sample common to 
all blots. 
 
4.2.4   Western blotting for GABAergic markers 
4.2.4.1   Optimization of protein loading for quantification 
Subsequent to the analysis of tissue samples for dopaminergic markers (see 
section 4.2.3) a report by Taylor et al. (2013) described how the assessment of optimal 
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protein loading for quantification purposes as an essential step in Western blotting, with 
excessive protein loading into a gel producing inaccurate quantification results. This is 
of particular concern with loading controls such as β-actin that are generally highly 
expressed. In such cases, consistent band densities among the sample lanes may not be 
the result of consistent protein expression among samples but rather may be caused by 
overloading of the gel, producing protein densities that are outside the linear dynamic 
range for accurate detection. 
In order to avoid this issue and to determine the quantitative linear dynamic 
range, a representative sample was created by pooling a portion of all prepared samples 
for a given brain area. From this representative sample, a 2-fold dilution series over 12 
dilutions was created (samples were diluted with HB), beginning at 80µg. A separate 
standard curve of band density vs. protein load was created for each primary antibody to 
be used.  
The optimal protein load for GAD65 and GAD67 was determined to be 
approximately 20µg (see Figure 4.1 for representative figures). At this concentration, 
sample bands were found to be detectable, but not saturated. However, depending on the 
antibody concentrations used, loading this amount of protein may produce band 
saturation for β-actin. Therefore, various primary and secondary antibody concentrations 
were tested with β-actin (see Figure 4.2) and antibody concentrations chosen that would 
not result in oversaturation. 
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Figure 4.1   Quantification of serial 2-fold dilutions to define the linear dynamic range 
for Western blot detection for GAD65 protein (A) and GAD67 protein (B).  
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Figure 4.2   Various primary and secondary antibody concentrations to define the linear 
dynamic range of Western blot detection for β-actin protein.  
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4.2.4.2   Procedure 
Samples were mixed with Laemmli buffer (Bio-Rad, Ontario, Canada) with beta-
mercaptoethanol (0.05%) added, and denatured by boiling for 3 minutes. Twenty µg of 
each sample was loaded into 10% bis-acrylamide Bio-Rad Mini-PROTEAN TGX stain 
free gels (Bio-Rad, ON, Canada) and run at a constant of 200volts. A standard sample 
common to all gels was loaded into the first lane of each gel to control for inter-gel 
variations. Protein was then transferred onto PVDF membranes using a Bio-Rad 
TransferBlot Turbo Transfer System (Bio-Rad, ON, Canada). All blots were notched for 
identification purposes. 
Following blocking with 5% milk in PBS-T for 1.5 hours at room temperature, 
blots were incubated overnight in mouse anti-GAD67 (1:2000, Millipore, USA) or rabbit 
anti-GAD65 (1:1000, Abcam, ON Canada), at 4
o
C. The following day, blots were rinsed 
3 times each in 10ml of PBS-T for 10 minutes each rinse. Blots were then incubated in 
the appropriate secondary (mouse 1:5000 or rabbit 1:5000, Sigma-Aldrich, USA) for 1.5 
hours at room temperature. Another 3 PBS-T rinses were then performed and protein 
band detection was conducted by a 1 minute incubation in a chemiluminescent detection 
reagent (Bio-Rad Clarity ECL substrate, Bio-Rad Laboratories, ON Canada) followed 
by UV exposure using a Bio-Rad ChemiDoc MP Image System (Bio-Rad Laboratories, 
ON Canada). Optical density of the bands was measured using ImageLab (version 4.1, 
Bio-Rad Laboratories, Bio-Rad, ON Canada) with values being normalized against β-
actin and the control sample common on all blots. See Appendix B for more information 
on quantification. 
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4.2.5   Data analysis 
Unless otherwise stated, 2-way ANOVAs were used (drug treatment X housing 
condition), with repeated measures (hemisphere) where appropriate (SPSS Version 19). 
Post-hoc comparisons were conducted using Bonferroni t-tests, with Levene’s test for 
equality of variance used where appropriate. A result of p < 0.05 indicated significance. 
Data for male and female animals were analyzed separately in order to remain consistent 
with the behavioural analyses, and because sex differences in protein expression in 
response to neonatal DOM treatment have been previously been observed (Adams-
Marriott, 2009; Gill et al, 2010, 2012; Robbins et al, 2013). 
 
4.3   Results 
4.3.1   Dopaminergic markers 
4.3.1.1   D1 receptor 
A 2-way ANOVA (drug treatment x housing condition) of D1 receptor protein 
expression in the PFC of male rats showed no significant effects for drug treatment [F1,12 
= 0.127, p = 0.727], or housing condition [F1,12 = 0.056, p = 0.816] and no interaction 
between these variables was present [F1,12 = 0.081, p = 0.781] (Figure 4.3A). A 
significant main effect for hemisphere was observed [F1,12 = 15.338, p = 0.002] with a 
finding of higher D1 receptor protein expression in the left PFC (1.007 ± 0.092) as 
compared to the right PFC (0.671 ± 0.029) (Figure 4.3C). No interactions were observed 
between hemisphere and any other variable. When the hemispheres were subsequently 
analyzed separately, no significant main effects were observed in any variable, in either 
hemisphere (see Table 4.1A). 
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Figure 4.3   D1 receptor protein expression in the combined hemispheres of PFC and 
hippocampus of male (A) and female (B) rats treated neonatally with DOM or saline and 
housed in isolation or groups of 4. Panels C and D show D1 receptor expression values 
broken down by hemisphere for males (C) and females (D). * Indicates a p value of < 
0.05.  
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Table 4.1   Results of statistical analyses for D1 receptor protein expression in the 
prefrontal cortex (A) and hippocampus (B) of male and female adult rats treated 
neonatally with DOM or saline and reared in social housing or in isolation.  
 
A. Prefrontal cortex 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 0.060 
p = 0.810 
F1,12 = 0.071 
p = 0.794 
F1,12 = 0.427 
p = 0.526 
F1,12 = 0.108 
p = 0.748 
Housing 
F1,12 = 0.094 
p = 0.764 
F1,12 = 0.025 
p = 0.876 
F1,12 = 0.004 
p = 0.948 
F1,12 = 0.385 
p = 0.547 
Drug x 
Housing 
F1,12 = 0.004 
p = 0.952 
F1,12 = 0.295 
p = 0.597 
F1,12 = 2.016 
p = 0.181 
F1,12 = 0.149 
p = 0.706 
 
 
B. Hippocampus 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 0.057 
p = 0.815 
F1,12 = 0.049 
p = 0.829 
F1,12 = 0.102 
p = 0.755 
F1,12 = 1.890 
p = 0.194 
Housing 
F1,12 = 0.261 
p = 0.619 
F1,12 = 1.022 
p = 0.332 
F1,12 = 0.067 
p = 0.800 
F1,12 = 0.078 
p = 0.785 
Drug x 
Housing 
F1,12 = 1.051 
p = 0.326 
F1,12 = 0.011 
p = 0.917 
F1,12 = 0.166 
p = 0.691 
F1,12 = 0.067 
p = 0.800 
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In females, no significant effects for drug treatment [F1,12 = 0.099, p = 0.758] or 
housing condition [F1,12 = 0.131, p = 0.724] were observed and no interaction between 
these variables was present [F1,12 = 0.275, p = 0.610] (Figure 4.3B). As with the males, a 
significant main effect for hemisphere was found [F1,12 = 19.753, p = 0.001] with D1 
receptor protein expression being greater in the left PFC (1.042 ± 0.075) than the right 
PFC (0.775 ± 0.046) (Figure 4.3D). However, no interactions were observed between 
hemisphere and any other variable and when the hemispheres were subsequently 
analyzed separately, no significant main effects were observed in any variable, in either 
hemisphere (Table 4.1A).  
In the hippocampus, a 2-way ANOVA (drug treatment x housing condition) of 
D1 receptor protein expression revealed no significant effects in the males for drug 
treatment [F1,12 < 0.001, p = 0.999], or housing condition [F1,12 = 0.037, p = 0.851] and 
no interaction between these variables was present [F1,12 = 0.640, p = 0.439]. No 
significant main effect for hemisphere was observed [F1,12 = 4.096, p = 0.066], although 
the value was approaching significance and had the same trend observed in the analyses 
of D1 expression in the PFC (see above) whereby D1 receptor expression appeared 
greater in the left hippocampus (1.056 ± 0.010) as compared to the right hippocampus 
(0.929 ± 0.071) at least in 3 of the 4 groups (Figure 4.3C). No interactions were 
observed between hemisphere and any other variable. When the hemispheres were 
subsequently analyzed separately in order to remain consistent with previous analyses, 
no significant main effects were observed in any variable in the left or right hemisphere 
(Table 4.1B). 
In females, no significant effects were found for drug treatment [F1,12 = 0.372, p 
= 0.554] or housing condition [F1,12 = 0.400, p = 0.539] and no interaction between these 
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variables was present [F1,12 = 0.053, p = 0.822]. Furthermore, no significant effect was 
observed for hemisphere [F1,12 = 0.005, p = 0.943] and no interactions were found 
between hemisphere and any of the other variables (Figure 4.3B). In order to remain 
consistent with previous analyses, the hemispheres were subsequently analyzed 
separately (Figure 4.3D) and no significant main effects were observed in any variable 
in either the left or right hemispheres, nor were any interactions present (Table 4.1B). 
 
4.3.1.2   D2 receptor 
A 2-way ANOVA (drug treatment x housing condition) of D2 receptor protein 
expression in the PFC of males revealed no significant effects for drug treatment [F1,12 = 
0.850, p = 0.375], or housing condition [F1,12 = 0.575, p = 0.463] and no interaction 
between these variables was present [F1,12 = 0.104, p = 0.752]. No significant main 
effect for hemisphere was observed [F1,12 = 0.045, p = 0.836] and no interactions were 
seen between hemisphere and any other variable (Figure 4.4A). When the hemispheres 
were subsequently analyzed separately (Figure 4.4C), no significant effects were 
observed in any variable, in either hemisphere (see Table 4.2A). 
In females, no significant effects for drug treatment [F1,12 = 0.031, p = 0.864] or 
housing condition [F1,12 = 0.004, p = 0.951] were found and no interaction between these 
variables was present [F1,12 = 0.144, p = 0.711]. Likewise, no main effect for hemisphere 
was found [F1,12 = 0.121, p = 0.733] and no interactions were observed between 
hemisphere and any other variable (Figure 4.4B). When the hemispheres were 
subsequently analyzed separately (Figure 4.4D), no significant effects were observed in 
any variable, in either hemisphere (see Table 4.2A).  
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Figure 4.4   D2 receptor protein expression in the combined hemispheres of PFC and 
hippocampus of male (A) and female (B) rats treated neonatally with DOM or saline and 
housed in isolation or groups of 4. Panels C and D show D1 receptor expression values 
broken down by hemisphere for males (C) and females (D). * Indicates a p value of < 
0.05. 
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Table 4.2   Results of statistical analyses for D2 receptor expression in the prefrontal 
cortex (A) and hippocampus (B) of male and female adult rats treated neonatally with 
DOM or saline and reared in social housing or in isolation.  
 
A. Prefrontal cortex 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 0.488 
p = 0.498 
F1,12 = 0.015 
p = 0.906 
F1,12 = 0.506 
p = 0.491 
F1,12 = 0.018 
p = 0.895 
Housing 
F1,12 = 0.174 
p = 0.684 
F1,12 = 0.025 
p = 0.878 
F1,12 = 0.592 
p = 0.456 
F1,12 = 0.018 
p = 0.895 
Drug x 
Housing 
F1,12 = 0.001 
p = 0.972 
F1,12 = 0.047 
p = 0.831 
F1,12 = 0.245 
p = 0.630 
F1,12 = 0.109 
p = 0.747 
 
 
B. Hippocampus 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 1.698 
p = 0.217 
F1,12 = 0.162 
p = 0.694 
F1,12 = 0.704 
p = 0.418 
F1,12 = 0.214 
p = 0.652 
Housing 
F1,12 = 1.712 
p = 0.215 
F1,12 = 0.469 
p = 0.507 
F1,12 = 0.077 
p = 0.786 
F1,12 = 0.257 
p = 0.621 
Drug x 
Housing 
F1,12 = 0.091 
p = 0.768 
F1,12 = 4.236 
p = 0.062 
F1,12 = 0.015 
p = 0.905 
F1,12 = 1.458 
p = 0.250 
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Analysis of D2 receptor expression in the hippocampus revealed a similar pattern 
to the PFC. A 2-way ANOVA (drug treatment x housing condition) of D2 receptor 
expression in males revealed no significant effects for drug treatment [F1,12 = 1.458, p = 
0.251], or housing condition [F1,12 = 0.765, p = 0.399] and no interaction between these 
variables was present [F1,12 = 0.008, p = 0.930] (Figure 4.4A). A significant main effect 
for hemisphere was observed [F1,12 = 6.576, p = 0.025], with more D2 receptor protein 
being found in the left hemisphere (1.196 ± 0.092) as compared to the right hemisphere 
(0.959 ± 0.093) (Figure 4.4C). No interactions were observed between hemisphere and 
any other variable. When the hemispheres were subsequently analyzed separately, no 
significant main effects were observed in any variable in the left or right hemisphere 
(Table 4.2B). 
In female rats, no significant effects were seen for drug treatment [F1,12 = 0.416, 
p = 0.531] or housing condition [F1,12 = 0.005, p = 0.947] although a significant 
interaction was found between drug treatment and housing condition [F1,12 = 5.072, p = 
0.044]. A significant main effect was also found for hemisphere [F1,12 = 5.382, p = 
0.039] with a greater amount of D2 receptor protein being found in the left hemisphere 
(1.348 ± 0.064) compared to the right hemisphere (1.072 ± 0.092) (Figure 4.4D). No 
interactions were found between hemisphere and any other variable. When the 
hemispheres were subsequently analyzed separately, no significant main effects were 
observed in any variable in either the left or right hemispheres, nor were any interactions 
present (Table 4.2B). 
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4.3.1.3   Tyrosine hydroxylase 
Analyses of TH protein expression in the PFC of male rats revealed no 
significant effect for drug treatment [F1,12 = 3.332, p = 0.093], or housing condition [F1,12 
= 0.510, p = 0.489] and no interaction between these variables was present [F1,12 = 
1.025, p = 0.331]. No significant main effect for hemisphere was observed [F1,12 = 
0.692, p = 0.442] and no interactions were found between hemisphere and any other 
variable (Figure 4.5A). When the hemispheres were subsequently analyzed separately, 
no significant effects were observed in any variable, in either hemisphere (see Table 
4.3A) although there was a consistent trend of increased TH protein in the PFCs of 
DOM treated rats, particularly in the single housed animals (see Figure 4.5C). 
Females showed no significant effects for drug treatment [F1,12 = 0.910, p = 
0.359] or housing condition [F1,12 = 0.055, p = 0.819] and no interaction between these 
variables was present [F1,12 = 0.034, p = 0.856]. Likewise, no main effect for hemisphere 
was found [F1,12 = 2.500, p = 0.140] and no interactions were observed between 
hemisphere and any other variable (Figure 4.5B). In order to remain consistent with the 
other analyses in this study, hemispheres were subsequently analyzed separately (Figure 
4.5D). No significant effects were observed in any variable, in either hemisphere (see 
Table 4.3A).  
Analysis of TH protein expression in the hippocampus revealed no significant 
effects in males for drug treatment [F1,12 = 0.171, p = 0.687], or housing condition [F1,12 
= 0.157, p = 0.699] and no interaction between these variables was present [F1,12 = 
0.015, p = 0.906]. No significant main effect for hemisphere was observed [F1,12 = 
3.019, p = 0.108] and no interactions between hemisphere and any other variable were 
found (Figure 4.5A). When the hemispheres were subsequently analyzed separately 
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Figure 4.5   Tyrosine hydroxylase expression in the combined hemispheres of PFC and 
hippocampus of male (A) and female (B) rats treated neonatally with DOM or saline and 
housed in isolation or groups of 4. Panels C and D show TH expression values broken 
down by hemisphere for males (C) and females (D).   
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Table 4.3   Results of statistical analyses for tyrosine hydroxylase protein expression in 
the prefrontal cortex (A) and hippocampus (B) of male and female adult rats treated 
neonatally with DOM or saline and reared in social housing or in isolation.  
 
A. Prefrontal cortex 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 4.674 
p = 0.052 
F1,12 = 1.629 
p = 0.226 
F1,12 = 2.008 
p = 0.182 
F1,12 = 0.069 
p = 0.797 
Housing 
F1,12 = 1.399 
p = 0.260 
F1,12 = 0.001 
p = 0.972 
F1,12 = 0.079 
p = 0.783 
F1,12 = 0.364 
p = 0.558 
Drug x 
Housing 
F1,12 = 1.598 
p = 0.230 
F1,12 = 0.015 
p = 0.904 
F1,12 = 0.538 
p = 0.477 
F1,12 = 0.086 
p = 0.774 
 
 
B. Hippocampus 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 0.503 
p = 0.492 
F1,12 = 0.031 
p = 0.863 
F1,12 = 0.048 
p = 0.831 
F1,12 = 0.063 
p = 0.805 
Housing 
F1,12 = 0.001 
p = 0.971 
F1,12 = 0.870 
p = 0.369 
F1,12 = 0.215 
p = 0.651 
F1,12 = 0.053 
p = 0.822 
Drug x 
Housing 
F1,12 = 0.142 
p = 0.713 
F1,12 = 0.367 
p = 0.556 
F1,12 = 0.074 
p = 0.791 
F1,12 = 0.002 
p = 0.966 
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(Figure 4.5C), no significant main effects were observed in any variable in the left or 
right hemisphere (Table 4.3B). 
No significant effects were seen in the hippocampus of female rats for drug 
treatment [F1,12 = 0.038, p = 0.848], housing condition [F1,12 = 0.001, p = 0.975] nor was 
an interaction between those two variables present [F1,12 = 0.015, p = 0.904]. A 
significant main effect was not found for hemisphere [F1,12 = 4.259, p = 0.061] and no 
interactions were found between hemisphere and any other variable (Figure 4.5B). When 
the hemispheres were subsequently analyzed separately (Figure 4.5D), no significant 
main effects were observed in any variable in either the left or right hemispheres, nor 
were any interactions present (Table 4.3B). 
 
4.3.2   GABA markers 
4.3.2.1   GAD65 
Analyses of GAD65 protein expression in the PFC of males revealed no 
significant effects for drug treatment [F1,12 = 0.015, p = 0.905], or housing condition 
[F1,12 = 0.285, p = 0.603] and no interaction between these variables was present [F1,12 = 
0.606, p = 0.451] (Figure 4.6A). No significant main effect for hemisphere was observed 
although the value was approaching significance [F1,12 = 4.510, p = 0.055] with a trend 
of higher GAD65 protein expression in the left hemisphere (0.867 ± 0.089) as compared 
to the right hemisphere (0.734 ± 0.087) (Figure 4.6C). No interactions were observed 
between hemisphere and any other variable. When hemispheres were further analyzed 
separately, no significant main effects were observed in any variable, in either 
hemisphere (see Table 4.4A). 
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Figure 4.6   GAD65 protein expression in the combined hemispheres of PFC and 
hippocampus of male (A) and female (B) rats treated neonatally with DOM or saline and 
housed in isolation or groups of 4. Panels C and D show GAD65 expression values 
broken down by hemisphere for males (C) and females (D). * Indicates a p value of < 
0.05.  
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Table 4.4   Results of statistical analyses for GAD 65 protein expression in the prefrontal 
cortex (A) and hippocampus (B) of male and female adult rats treated neonatally with 
DOM or saline and reared in social housing or in isolation. * indicates a significant main 
effect or an interaction for that/those variable(s) (p < 0.05). 
 
A. Prefrontal cortex 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 0.170 
p = 0.687 
F1,12 = 1.163 
p = 0.302 
F1,12 = 0.034 
p = 0.856 
F1,12 = 0.007 
p = 0.933 
Housing 
F1,12 = 0.103 
p = 0.754 
F1,12 = 0.003 
p = 0.959 
F1,12 = 0.475 
p = 0.504 
F1,12 = 0.639 
p = 0.439 
Drug x 
Housing 
F1,12 = 0.715 
p = 0.414 
F1,12 = 0.016 
p = 0.901 
F1,12 = 0.388 
p = 0.545 
F1,12 = 0.264 
p = 0.617 
 
 
B. Hippocampus 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 0.558 
p = 0.469 
F1,12 = 0.644 
p = 0.438 
F1,12 = 1.401 
p = 0.259 
F1,12 = 0.442 
p = 0.519 
Housing 
F1,12 = 0.174 
p = 0.684 
F1,12 = 0.286 
p = 0.602 
F1,12 = 4.999 
p = 0.045* 
F1,12 = 0.442 
p = 0.519 
Drug x 
Housing 
F1,12 = 0.147 
p = 0.684 
F1,12 = 0.527 
p = 0.482 
F1,12 = 2.179 
p = 0.166 
F1,12 = 5.286 
p = 0.040* 
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In females, there were no significant effects for drug treatment [F1,12 = 0.567, p = 
0.466] or housing condition [F1,12 = 0.070, p = 0.795] and no interaction between these 
variables was present [F1,12 = 0.082, p = 0.779] (Figure 4.6B). A significant main effect 
for hemisphere was found [F1,12 = 8.561, p = 0.013] with GAD65 protein expression 
being greater in the left hemisphere (0.846 ± 0.079) versus the right hemisphere (0.646 ± 
0.041) (Figure 4.6D), however, no interactions were observed between hemisphere and 
any other variable. When the hemispheres were subsequently analyzed separately, no 
significant main effects were observed in any variable, in either hemisphere (see Table 
4.4A).  
Analysis of GAD65 protein expression in the hippocampus revealed no 
significant effects in males for drug treatment [F1,12 = 1.161, p = 0.302], or housing 
condition [F1,12 = 0.459, p = 0.511] and no interaction between these variables was 
present [F1,12 = 0.924, p = 0.355] (Figure 4.6A). A significant main effect for 
hemisphere was observed [F1,12 = 37.284, p < 0.001] with higher GAD65 protein 
expression in the left hippocampus (0.744 ± 0.067) compared to the right hippocampus 
(0.328 ± 0.050) (Figure 4.6C). No interactions between hemisphere and any other 
variable were present. When the hemispheres were subsequently analyzed separately, no 
significant main effects were observed in any variable in the left hemisphere (Table 
4.1B) but a significant main effect for housing condition was found in the right 
hemisphere (F1,12 = 4.999, p = 0.045]. When this effect was investigated further using t-
tests, no significant differences were observed among any of the groups (Table 4.4B). 
Interestingly, single housed males showed a general trend of increased GAD65 protein 
in the hippocampus of DOM treated rats compared to saline treated rats. 
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Females showed no significant effects for drug treatment [F1,12 = 0.070, p = 
0.796] or housing condition [F1,12 = 0.586, p = 0.459] and no interaction between these 
variables was present [F1,12 = 3.171, p = 0.100] (Figure 4.6B). A significant main effect 
for hemisphere was found [F1,12 = 15.395, p = 0.002] with GAD65 protein expression 
being greater in the left hippocampus (0.670 ± 0.044) versus the right hippocampus 
(0.381 ± 0.035) (Figure 4.6D). However, no interactions were observed between 
hemisphere and any other variable. When the hemispheres were subsequently analyzed 
separately, no significant main effects were observed in any variable in the left 
hemisphere (Table 4.4B) but a significant interaction between drug treatment and 
housing condition was found in the right hemisphere [F1,12 = 5.286, p = 0.040]. When 
this effect was investigated further using t-tests, no significant differences were observed 
among any of the groups although there was a consistent trend in the single housed rats 
whereby DOM treated rats showed less GAD65 protein than saline treated rats. 
Additionally, in rats that received DOM treatment there was a general trend for single 
housed rats to have less hippocampal GAD65 than group housed rats. 
 
4.3.2.2   GAD67 
Analyses of GAD67 protein expression in the PFC of male rats revealed no 
significant effects for drug treatment [F1,12 = 0.232, p = 0.639], or housing condition 
[F1,12 = 0.178, p = 0.681] and no interaction between these variables was present [F1,12 = 
0.018, p = 0.896] (Figure 4.7A). A significant main effect for hemisphere was observed 
[F1,12 = 10.402, p = 0.007] with a finding of higher GAD67 protein expression in the left 
PFC (0.520 ± 0.073) compared to the right PFC (0.342 ± 0.056) (Figure 4.7C). No 
interactions were observed between hemisphere and any other variable. When the  
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Figure 4.7   GAD 67 protein expression in the combined hemispheres of PFC and 
hippocampus of male (A) and female (B) rats treated neonatally with DOM or saline and 
housed in isolation or groups of 4. Panels C and D show GAD67 expression values 
broken down by hemisphere for males (C) and females (D). * Indicates a p value of < 
0.05.  
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hemispheres were subsequently analyzed separately, no significant main effects were 
observed in any variable, in either hemisphere (see Table 4.5A). 
In females no significant effects were seen for drug treatment [F1,12 = 0.046, p = 
0.834] or housing condition [F1,12 = 0.043, p = 0.840] and no interaction between these 
variables was present [F1,12 = 0.056, p = 0.474] (Figure 4.7B). A main effect for 
hemisphere was found [F1,12 = 6.967, p = 0.022] with GAD 67 protein expression being 
greater in the left PFC (0.571 ± 0.061) versus the right PFC (0.354 ± 0.023) (Figure 
4.7D). However, no interactions were observed between hemisphere and any other 
variable and when the hemispheres were subsequently analyzed separately, no 
significant main effects were observed in any variable, in either hemisphere (see Table 
4.5A).  
In the hippocampus, analysis of GAD67 protein expression revealed no 
significant effects in males for drug treatment [F1,12 = 0.056, p = 0.817], or housing 
condition [F1,12 = 0.014, p = 0.912] and no interaction between these variables was 
present [F1,12 = 0.240, p = 0.633] (Figure 4.7A). No significant main effect for 
hemisphere was observed [F1,12 = 4.129, p = 0.065] but the same trend of higher GAD67 
protein in the left hippocampus (0.437 ± 0.096) compared to the right hippocampus 
(0.223 ± 0.035) was present (Figure 4.7C). No interactions were observed between 
hemisphere and any other variable. When the hemispheres were subsequently analyzed 
separately, no significant main effects were observed in any variable in the left or right 
hemisphere. 
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Table 4.5   Results of statistical analyses for GAD 67 protein expression in the prefrontal 
cortex (A) and hippocampus (B) of male and female adult rats treated neonatally with 
DOM or saline and reared in social housing or in isolation. 
 
A. Prefrontal cortex 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 0.728 
p = 0.410 
F1,12 = 1.179 
p = 0.679 
F1,12 = 0.006 
p = 0.939 
F1,12 = 0.176 
p = 0.682 
Housing 
F1,12 = 0.001 
p = 0.972 
F1,12 = 0.188 
p = 0.673 
F1,12 = 0.880 
p = 0.367 
F1,12 = 0.217 
p = 0.650 
Drug x 
Housing 
F1,12 = 0.187 
p = 0.673 
F1,12 = 0.602 
p = 0.453 
F1,12 = 0.075 
p = 0.789 
F1,12 = 0.113 
p = 0.743 
 
 
B. Hippocampus 
Hem. Left Right 
Sex Male Female Male Female 
Drug 
F1,12 = 0.026 
p = 0.874 
F1,12 = 0.312 
p = 0.587 
F1,12 = 0.083 
p = 0.778 
F1,12 = 2.501 
p = 0.140 
Housing 
F1,12 = 0.197 
p = 0.665 
F1,12 = 0.016 
p = 0.903 
F1,12 = 0.798 
p = 0.389 
F1,12 = 2.757 
p = 0.123 
Drug x 
Housing 
F1,12 = 0.194 
p = 0.668 
F1,12 < 0.001 
p = 0.989 
F1,12 = 0.093 
p = 0.765 
F1,12 = 4.023 
p = 0.068 
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In females, no significant effects were seen for drug treatment [F1,12 = 0.003, p = 
0.960] or housing condition [F1,12 = 0.480, p = 0.502] and no interaction between these 
variables was present [F1,12 = 0.473, p = 0.505]. Furthermore, no significant effect was 
observed for hemisphere [F1,12 = 2.618, p = 0.132] and no interactions were found 
between hemisphere and any of the other variables (Figure 4.7B). In order to remain 
consistent with previous analyses, the hemispheres were subsequently analyzed 
separately (Figure 4.7D) and no significant main effects were observed in any variable 
in either the left or right hemispheres, nor were any interactions present (Table 4.5B). 
 
4.4   Discussion 
In contrast to the abundant behavioural effects described in Chapter 3, there was 
very little indication of change in any of the protein markers assessed in this study. No 
statistically significant differences in D1 receptor protein, D2 receptor protein or TH 
protein were observed among any experimental group, in either sex. Interestingly, there 
was a tendency for increased TH protein in the PFCs of male DOM treated rats which 
was particularly noticeable in the single housed males, but this was not statistically 
significant. As indicated in Figure 4.5A/C, this increased TH was accompanied by a 
large degree of variability. When this effect was investigated further by looking at the 
individual data points, it was clear that this increased mean and large variability was not 
due to a single outlier, with all animals in the DOM treated/single housed group 
demonstrating very different amounts of TH in the PFC. This finding of large variability 
within groups was shown to a lesser extent in other markers and could indicate a 
potential explanation for the lack of significant differences observed in this study. It 
could be that differences are present in individual animals but not consistently within all 
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animals in a given experimental group. In other words, an effect that is present in some 
individual animals is being hidden by those animals that did not show a change when we 
combine all animals in a given group together for statistical analysis. This idea is 
expanded upon further in Appendix C. 
Another interesting trend was observed with the GABAergic markers. As with 
the dopaminergic markers, no significant differences were found between experimental 
groups in either GAD65 or GAD67 protein. However, male rats did show a trend of 
increased GAD65 in the right hippocampus of DOM treated rats that were housed in 
isolation as compared to DOM treated rats that were housed in groups (Figure 4.6 A/C) 
and in fact this difference would have been statistically significant if the 1-tailed value 
was used. The opposite trend was observed in females where DOM treated, single 
housed rats appeared to have less GAD65 protein in the right hippocampus compared to 
DOM treated rats that were group housed (Figure 4.6 B/D) and again, this difference 
would be statistically significant if 1-tailed values were used. It is interesting that these 
trends were present in the right hippocampus alone, as the GAD67 data indicates the 
trends of lowered GAD67 protein due to DOM treatment are found primarily in the left 
PFC and left hippocampus of both males and females (Figure 4.7). 
The lack of significant findings in this study is surprising given that these 
neurotransmitter systems are known in the literature to be associated with the 
behavioural changes observed in Chapter 3 (see section 4.1). However, while both the 
DA and GABA systems are known to be involved, these are very complex behaviours 
which presumably involve many brain areas and multiple neurotransmitter systems. 
While the reasoning for investigating these markers was appropriate, it is certainly 
possible that it is changes to other brain areas that are responsible for the significant 
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behavioural effects observed in Chapter 3. For example, DA transmission in the NAc is 
thought to play an important role in LI and therefore could be an area for future study 
using this model (Han et al, 2012; Shao et al, 2009; Weiner, 2003). It is also possible 
that it is small alterations in a variety of brain areas and the resulting changes in how 
those areas interact with each other that are responsible for the behavioural effects 
previously observed. Another possibility is that these systems have changed, even within 
the areas studied, but that the investigation of other markers would have shown better 
results. A recent study by (Pehrson et al, 2013) found that attentional processing was 
impaired as a result of a pharmacological reduction in GABAA receptor functioning but 
was unaffected by a reduction in GAD67. This finding suggests that it may not be the 
concentration of protein that is important to the role of GABA in attentional processing, 
but rather the functional activity of the system. 
It is also possible that there are changes in these markers within these brain areas, 
but they were not detected. One issue with protein analysis by Western blot, and indeed, 
a possible explanation for why we did not observe changes, is that only somewhat larger 
brain areas can be investigated because of the amount of protein required. In this 
experiment the hippocampus was taken as one structure (although right and left 
hemispheres were separated). Also in the case of the PFC, the entire PFC was taken and 
homogenized. While processing the tissue in this manner is necessary for Western 
blotting, it does have limitations and makes it unlikely that differences localized to only 
some subsections of a structure might be detected. While past studies using the neonatal 
DOM model have suggested changes to both the DA and GABA systems, the changes 
have often been slight (often region specific, sex specific or hemisphere specific) 
(Adams-Marriott, 2009; Gill et al, 2010, 2012; Robbins et al, 2013). Differences in 
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experimental design are another possible explanation for why we did not observe those 
same changes. For example, we were not able to look at the ventral versus dorsal 
hippocampus, nor were we able to assess the various subfields of the PFC. Therefore, if 
very small differences existed in only a small region of the brain, it is conceivable that 
this difference would no longer be detectable; the effect having been diluted by the other 
brain tissue during homogenization and processing.  
It is important to recognize that measuring protein concentrations (as was done in 
this study) does not provide conclusive information about the activity of those systems 
as it does not measure that activity itself. It is theoretically possible for the total amount 
of receptor protein to remain the same, but for the functional properties of those 
receptors to be altered (e.g. posttranslational modification). It is also possible for other 
aspects of neurotransmission within a system to have changed (e.g. neurotransmitter 
synthesis, reuptake, degradation) while the receptor concentrations remain the same. 
Along this same line of thinking, it is interesting to note that in this study it appears that 
D1 and D2 receptor protein levels are more consistent across the experimental groups, 
while greater group differences are observed for TH, GAD65 and GAD67, which are 
implicated in the synthesis of DA and GABA respectively rather than the receptors 
themselves. Thus, it might be helpful in future studies to use other methods (e.g. high-
performance liquid chromatography) to measure activity in a more direct manner. 
Additionally, it could be argued that the variability within groups appears to be higher in 
TH, GAD65 and GAD67 as compared to D1 and D2, lending further support for the idea 
that perhaps changes in these marker have occurred, but that they have been masked by 
the high degree of variability within some of the treatment groups. 
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Interestingly, the most consistent finding of this study was significant 
hemispheric differences in the overall amount of protein expression. These differences 
were found in at least one brain area for all protein markers and always revealed higher 
protein in the left hemisphere, except in the case of TH, which was higher in the right 
hemisphere. The issue of lateral asymmetry of neurotransmitter systems in the brain has 
been a topic of debate. Lateralization is well established in animals, with results in 
healthy rats including increased GAD in the left striatum vs. the right striatum (Guarneri 
et al, 1985), increased D2 in the left striatum vs. the right striatum (Schneider et al, 
1982) and decreased D1, D2 and DA in the left cortex vs. the right cortex (Nowak, 
1989). With humans, some post-mortem studies on the brains of healthy human subjects 
indicate no differences between the hemispheres (Rossor et al, 1980), while other 
studies suggest that differences do exist (Glick et al, 1982). A study by Glick et al, 
(1982) looked at a number of brain areas not assessed in this study (in caudate, putamen 
and globus pallidus), but never-the-less, indicated a number of interesting findings 
including that DA was greater in the left hemisphere, that there was a significant trend 
for brains with lower overall DA levels to be left-biased and those brains with overall 
higher DA levels to be right biased. They also concluded that many of their finding had 
been previously reported in rats, indicating that rodents and humans may share similar 
right-left asymmetries in neurotransmitters (Glick et al, 1982). 
A number of lateralization differences also have been found in both people with 
schizophrenia (DeLisi et al, 1991) as well as in current animals models (Hikida et al, 
2007; Pletnikov et al, 2008), with the left hemisphere often being affected to a greater 
extent than the right. Specifically (Reynolds, 1983) found increased DA in the left 
amygdala vs. the right amygdala of people with schizophrenia. 
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Regarding the specific finding of higher proteins for all markers in the left 
hemisphere as compared with the right (except in the case of TH) a study by (Zaborszky 
and Vadasz, 2001) used a series of genetic mouse models known to express low, 
medium and high amounts of TH activity. Using these mice, they investigated TH and 
DA receptors in the mesencephalicc DA system and found an inverse relationship 
between TH and the number of DA neurons. This is intriguing, as all markers in the 
study described in this chapter were higher in the left hemisphere (including D1 and D2 
receptor protein) except for TH, which was higher in the right. This may indicate some 
sort of compensatory relationship between these markers of DA activity.  
While the results of investigations into lateralization of neurotransmitter systems 
in the brains of both healthy human and animal subjects, as well as those in the clinical 
population and models are unclear and often contradictory, it does appear that 
hemispheric differences are not uncommon. Therefore it is perhaps not surprising that 
hemispheric differences were found in this study and that it only seemed unusual since 
carrying out separate analyses for each hemisphere seems relatively uncommon. 
In conclusion, while some interesting trends were observed, no significant 
differences were found in the protein expression of D1 receptors, D2 receptors, TH, 
GAD65 or GAD67. It is possible that changes in these systems have occurred but were 
not observed using this experimental design (a further investigation of correlations 
between this data and the data from Chapter 3 is explored in Appendix C). It is also 
possible that changes in other neurotransmitter systems and/or other brain areas are 
responsible for the behavioural effects observed in Chapter 3.  
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Summary of the main results, general discussion and conclusions 
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5.1   Goals of the thesis 
The primary purpose of the experiments described herein was to better 
understand how early developmental factors can have a long lasting effect on the CNS 
and how such alterations may contribute to understanding the development of 
neuropsychiatric disorders. This was accomplished by investigating the effects of both 
neonatal low-dose DOM treatment and social isolation rearing on behavioural measures 
of attentional processing and the region-specific expression of relevant protein markers 
in the brains of those same animals. The use of these two paradigms was previously 
reported to produce alterations in attentional processing in rats, and the exploration of 
each alone and in combination, was a novel approach to investigating the “two-hit” 
hypothesis of psychiatric disease.  
 
5.2   Effect of neonatal low-dose DOM treatment and social isolation rearing on 
behavioural measures of attentional processing 
Following the establishment of experimental protocols outlined in Chapter 2, the 
experiments in Chapter 3 investigated the effects of neonatal low-dose DOM treatment 
and social isolation rearing on LI and PPI, two behavioural measures of attentional 
processing. Results indicated that both behaviours were affected, but the effects 
observed and the degree of change varied greatly depending on the sex of the animal, the 
test used, and the particular measure being examined. 
The results of LI testing found that neonatal DOM treatment completely 
abolished the significant LI effect observed in male saline-treated rats at 48 hours post-
testing, regardless of housing condition. Isolation housing alone also resulted in a lack of 
statistically significant LI in males, although the effect was not as dramatic as that seen 
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in DOM treated rats. When male rats were tested again one week later, significant LI 
was seen only in the DOM treated rats that were single-housed and was not observed in 
any other experimental groups. 
Very different results were obtained in female rats where both single and group-
housed rats treated with DOM displayed significant LI at 48 hours, while neither of the 
saline treated groups did (although both groups of saline-treated female rats showed a 
tendency toward significant LI). When tested again one week later, no LI effects were 
observed in any group of female rats. 
Collectively, these results suggest that both of the early life interventions used 
affected LI, but perhaps the effects of DOM manifest mainly in the short-term whereas 
social isolation produces longer lasting disruptions of LI. It was concluded that neonatal 
treatment with DOM is highly disruptive to the normal development of LI in male rats 
and to a lesser extent female rats, however the lack of a statistically significant LI effect 
in groups of female rats in this study may be a function of variability and small sample 
size. 
Both neonatal DOM treatment and social isolation rearing had a profound effect 
on the PPI of male and to a lesser extent, female rats, but these effects were different for 
the various measures of PPI. Social isolation significantly lowered the amplitude of PPI 
in male rats which is consistent with previous literature using this model (Domeney and 
Feldon, 1998; Geyer et al, 1993; Stevens et al, 1997). Interestingly, while neonatal 
DOM treatment alone did not produce any effect on PPI amplitude, it appeared to make 
male rats refractory to the expected effects of social isolation on PPI. When the data 
were analyzed for latency (as opposed to amplitude) social isolation and DOM treatment 
caused an additive increase in PPI startle latency that was observed in both male and 
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female rats. These results indicate that neonatal DOM treatment has a strong effect on all 
measures of PPI assessed in this study although it appears to be countering the ability of 
isolation rearing to affect startle amplitude and working in an additive manner with 
isolation rearing to affect startle latency. 
It is important to point out that the behavioural changes observed in these 
experiments cannot be attributed to many other factors that showed no indication of 
differences between the groups. For LI these other factors included the amount of water 
consumed during training and rebaseline, the latency to begin drinking during training 
and rebaseline, and the amount of water consumed in the homecage (see sections 
3.3.2.1, 3.3.2.2 and 3.3.2.3). For PPI these other factors included the weight of the 
animals, their baseline startle level, movement during testing and their habituation (see 
sections, 3.3.1 and 3.3.3). Additionally, it is unlikely that the observed changes were due 
to differences in the ability of treated animals to hear the tone because none of the 
experimental groups showed differences in baseline startle behaviours, indicating they 
were able to hear the auditory queues without issue. 
One of the consistent findings in this thesis was the differences between male 
and female rats. These differences are not necessarily surprising given the multitude of 
sex differences previously observed in the neonatal domoate model (Adams et al, 2009; 
Burt et al, 2008; Doucette et al, 2007; Gill et al, 2010b, 2012; Marriott et al, 2012; 
Robbins et al, 2013; Ryan et al, 2011), as well as the clinical populations these 
interventions are seeking to represent (Häfner, 2003; Rao and Kölsch, 2003; Salokangas 
et al, 2003). Furthermore, sex-dependent baseline differences in the behaviours in 
question have been observed in both healthy populations (Klosterhalfen et al, 2005) and 
in the clinical population (Kumari et al, 2004; Lubow et al, 2001). While the precise 
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cause of the sex differences observed in this study are unclear, one possibility could be 
that the neonatal DOM administration protocol affected males and females differently. 
Developmental variations in neurotransmitter systems thought to be implicated in these 
behaviours could be one possibility. For example, while the developmental shift in 
GABA from being excitatory (depolarizing) to inhibitory (hyperpolarizing) (see section 
1.3.3.3) occurs by the second week of postnatal life, the precise age of the shift may 
depend on sex, with the shift potentially occurring earlier in females than in males 
(Galanopoulou, 2008; Nuñez and McCarthy, 2007). If female rats have already 
undergone this developmental shift by the time the DOM treatment begins but the males 
have not, it is likely that the treatment which is presumed to affect overall 
excitatory/inhibitory balance in the brain, will affect the sexes differently. 
 
5.3   Effects of neonatal low-dose DOM treatment and social isolation rearing on 
select protein expression in the brain 
Following the finding of significant behavioural alterations in Chapter 3, Chapter 
4 sought to investigate protein markers of neurotransmitter systems of interest, selected 
based on the current understanding of the brain areas and systems involved in the 
observed behavioural changes, their involvement in disorders observed in the human 
clinical population, their role in attentional processing, and the results of previous 
findings in these models.  
No significant differences were observed in any of the proteins measured, in 
either sex, in any of the brain areas, although some interesting trends were present. 
There was a tendency for increased TH protein expression in the PFCs of male DOM 
treated rats which was particularly noticeable in the single housed males. This finding is 
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in contrast to the study by Robbins et al, (2013) who found less TH in the right mPFC of 
DOM treated male rats as compared to saline treated male rats, however there were three 
major differences between the two studies. The experiments described by Robbins et al, 
(2013) quantified TH using immunohistochemistry that determined the number of cells 
showing TH immunoreactivity, not the concentration of TH as was measured herein. 
Additionally, Robbins et al, (2013) housed the rats in groups of 2 or 3, which could also 
contribute to differences observed between that study and the present work. Finally, the 
animals used in that study were considerably older (8-9 months of age) than the animals 
in the present study. The work in this thesis also found that male rats showed a trend 
toward increased concentrations of GAD65 in the right hippocampus of DOM treated 
rats that were housed in isolation as compared with DOM treated rats that were housed 
in groups, while the opposite effect was found in female rats (i.e. DOM treated, single 
housed females appeared to have less GAD65 protein in the right hippocampus 
compared to DOM treated females that were group housed). Significant hemispheric 
differences in the overall amount of protein expression were also found with all markers 
showing higher values in the left hemisphere, with the exception of TH, which was 
higher in the right hemisphere. However, these differences were not group dependent. 
While the results reported in Chapter 4 indicated no significant differences 
between groups for any of the protein markers measured, obvious visible differences in 
band intensity were observed through a visual inspection of the blots, suggesting 
considerable variability between individuals. To further investigate this observation, a 
correlational analysis was undertaken to compare the behavioural results described in 
Chapter 3, with the protein marker data from Chapter 4 for individual rats. The results of 
those analyses are presented in Appendix C. Results indicated a number of significant 
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correlations in both males and females, suggesting that neonatal DOM treatment and 
social isolation rearing may have lead to subtle, but functionally-relevant, changes in the 
DA and GABA systems of individual animals, but that these changes are sufficiently 
variable within groups that they mask any effect when a group is analyzed as a whole. 
 
5.4   Assessing the interaction between neonatal low-dose DOM treatment and 
social isolation rearing in rats to better model aspects of human neuropsychiatric 
disorder 
 One of the original hypotheses directing the experimental work described in this 
thesis was that neonatal low-dose DOM treatment during the second week of postnatal 
life combined with social isolation rearing from weaning would lead to more dramatic 
and consistent behavioural and neurochemical changes than either intervention alone. 
This was found to be the case with regard to some, but not all experimental measures 
assessed. 
 In the case of LI, neonatal DOM treatment and social isolation rearing both 
produced deficits in LI behaviour, but the response to the two interventions was quite 
different and, with one exception (see below) the effects did not appear to be additive 
(although in male rats at 48 hours the LI phenomenon was completely abolished by 
DOM thereby precluding any additional response produced by housing condition). In the 
case of PPI, it was found that social isolation decreased PPI amplitude, but that DOM 
treatment made isolation housed animals refractory to the housing effect while 
producing no changes in PPI amplitude when used alone. Interestingly, both isolation 
rearing and DOM produced an additive increase in the latency to maximum startle. 
These results indicate that different pathways are likely responsible for PPI amplitude 
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and PPI latency. This is a novel finding and may serve as a basis for further dissecting 
the circuitry responsible for PPI. Overall, it can be concluded that neonatal DOM 
treatment and social isolation rearing both impair attentional processing in adult male, 
and to a lesser extent female rats, although the mechanisms by which this occurs may be 
different. 
Further support for this theory of a dissociation between mechanisms was 
provided by the results of the correlational analyses described in Appendix C. Not only 
did the results suggest that different systems may be responsible for different aspects of 
PPI behaviour, with the DA system appearing more important in the regulation of PPI 
amplitude, and the GABA system being more important for the regulation of PPI 
latency, but they support the notion that the two interventions (neonatal DOM treatment 
and social isolation rearing) may be exerting their effects primarily through changes in 
different neurotransmitter systems. This was illustrated by the fact that animals that 
experienced DOM treatment alone showed correlation between PPI latency behaviour 
and the GABA system, while those animals that experienced the isolation housing 
condition alone showed negative correlations between PPI amplitude behaviour and DA 
system markers, as well as positive correlations between PPI latency behaviour and DA 
system markers. Rats that received both neonatal DOM treatment and social isolation 
rearing thus displayed all of these correlations.  
A relatively new path for research in the field is that of the 2-hit hypothesis of 
neuropsychiatric disease. According to this theory, disruption to the early development 
of the CNS is caused by genetic or environmental factors (first hit) resulting in long-
term vulnerability of the organism to a “second hit” which leads to the onset of 
symptoms. Similar “multiple-hit” theories also exist (Maynard et al, 2001). The data 
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presented in this thesis contribute to a better understanding of this theory and highlight 
future avenues for research. The findings illustrate the ability of different models to 
produce a variety of effects when combined that are not limited to a simple combination 
of the effect of each model alone. Furthermore, we cannot assume that just because two 
models may have similar behavioural profiles that those profiles arise from the same 
neurobiological change. Likewise, just because two people with a given disorder may 
display similar symptom profiles, does not necessarily mean that their symptoms are the 
result of identical neurological abnormalities or an identical neurological history. In fact, 
it is possible that the extensive heterogeny observed in a disorder like schizophrenia can 
be attributed, at least in part, to the variety of paths that may lead to the development of 
the disease and the multitude of factors that are interacting to produce the resulting 
illness. 
 
5.5   Future directions 
The results of this thesis have raised a number of points of consideration with 
regard to both improvements on the current study design and future directions for this 
line of research. 
The outcomes of these studies might have been clearer if a larger number of 
animals had been used. This is particularly true for the LI experiment in Chapter 3 and 
the post-hoc correlational analyses described in Appendix C. In behavioural testing, 
group numbers of 8-12 are generally considered to be ideal. While those numbers were 
used for PPI testing, the method of LI testing (where each experimental group must be 
further divided into PE and NPE groups) cut the number of animals in half, resulting in n 
= 6 (see Figure 3.1). While this smaller number of animals was sufficient to produce the 
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dramatic loss of LI observed in the DOM treated males, larger groups might have 
clarified some of the other weaker effects that were observed, particularly with regard to 
the females where there was a larger amount of variability. It would also have been 
interesting to have a larger number of animals for the correlational analysis, wherein that 
would have theoretically provided more accurate correlation results and may have 
clarified some of the effects that were observed, again, particularly in the female rats. 
 As stated in section 5.2, the developmental shift in GABA from excitatory 
(depolarizing) to inhibitory (hyperpolarizing) raises an important issue for future studies. 
It is possible that the DOM treatment protocol used in this work is not affecting males 
and females in the same manner. Therefore, future work with this model may want to 
consider assessing the effects of different timing of the DOM administration on the sex-
dependent differences which have been repeatedly observed. There may also be 
differences in DOM potency between male and female rats, necessitating a different 
dosage of the drug. While Doucette et al. (2000) found no sex-dependent differences in 
neonatal rats tested for behavioural toxicity, the more subtle changes inherent in this 
model may be influenced by sex differences that alter the effective concentration of 
DOM at the site(s) of action. 
Consistent with much previously published work on this model, the results of the 
current studies provide further support for the belief that the neurodevelopmental effects 
of neonatal DOM treatment change over time. While previous studies demonstrated a 
decrease in PPI startle amplitude in young adult animals following neonatal DOM 
treatment (Adams et al, 2008; Marriott et al, 2012), that effect was not observed in the 
older adult animals used in this study. A study that investigates the potential changes to 
both PPI amplitude and latency behaviour across a variety of ages would provide 
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information not only regarding the effects of neonatal DOM treatment on PPI, but on 
how the various systems that affect the different measures of PPI behaviour change over 
time. This research may lead to new and valuable data on how the brain changes during 
the progression of neurological diseases that originate in development, in addition to 
providing further refinement of the neonatal DOM model by defining the experimental 
variables necessary to reliably produce the behavioural alterations. 
 It would also be interesting to investigate other protein markers in the brains of 
these animals. While the results of Chapter 4 indicated no significant overall changes in 
the concentrations of markers of the DA and GABA systems, the results of Appendix C 
indicated that there may, in fact, be subtle alterations in these systems. One option for 
future study would be to further investigate the potential changes to the DA and GABA 
systems in these models using other means, for example, a functional measure such as 
electrophysiology or uptake of fluorescent dyes. However, it would also be of value to 
pursue the contribution of other neurotransmitter systems. While it would make sense to 
expand on the investigation of markers of the Glu system given that DOM is a Glu 
agonist, other systems may also be implicated and provide further avenues of research 
(see section 1.3.3.4). One possibility may be the cholinergic system, particularly the α7 
nicotinic receptor that has been implicated in neuropsychiatric illness (see Young and 
Geyer, 2013 for review). 
From a methodological standpoint, the results of this work support some 
methods not commonly used in the literature. The repeated testing of LI behaviour 
following conditioning, the assessment of multiple measures of PPI behaviour including 
latency to max startle amplitude, and investigations into correlations between observed 
behavioural changes and other measures such as the protein analysis all contributed 
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greatly to the results of this work. While these methods may not be standard practice (or 
even present in the literature), their use in this work provided invaluable insight not only 
into the effects of the experimental variables on brain and behaviour, but also on how 
the brain influences the observed behaviours and the implications of all of these factors 
in understanding neurodevelopmental disorders. 
Finally, while early studies indicated that neonatal low-dose DOM treatment 
showed promise as an animal model of temporal lobe epilepsy (Bernard et al, 2007; 
Doucette et al, 2004, 2007; Gill et al, 2009, 2010a, 2010b; Perry et al, 2009) and later 
work indicated the potential to model certain aspects of schizophrenia (Adams et al, 
2008; Marriott et al, 2012), the work described in this thesis has further contributed to 
our understanding of the neonatal DOM model and highlighted its ability to illustrate 
aspects of a number of disorders. The finding of strong and consistent deficits in 
behavioural measures of attentional processing and potential changes in the systems 
involved indicates that neonatal low-dose DOM treatment may not be a model of only 
one disorder, but rather a model of the progressive neurological dysfunction seen in a 
wide variety of disorders. Furthermore, a significant positive characteristic of this model 
is that the changes observed do not result from a single large scale insult occurring to the 
developed brain, but rather, are due to small changes in the normal process of CNS 
development that have long lasting and far reaching implications to the adult being. This 
approach to modeling disease progression and disease co-morbidities is consistent with 
many of the current theories on clinically-relevant brain dysfunction originating early in 
life and thereby highlights the utility of future studies employing a “multi-hit” approach 
to the study of neuropsychiatric disorders. 
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5.6   Conclusion 
In conclusion, the findings described in this thesis indicate that both neonatal 
low-dose DOM treatment and social isolation rearing affect the development of normal 
attentional processing in rats. However, each paradigm may exert these effects through 
different systems, and these different systems may be responsible for different aspects of 
the behavioural changes that were observed. Furthermore, the findings reinforce the 
importance of fully investigating the chosen behavioural measures.  
In contrast to the popular belief that combining two different models will 
produce a new model that is simply an additive combination of the two, the results of 
this work have shown that different precipitating factors may act in an additive manner, 
or they may act against each other to mask any effects, or only one factor may be 
exerting an effect on a given measure. This finding indicates that multi-hit models have 
great potential to increase our understanding of neuropsychiatric disorders by better 
modeling the currently understood etiology of the diseases and by allowing for a more 
in-depth study of the complex interactions that play a role in disease development. 
Further research into the understanding of the multi-hit model of neuropsychiatric 
disorders may thus explain the large variety of symptom profiles observed within a 
single disorder and serve to guide further research using animal models to study 
complex human neuropsychiatric diseases. 
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Analysis of prepulse inhibition data output 
 
  
229 
 
A.1   Detailed analysis of prepulse inhibition data output 
 Prepulse inhibition testing (as described in section 3.2.3) provides extensive data 
output that can be used to calculate a variety of measures and assess multiple different 
behaviours. Table A.1 shows the output that is obtained from one trial, for one animal. 
The values of the specific columns are as follows: 
Trial: The number of that specific trial 
Trial type: The type of trial 
Start: The movement detected by the accelerometer in the 1 ms that precedes the 
auditory stimulus 
Vmax: The point of maximum startle amplitude for that trial 
Tmax: The latency in ms to reach the point of maximum startle amplitude for 
that trial 
Avg: The average startle amplitude for that trial. Obtained by averaging the 100 
amplitude measures taken every 1 ms for 100 ms after the onset of the pulse 
stimulus 
After obtaining the complete data set for a particular animal, it is necessary to 
inspect the output and confirm that all of the values can be attributed to startle behaviour 
and not due to the movement of the animal during testing. This is done by comparing the 
“start” value to the “avg” value for each trial. If “start” ≥ “avg” this indicates that the 
animal was likely moving before the beginning of the auditory stimulus, thereby making 
the startle values unreliable and the data for that trial is discarded. If “start” < “avg” this 
indicates that either the animal was not moving before the beginning of the auditory 
stimulus or that the animal was moving minimally and this movement likely did not 
interfere with measuring startle behaviour. The data from this trial is kept for further  
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Table A.1   Prepulse inhibition data output from one animal on a representative trial. 
 
Trial Trial Type Start Vmax Tmax Avg 
12 startle alone pulse trial 0 1064 35 339 
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analysis. This procedure is conducted for every type of trial except for “no stimulus” 
trials, as trials of this type do not include an auditory stimulus of any kind and are 
specifically an assessment of the animal’s movement during testing. 
For most measures (all but “initial startle”), multiple trials of each type are 
conducted and the values are averaged to provide a single value which can then be used 
in the calculation of the various measures of interest. Table A.2 displays a full data set 
for a particular animal and illustrates how the various trial types are averaged in order to 
obtain the necessary values. Values provided at this step of data analysis include: 
(A) Initial startle: The startle of the animal on the first trial of testing (120 dBs). 
Used as a standalone value. 
(B) Startle at the beginning of testing: Average startle values of the animal 
during trials 2-6 (120 dBs). Used to normalize startle, to establish baseline startle 
behaviour for that animal and to calculate startle habituation during testing. 
(C) Movement during testing: Average movement of the animal during trials 
when no auditory stimulus is presented. Used to determine the movement of the 
animal during testing. 
(D) 74 dBs prepulse startle: Average startle of the animal in trials where a 
prepulse 4 dBs above the background is presented before the startle pulse (120 
dBs). Used in the calculation of PPI behaviours. 
(E) 78 dBs prepulse startle: Average startle of the animal in trials where a 
prepulse 8 dBs above the background is presented before the startle pulse(120 
dBs). Used in the calculation of PPI behaviours. 
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Table A.2   Complete PPI data output for a single animal. 
Block Trial Trial Type Start V Max T Max Avg. Measure 
Block 
1 
1 startle alone pulse trial 10 2583 45 806 Initial startle (A) 
2 startle alone pulse trial 5 845 41 222 Averaged 
 
baseline startle at the 
beginning of testing 
(B) 
3 startle alone pulse trial 5 645 19 177 
4 startle alone pulse trial 0 952 64 325 
5 startle alone pulse trial 0 1226 35 413 
6 startle alone pulse trial 0 1616 39 540 
Block 
2 
8 no stimulus trial 0 0 0 0 
 
Averaged 
 
movement during testing 
 
(C) 
16 no stimulus trial 0 10 73 3 
19 no stimulus trial 0 0 0 0 
20 no stimulus trial 5 5 0 1 
24 no stimulus trial 20 20 0 10 
27 no stimulus trial 0 5 34 1 
31 no stimulus trial 10 10 0 3 
42 no stimulus trial 5 15 51 5 
15 PPI trial 74 dBs 0 698 35 169 
Averaged 
 
startle with a prepulse 4 
dBs above background 
 
(D) 
18 PPI trial 74 dBs 0 659 37 182 
21 PPI trial 74 dBs 5 1016 35 231 
28 PPI trial 74 dBs 0 259 21 86 
30 PPI trial 74 dBs 5 127 35 44 
34 PPI trial 74 dBs 0 391 36 94 
46 PPI trial 74 dBs 10 479 53 148 
47 PPI trial 74 dBs 0 679 45 199 
7 PPI trial 78 dBs 0 332 52 118 
 
Averaged 
 
startle with a prepulse 8 
dBs above background 
 
(E) 
11 PPI trial 78 dBs 5 552 35 185 
22 PPI trial 78 dBs 5 566 37 152 
33 PPI trial 78 dBs 5 298 20 79 
35 PPI trial 78 dBs 0 181 45 57 
38 PPI trial 78 dBs 0 425 50 133 
43 PPI trial 78 dBs 39 449 36 114 
45 PPI trial 78 dBs 5 337 37 89 
9 PPI trial 82 dBs 5 522 43 168 
Averaged 
 
startle with a prepulse 12 
dBs above background 
 
(F) 
10 PPI trial 82 dBs 0 293 36 94 
23 PPI trial 82 dBs 0 298 23 110 
39 PPI trial 82 dBs 10 210 20 84 
44 PPI trial 82 dBs 5 522 20 177 
48 PPI trial 82 dBs 59 400 47 108 
50 PPI trial 82 dBs 15 1191 36 300 
53 PPI trial 82 dBs 0 337 44 98 
13 PPI trial 86 dBs 0 542 36 114 
Averaged 
 
startle with a prepulse 16 
dBs above background 
 
(G) 
17 PPI trial 86 dBs 0 322 38 88 
26 PPI trial 86 dBs 0 205 22 71 
29 PPI trial 86 dBs 0 298 37 62 
40 PPI trial 86 dBs 10 259 58 92 
41 PPI trial 86 dBs 20 801 22 263 
51 PPI trial 86 dBs 20 1074 37 295 
54 PPI trial 86 dBs 0 303 43 97 
12 startle alone pulse trial 0 1064 35 339 Averaged 
 
startle without the 
14 startle alone pulse trial 0 1772 36 538 
25 startle alone pulse trial 15 2920 65 794 
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32 startle alone pulse trial 0 815 36 244 presence of a prepulse 
 
(H) 
36 startle alone pulse trial 0 410 20 98 
37 startle alone pulse trial 5 693 44 201 
49 startle alone pulse trial 0 801 52 227 
52 startle alone pulse trial 0 474 18 107 
Block 
3 
55 startle alone pulse trial 0 879 19 271 Averaged 
 
Baseline startle at the end 
of testing 
(I) 
56 startle alone pulse trial 0 591 36 168 
57 startle alone pulse trial 5 664 36 244 
58 startle alone pulse trial 5 625 20 150 
59 startle alone pulse trial 0 620 34 164 
 
Note: While the trials for Blocks 1 and 3 are displayed in the order they were conducted, 
all of the trials in Block 2 were conducted in random order. Block 2 trial values have 
thus been sorted by trial type in this table but the actual order of the trials can be seen by 
observing the values in the “Trial” column, which show the actual order that each animal 
experience the trials. 
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(F) 82 dBs prepulse startle: Average startle of the animal in trials where a 
prepulse 12 dBs above the background is presented before the startle pulse (120 
dBs). Used in the calculation of PPI behaviours. 
(G) 86 dBs prepulse startle: Average startle of the animal in trials where a 
prepulse 16 dBs above the background is presented before the startle pulse (120 
dBs). Used in the calculation of PPI behaviours. 
(H) 120 dBs pulse alone startle: Average startle of the animal when a 120 dBs 
pulse is presented alone, without being preceded by a prepulse. Used in the 
calculation of PPI behaviours. 
 (I) Startle at the end of testing: Average startle values of the animal during the 
last 5 startle alone pulse trials (120 dBs). Used to calculate baseline startle at the 
end of testing and to calculate startle habituation during testing. 
Each of these values illustrates a particular behavioural measure for each of the 3 
PPI measures of interest: (1) the maximum startle amplitude (Vmax), (2) the average 
startle amplitude (%PPI), and (3) the latency to maximum startle amplitude (Tmax). In 
the case of some measures, the values that are produced by this step provide the single 
data point needed from each animal for further statistical analysis. This is the case for 
(A) initial startle, (B) Startle at the beginning of testing, (C) Movement during testing, 
and (I) Startle at the end of testing. For other measures, namely the measures concerned 
with the specific startle inhibition behaviours, further calculations are needed. These PPI 
measures are depicted in Figure 3.3. Values for Vmax and %PPI are calculated 
according to the following formula: Vmax or %PPI = 100-(100*(X/Y)). Values for 
Tmax were calculated using the following formula: Tmax = X-Y. For both formulas, the 
value for X can be replaced by the previously calculated values obtained for (D), (E), (F) 
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or (G), depending on the prepulse dB level you are interested in assessing, and the value 
for Y will always be replaced by the startle alone value you calculated (H). For assessing 
startle habituation during testing the formula (B) – (I) is used. 
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Appendix B 
 
 
 
A comparison of two methods of Western blot quantification 
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B.1   Introduction 
There are a variety of software programs available for the quantification of 
Western blot data. The programs can vary widely in the amount of automation vs. input 
required by the user, and in the amount of time it takes to complete quantification. While 
theoretically all software and equipment should be measuring the same thing in the same 
way, in reality there are often major differences in the output. 
 When the protein analysis portion of the work described in this thesis first began, 
the blot images were visualized and captured with a UVP BioSpectrum Imaging System 
(UVP, CA, USA) and quantified using ImageJ (NIH). ImageJ allows for a reliable and 
transparent method for the quantification of protein bands, however compared with other 
available software, it is quite labour intensive and relies heavily on user input, increasing 
the likelihood of user error and/or bias influencing the results. Additionally, ImageJ 
provides the output of only raw numerical values that require a further multi-step 
manipulation process using a spreadsheet program in order to obtain the normalized 
values necessary for statistical analysis. This method was used successfully for the 
analysis of all DA system markers assessed in Chapter 4 (D1 receptor, D2 receptor and 
TH protein).  
At a later stage in the study, new lab equipment was acquired. In addition to 
allowing for faster image visualization and capture with the new hardware (Bio-Rad 
ChemiDoc MP Image System, Bio-Rad Laboratories, ON, Canada), the accompanying 
software (ImageLab, version 4.1, Bio-Rad Laboratories, Bio-Rad, ON, Canada) would 
allow for faster quantification, providing a more automated method of analysis than the 
previously used ImageJ software.  
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While a more efficient method of quantification was desirable, it was first 
necessary to determine if the new “Image Lab” method was quantifying protein 
concentration on the blots in a comparable manner to the old “ImageJ” method. The 
purpose of this small study was to compare the two methods of quantification to assess if 
they were quantifying protein in a comparable manner and giving similar outputs of 
protein concentration. The aim was to determine if it would be acceptable to proceed 
with the newer, more efficient analysis method for the second portion of the study 
(GABAergic system markers). 
 
B.2   Materials and methods 
 A blot from the experiments described in Chapter 4 was chosen at random for 
use in this study. The blot held protein samples from the left PFC and contained a 
standard sample common to all blots (used to control for inter-blot variations within the 
study). All experimental groups were equally represented on the blot. The blot was 
probed for GAD67 protein and β-actin protein (as a loading control), as described in 
section 4.2.4.2. The image of the blot was captured using the Bio-Rad ChemiDoc MP 
Image System (Bio-Rad Laboratories, ON, Canada). 
 Quantification of the blot image was conducted with both ImageLab and ImageJ. 
Any subsequent data manipulation was done using Microsoft Excel 2007 (Microsoft 
Corporation, USA). Using each system, a raw value was obtained for each band. The 
raw values for each band were normalized first to a reference band (the standard sample 
common on all blots) and then normalized to the loading control (β-actin). 
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The various output values obtained included: 
Raw value (RV): The raw output depicting the size and intensity of the band 
Relative density (RD): The value of the band of interest, normalized to the 
reference band. (RD = RV of band of interest / RV of reference band). 
Adjusted density (AD): The value of the band of interest, normalized to both the 
reference band and the loading control. (AD = RD of band of interest for a given 
lane / RD of band of loading control for the same lane). 
 
B.3   Results 
Table B.1 shows the results for the ImageJ output. The RVs were produced by 
the software while the RD and AD values were calculated using a spreadsheet. Table 
B.2 shows the results for the ImageLab output. The RV and RD values were produced 
by the software while the AD values were calculated using a spreadsheet. Table B.3 
compares the AD values for the blot that were obtained from the data supplied by both 
ImageJ and ImageLab. 
 
B.4   Discussion 
Both the ImageJ and ImageLab programs provide reliable and transparent 
methods of Western blot analysis. While the RVs differed widely between the two 
programs, once the raw output was normalized the values were very similar, indicating 
that both methods of quantification produce valid data. 
Analysis by the ImageLab software is more efficient than with ImageJ, requiring 
less image preparation and providing a faster method for lane and band selection. 
ImageLab may also lessen the opportunity for user error and bias by automatically 
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Table B.1   ImageJ output for the Western blot quantification of GAD67 (A) and β-actin 
(B) protein in the left PFC of adult rats treated neonatally with DOM or saline and 
housed in isolation or groups of 4. 
 
 
A. GAD67 
Lane Raw Value Relative Density Adjusted Density 
Lane 1 9740.296 1 1 
Lane 2 2246.912 0.230682 0.293252 
Lane 3 2614.154 0.268385 0.331202 
Lane 4 3978.347 0.408442 0.456807 
Lane 5 3569.518 0.366469 0.548110 
Lane 6 3524.933 0.361892 0.465421 
Lane 7 4644.882 0.476873 0.547432 
Lane 8 3951.640 0.405700 0.469681 
Lane 9 7760.246 0.796716 0.838134 
 
 
B. β-actin 
Lane Raw Value Relative Density 
Lane 1 14517.44 1 
Lane 2 11419.90 0.786633 
Lane 3 11764.02 0.810337 
Lane 4 12980.39 0.894124 
Lane 5 9706.44 0.668605 
Lane 6 11288.15 0.777558 
Lane 7 12646.27 0.871109 
Lane 8 12539.85 0.863779 
Lane 9 13800.02 0.950583 
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Table B.2   ImageLab output for the Western blot quantification of GAD67 (A) and  
β-actin (B) protein in the left PFC of adult treated neonatally with DOM or saline and 
housed in isolation or groups of 4. 
 
 
A. GAD67 
Lane Raw Value Relative Density Adjusted Density 
Lane 1 5600363 1 1 
Lane 2 1382493 0.246858 0.3108181 
Lane 3 1410701 0.251895 0.3044218 
Lane 4 2166899 0.386921 0.4668032 
Lane 5 2030288 0.362528 0.5677748 
Lane 6 2007799 0.358512 0.4793277 
Lane 7 2593072 0.463019 0.5505205 
Lane 8 2212350 0.395037 0.4758432 
Lane 9 4299398 0.767700 0.8162564 
 
 
B. β-actin 
Lane Raw Value Relative Density 
Lane 1 2661528 1 
Lane 2 2113837 0.794219 
Lane 3 2202288 0.827453 
Lane 4 2206072 0.828874 
Lane 5 1699403 0.638507 
Lane 6 1990685 0.747948 
Lane 7 2238494 0.841056 
Lane 8 2209555 0.830183 
Lane 9 2503202 0.940513 
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Table B.3   A comparison of Adjusted Density values for the Western blot quantification 
of GAD67 protein in the left PFC of adult rats treated neonatally with DOM or saline 
and housed in isolation or groups of 4, produced by ImageJ and ImageLab software 
programs. 
 
 
Lane ImageJ ImageLab 
Lane 1 1 1 
Lane 2 0.29 0.31 
Lane 3 0.33 0.30 
Lane 4 0.46 0.47 
Lane 5 0.55 0.57 
Lane 6 0.47 0.48 
Lane 7 0.55 0.55 
Lane 8 0.47 0.48 
Lane 9 0.84 0.82 
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defining lanes and bands before requiring approval from the user. Finally, ImageLab 
performs some of the normalization automatically, decreasing the amount of 
manipulation required in a spreadsheet before data analysis can begin. However, it is 
worth noting that both ImageLab and ImageJ rely on the user to determine the 
boundaries of the bands and so, involve a degree of subjectivity. It is therefore 
recommended that a single person quantify all of the blots for a given marker, for a 
given study, in order to avoid any questions of inter-rater reliability. 
 In conclusion, both programs can reliably quantify Western blot data. ImageLab 
was chosen to be used for the remainder of the study outlined in Chapter 4 as it was 
found to be both reliable, efficient and decreased the opportunity for user error and bias. 
 
 
 
  
244 
 
 
 
 
 
 
 
Appendix C 
 
 
 
Investigating correlations between previously reported behavioural changes and 
protein markers relevant to altered attentional processing  
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C.1   Introduction 
 The finding of no change in any of the protein markers assessed in Chapter 4 was 
surprising given the considerable behavioural changes observed in Chapter 3. These 
results could be due to a number of factors, as outlined in the discussion of Chapter 4. 
However, while there were no statistically significant differences between experimental 
groups, a visual inspection of the Western blots themselves revealed obvious differences 
between animals. These differences were particularly noticeable in markers of GAD65, 
GAD67 and TH protein (see Figure C.1 for examples of various blots). Such striking 
visual differences called into question the previously observed results and indicated that 
perhaps the experimental manipulations were resulting in changes to the protein 
markers, but that the changes were highly varied among the individual animals thereby 
producing obvious visual differences, but not statistically significant group differences. 
 Studies have occasionally assessed correlations between PPI and other measures, 
including other assessments of cognition and attention (Bitanihirwe et al, 2011; Singer et 
al, 2013) as well as symptoms of psychopathology in the clinical population (Braff et al, 
1999; Wang et al, 2013). Analysis of correlations between behavioural data and 
neurochemical measures of alterations in brain composition is uncommon in the 
literature surrounding animal models of neuropsychiatric disorders. There are, however, 
a small number of studies that have found individual correlations between PPI and 
measures of DA and GABA functioning. A study by Feifel (1999) showed that 
individual differences in baseline PPI displayed by adult male Sprague-Dawley rats were 
correlated to differences in sensitivity of the PPI response to apomorphine and 
haloperidol administration (drugs that affect the DA system). A study by 
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Figure C.1   Results of Western blot analysis of protein expression for GAD65 in the 
right hippocampus (A), GAD67 in the left hippocampus (B), D1 receptors in the right 
PFC (C), and TH in the left PFC (D) in the brains of rats treated neonatally with 20µg/kg 
DOM or saline and housed in groups of 4 or in isolation from weaning until adulthood. 
Top bands indicate the protein of interest while bottom bands display β-actin protein.  
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Nyffeler et al, (2006) used a model of maternal immune activation (see section 1.5.4.1) 
and found that PolyI:C treatment resulted in a significant increase in GABAA receptor 
subunit α2 immunoreactivity in the hippocampus and amygdala. Interestingly these 
authors found a correlation between α2 immunoreactivity and PPI behaviour in the 
control animals, but not in those animals from the PolyI:C group. 
The purpose of the additional analyses described in this Appendix was to further 
investigate the potential changes that result from neonatal DOM treatment and social 
isolation rearing, by combining the data from previous studies and looking for 
correlations between the observed behavioural changes and measures of protein 
expression. In doing so, the aim was to clarify if in fact no changes to the protein 
markers of interest had occurred, or if perhaps the changes were simply occurring in 
individual animals but not the experimental groups as a whole. 
 
C.2   Materials and methods 
C.2.1   Experimental animals 
 The data used for this analysis was obtained from the PPI testing described in 
Chapter 3, and the Western blot-derived protein analyses described in Chapter 4. The 
protein value for all markers of interest was matched with the PPI data for each 
individual animal, providing an n = 4 for each sex in each experimental group. Results 
from LI testing were not able to be matched to the protein data because of the necessity 
for all experimental groups to be further subdivided for LI testing into PE and NPE 
groups (see Figure 3.1), giving an n = 1 or 2. Thus PPI was the only behavioural 
measure used in this analysis. 
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C.2.2   Data analysis 
 Prepulse inhibition data for each individual animal was collapsed across the 4 
prepulse levels giving a single value for each of the PPI measures; Vmax, Tmax and 
%PPI (see section 3.2.3 for details) providing 3 PPI measures for each animal. Western 
blot data was kept as is, providing 6 measures for each animal (left PFC, right PFC, total 
PFC, left hippocampus, right hippocampus and total hippocampus) for each of the 5 
protein markers of interest (D1 receptor, D2 receptor, TH, GAD65 and GAD67). 
Pearson correlations were conducted comparing the PPI startle behaviour measures to 
the protein concentration measures for each individual animal. A p value of < 0.05 
indicates a significant correlation between those 2 variables. Because of the sex 
differences found in many previous measures (both behavioural and neurochemical), 
data for males and females was analyzed separately. 
 
C.3   Results 
A large number of significant correlations were found in the DOM-treated and 
single housed rats in all measures and both brain areas. All significant results are shown 
in Tables C.1-C.5 for male rats and in Tables C.6-C.10 for female rats, with specific 
results of interest discussed below. Results for the two measures of PPI amplitude (%PPI 
and Vmax) always produced similar results and are listed together in the discussion of 
the findings, although only one of the two may have been statistically significant for a 
given analysis. 
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Table C.1   Results of Pearson correlation analyses for PPI measures and D1 receptor 
protein expression in the PFC and hippocampus of male rats (n = 4 animals per group). 
For each region correlations were calculated for left hemisphere (L), right hemisphere 
(R) and left and right hemispheres combined. Values for Pearson’s r and p are reported 
where p < 0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk.  
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s r = -0.971 
p = 0.029 
n.s n.s n.s n.s 
Vmax n.s r = -0.958 
p = 0.042 
n.s r = -0.954 
p = 0.046 
n.s* n.s* 
Tmax r = 0.987 
p = 0.013 
n.s r = 0.998 
p = 0.002 
n.s n.s n.s 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s * n.s * n.s n.s n.s 
Vmax n.s * r = -0.983 
p = 0.017 
n.s * n.s n.s n.s 
Tmax n.s n.s * n.s n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s * n.s n.s n.s n.s 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
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Table C.2   Results of Pearson correlation analyses for PPI measures and D2 receptor 
protein expression in the PFC and hippocampus of male rats (n = 4 animals per group). 
For each region correlations were calculated for left hemisphere (L), right hemisphere 
(R) and left and right hemispheres combined. Values for Pearson’s r and p are reported 
where p < 0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk.  
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s * 
 
n.s r = 0.977 
p = 0.023 
n.s 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s * n.s n.s n.s 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s * r = -0.959 
p = 0.041 
n.s n.s n.s 
Vmax n.s n.s r = -0.958 
p = 0.042 
n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
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Table C.3   Results of Pearson correlation analyses for PPI measures and TH protein 
expression in the PFC and hippocampus of male rats (n = 4 animals per group). For each 
region correlations were calculated for left hemisphere (L), right hemisphere (R) and left 
and right hemispheres combined. Values for Pearson’s r and p are reported where p < 
0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk. 
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s * n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax r = 0.958 
p = 0.042 
r = 0.995 
p = 0.005 
r = 0.987 
p = 0.013 
n.s n.s n.s 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s * 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s * 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s r = -0.984 
p = 0.016 
n.s 
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Table C.4   Results of Pearson correlation analyses for PPI measures and GAD65 protein 
expression in the PFC and hippocampus of male rats (n = 4 animals per group). For each 
region correlations were calculated for left hemisphere (L), right hemisphere (R) and left 
and right hemispheres combined. Values for Pearson’s r and p are reported where p < 
0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk. 
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s r = 0.985 
p = 0.015 
n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s * n.s n.s * n.s n.s n.s 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax r = -0.963 
p = 0.037 
r = -0.969 
p = 0.031 
r = -0.977 
p = 0.023 
n.s * r = -0.990 
p = 0.010 
r = -0.953 
p = 0.047 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s * n.s 
Vmax n.s * n.s n.s * n.s n.s * n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
 
  
253 
 
Table C.5   Results of Pearson correlation analyses for PPI measures and GAD67 protein 
expression in the PFC and hippocampus of male rats (n = 4 animals per group). For each 
region correlations were calculated for left hemisphere (L), right hemisphere (R) and left 
and right hemispheres combined. Values for Pearson’s r and p are reported where p < 
0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk. 
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s * n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s * n.s n.s 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s * n.s * n.s * n.s r = -0.977 
p = 0.023 
n.s * 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s * n.s * n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
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Table C.6   Results of Pearson correlation analyses for PPI measures and D1 receptor 
protein expression in the PFC and hippocampus of female rats (n = 4 animals per group). 
For each region correlations were calculated for left hemisphere (L), right hemisphere 
(R) and left and right hemispheres combined. Values for Pearson’s r and p are reported 
where p < 0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk. 
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s * n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s * n.s n.s 
Tmax n.s r = -0.980 
p = 0.020 
n.s * n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s r = 0.959 
p = 0.041 
n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
 
  
255 
 
Table C.7   Results of Pearson correlation analyses for PPI measures and D2 receptor 
protein expression in the PFC and hippocampus of female rats (n = 4 animals per group). 
For each region correlations were calculated for left hemisphere (L), right hemisphere 
(R) and left and right hemispheres combined. Values for Pearson’s r and p are reported 
where p < 0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk. 
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s 
 
n.s n.s 
Tmax n.s n.s n.s n.s r = 0.972 
p = 0.028 
n.s * 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s r = 0.974 
p = 0.026 
n.s * 
Tmax n.s n.s n.s n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s r = 0.999 
p = 0.001 
n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
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Table C.8   Results of Pearson correlation analyses for PPI measures and TH protein 
expression in the PFC and hippocampus of female rats (n = 4 animals per group). For 
each region correlations were calculated for left hemisphere (L), right hemisphere (R) 
and left and right hemispheres combined. Values for Pearson’s r and p are reported 
where p < 0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk. 
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s r = -0.976 
p = 0.024 
n.s * n.s n.s n.s 
Vmax n.s r = -0.998 
p = 0.002 
r = -0.971 
p = 0.029 
n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s r = -0.996 
p = 0.004 
Vmax n.s n.s n.s n.s n.s r = -0.953 
p = 0.047 
Tmax n.s n.s n.s n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s r = -0.956 
p = 0.044 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s * r = 0.989 
p = 0.011 
r = 0.962 
p = 0.038 
n.s n.s n.s 
Vmax n.s r = 0.984 
p = 0.016 
n.s * n.s n.s n.s 
Tmax n.s n.s n.s n.s r = 0.958 
p = 0.042 
n.s * 
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Table C.9   Results of Pearson correlation analyses for PPI measures and GAD65 protein 
expression in the PFC and hippocampus of female rats (n = 4 animals per group). For 
each region correlations were calculated for left hemisphere (L), right hemisphere (R) 
and left and right hemispheres combined. Values for Pearson’s r and p are reported 
where p < 0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk. 
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s * n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s * r = 0.954 
p = 0.046 
n.s n.s n.s 
Vmax n.s n.s * n.s * n.s n.s n.s 
Tmax n.s * n.s n.s n.s n.s n.s 
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Table C.10   Results of Pearson correlation analyses for PPI measures and GAD67 
protein expression in the PFC and hippocampus of female rats (n = 4 animals per group). 
For each region correlations were calculated for left hemisphere (L), right hemisphere 
(R) and left and right hemispheres combined. Values for Pearson’s r and p are reported 
where p < 0.05. Correlations where 0.05 < p < 0.1 are marked with an asterisk. 
 
A.   DOM/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s r = 0.953 
p = 0.047 
 
B.   Saline/single 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
C.   DOM/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax r = 0.956 
p = 0.044 
n.s r = 0.978 
p = 0.022 
n.s n.s n.s 
Tmax n.s n.s n.s n.s n.s n.s 
 
D.   Saline/group 
 L-PFC R-PFC PFC L-Hipp R-Hipp Hipp 
%PPI n.s n.s n.s n.s n.s n.s 
Vmax n.s n.s n.s n.s n.s n.s 
Tmax n.s r = -0.964 
p = 0.036 
n.s n.s n.s n.s 
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C.3.1   Significant correlations in males 
Male rats that received DOM treatment and that were raised in isolation showed 
the largest number of correlations of all the experimental groups. Results of the DA 
system markers included significant negative correlations between %PPI/Vmax and D1 
receptor protein in the PFC and hippocampus (Table C.1A), as well as significant 
positive correlations between Tmax and D1 receptor (Table C.1A) and TH (Table C.3A) 
protein in the PFC and with D2 expression in the hippocampus (Table C.2A). 
Correlations for GABA system markers included significant positive correlations 
between %PPI/Vmax and GAD65 in the PFC (Table C.4A). 
 For the male rats that received only saline treatment but were housed in isolation, 
a significant negative correlation between %PPI/Vmax and D1 receptor protein in the 
PFC was observed (Table C.1B), but no significant effects were found in any other 
measures. 
 In the case of male rats that received DOM treatment neonatally but who were 
housed in groups, no significant correlations were observed between PPI measures and 
any marker of the DA system. However, significant negative correlations were found 
between Tmax and GAD65 protein in both the PFC and the hippocampus (Table C.4C) 
with values for the same comparisons approaching significance for GAD67 (Table 
C.5C). 
 In those animals that received saline treatment and were housed in groups, a 
significant correlation was observed between %PPI/Vmax and D2 receptor protein in the 
PFC (Table C.2D), as well as a negative correlation between Tmax and TH protein in 
the hippocampus (Table C.3D). No significant correlations were observed for the 
markers of GABA. 
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C.3.2   Significant correlations in females 
Similar to the results in males, female rats that received DOM treatment and who 
were raised in isolation showed significant negative correlations between %PPI/Vmax 
and TH protein in the PFC (Table C.8A), as well as a significant positive correlation 
between Tmax and D2 receptor protein in the hippocampus (Table C.7A). However, 
they also showed a significant positive correlation between Tmax and GAD67 protein in 
the hippocampus (Table C.10A). 
For the female rats that received only saline treatment but who were housed in 
isolation, a significant negative correlation between Tmax and D1 was observed (Table 
C.6B). A significant positive correlation was also found between %PPI/Vmax and D2 
receptor protein in the hippocampus (Table C.7B) and a significant negative correlation 
was seen between %PPI/Vmax and TH in the hippocampus (Table C.8B). No 
correlations were seen with any measure of the GABA system. 
In the case of female rats who received DOM treatment neonatally but that were 
housed in groups, positive correlations were found between %PPI/Vmax and D1 (Table 
C.6C) and D2 receptor protein (Table C.7C) in the hippocampus. Additionally, negative 
correlations were observed between Tmax and TH protein in the hippocampus (Table 
C.8C). Lastly, a positive correlation was seen between %PPI/Vmax and GAD67 in the 
PFC (Table C.10C).  
In those animals that received saline treatment and that were housed in groups, a 
significant positive correlation was found for %PPI/Vmax and TH protein in the PFC as 
well as for Tmax and TH protein in the hippocampus (Table C.8D). A positive 
correlation between GAD65 and %PPI/Vmax was observed in the PFC (Table C.9D), 
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and a negative correlation between Tmax and GAD67 was seen in the PFC (Table 
C.10D). 
 
C.4   Discussion 
 The results of the post-hoc analyses conducted show extensive correlations 
between the observed behavioural changes described in Chapter 3 and the measures of 
protein concentrations obtained in Chapter 4. A series of interesting and consistent 
trends were observed in male rats. A combination of neonatal DOM treatment and social 
isolation rearing resulted in negative correlations between measures of PPI amplitude 
(%PPI/Vmax) and DA system measures in the PFC and hippocampus, while positive 
correlations were found between PPI latency (Tmax) and DA markers in both regions. 
The correlations went in the opposite direction for enzyme markers of GABA with 
positive correlations found between %PPI/Vmax and GAD, and a non-significant 
tendency toward negative correlations found between Tmax and GAD isoforms. 
Social isolation housing alone resulted primarily in correlations between PPI and 
DA system markers. Significant negative correlations were found between %PP/Vmax 
and DA system markers and there was a non-significant tendency toward positive 
correlations between Tmax and markers of the DA system. No correlations with GABA 
system markers were observed. Interestingly and in contrast, neonatal DOM treatment 
alone resulted in negative correlations between Tmax and markers of GABA system 
while no significant correlations with markers of the DA system were observed. 
Although some significant correlations were found in female rats, they were not 
as clear or as consistent as those observed in males, although it must be noted that 
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female rats exhibited minimal changes in PPI behaviour compared to males (see Chapter 
3).  
 While it is not possible to make any claims of causation based on these results 
alone, the finding of these correlational relationships is intriguing and raises a number of 
ideas. It seems likely that the different measures of PPI behaviour may be affected by 
different systems, because the results here have indicated a link between the amplitude 
of startle (as measured by %PPI and Vmax) and the DA system, and a link between the 
speed of startle (as indicated by Tmax) and the GABA system. Furthermore, while no 
significant effects were observed in the western blot analyses of grouped data (Chapter 
4), it does seem possible that alterations in the DA and GABA systems may be 
implicated in the behavioural changes produced by neonatal DOM treatment and social 
isolation rearing. Specifically, it seems that DOM may be affecting the GABA system 
more so than the DA system, and that social isolation rearing may be affecting the DA 
system more so than the GABA system.  
 Finally, these results lend support to the theory that neonatal DOM treatment and 
social isolation rearing may affect both the DA and GABA systems (albeit differently), 
but that the experiments conducted in Chapter 4 were not able to detect those changes. It 
is possible that a variety of modifications to the study design (different markers, 
different brain areas, or a different means of measurement), or possibly measures of 
dopaminergic and/or GABAergic function rather than neurochemistry, could have 
detected alterations, but it is also possible that variability between individual animals 
among the groups could have lead to no statistically significant changes being detected. 
These findings highlight the importance of investigating the results of individual 
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animals, particularly when attempting to model disorders that are complex and 
heterogeneous, as are many neurodevelopmental disorders (Kirkpatrick et al, 2001).  
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